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Post-transplant lymphoproliferative disease (PTLD) is a life-threatening complication after solid 
organ, bone-marrow and haematopoietic stem cell transplantation. While early diagnosis is 
known to predict encouraging outcomes, no specific markers exist for the early detection of 
PTLD. Epstein-Barr virus (EBV) infection is considered to be an important risk factor for PTLD. 
However, the correlations between EBV DNA loads and the onset of PTLD are inconclusive. 
The aim of this study was to identify potential biomarkers for the early onset of PTLD. To 
accomplish this, we examined EBV and cellular gene expression patterns in (i) the context of 
EBV lytic induction in a lymphoblastoid cell line (LCL) model system, (ii) PTLD versus non-
PTLD transplant patients. In addition we examined the contributions of lytic virus replication vs. 
latent infection to the onset of PTLD. We used real-time two-step RT-PCR assays with SYBR 
green detection to analyse EBV gene expression (76 lytic, 12 latent [n = 88 genes]), following 
12-O-tetradecanoyl-13-phorbol acetate/sodium butyrate (TPA/NaB) induction of Raji cells. We 
identified 22 highly induced EBV genes (>90-fold) at 24 hrs post-induction. Using genome-wide 
Affymetrix microarrays, we identified cellular genes that were highly differentially expressed 
and regulated during the EBV lytic induction phase, 112 of which were regulated specifically by 
EBV, and 14 chosen for further study. We developed and validated real-time two-step TaqMan 
RT-PCR assays for clinical validation. Altogether, we evaluated 17 cellular and 14 EBV 
candidate genes in whole blood from paediatric solid organ transplant (SOT) recipients and adult 
umbilical cord transplant (UBCT) recipients, with and without PTLD. We detected a higher 
number and level of expression of EBV latent and lytic genes in PTLD patients, notably, BALF5, 
EBNA-LP and LMP-1, and in association with viral loads. Further, we detected latency III and 
more varied EBV latent gene expression patterns in PTLD. We also detected four cellular genes 
(CXCL9, CXCL10, CDC2, and CHI3L1) that were differentially expressed in PTLD vs. non-
PTLD patients. To conclude, these findings suggest a basis for the likely microenvironment in 
which PTLD could develop. Further evaluation of candidate EBV and cellular markers could 
facilitate a more specific diagnosis of PTLD.  
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1.1  EPSTEIN-BARR VIRUS 
 
1.1.1 Classification of Epstein-Barr virus    
Over 100 herpesviruses have been discovered, several of which are human herpesviruses  of the 
herpesviridae family Alpha-, Beta-, and Gammaherpesvirinae, and infect the sensory ganglia, 
secretory glands and lymphoid or epithelial cells, respectively (Table 1.1) (Edelman, 2005). 
Epstein-Barr virus (EBV) or Human herpesvirus 4 (HHV-4) is classified as a member of the 
genus Lymphocryptovirus (LCV), which belongs to the subfamily Gammaherpesvirinae within 
the Herpesviridae family (Fields et al., 2007). The gammaherpesvirus family contains two 
genera, the lymphocryptovirus (LCV) and rhadnovirus (RDV). EBV is the only LCV and HHV-
8 the only RDV. A common feature shared amongst many of the viruses in the LCV genus is 
their lymphotropism; defined as their ability to infect B and T lymphocytes (Fields et al., 2007). 
 
Table 1-1 Classification of human herpesviruses 
Herpesvirus subfamily Herpesvirus 
Alphaherpesviruses Herpes simplex viruses 1 (HSV-1) 
Alphaherpesviruses Herpes simplex viruses 2  (HSV-2) 
Betaherpesviruses Varicalla-zoster virus (VZV) 
Betaherpesviruses Human cytomegalovirus (HCMV) 
Betaherpesviruses Human herpesviruses 6 (HHV-6) 
Betaherpesviruses Human herpesviruses 7 (HHV-7) 
Gammaherpesviruses Human herpes virus 4 (HHV-4)/Epstein-Barr virus (EBV) 




1.1.2 Structure of EBV 
As for other herpesviruses, the EBV virion is approximately 200 nm in diameter and consists of 
four common elements, a toroid-shaped protein core containing the linear double-stranded DNA 
genome, an icosahedral capsid, an amorphous protein tegument and an outer lipid envelope 
(Figure 1.0) (Fields et al., 2007).  
 






                
 
Figure 1-1 Structure of Herpesviruses 
Electron micrograph of a herpesvirus particle (diameter ~ 120-200 nm). The herpesvirus virion structure consists of 
a double-stranded DNA genome within an icosahedral capsid surrounded by tegument and an outer lipid envelope 
with numerous glycoprotein projections (Young and Rickinson, 2004). EBV is approximately 200 nm in diameter. 
The core contains the 172 kbp linear, double-stranded DNA genome, surrounded by the capsid, a 100-120 nm 
protein shell with T = 16 icosahedral symmetry made up of 162 capsomers, and the entire core and DNA genome 
termed nucleocapsid. The tegument surrounds the capsid and consists of 1-20 proteins. The envelope is the outer 










1.1.3  EBV genome and organisation 
The EBV genome is a linear, double-stranded DNA, approximately 172 kbp in length, and with a 
60% G+C content (Fields et al., 2007). Upon infection, the genome circularises into a double-
stranded episome (Figure 1.2). The EBV genome consists of four components common to all 
herpesviruses, including  a large unique (U) region flanked by series of 0.5 Kb terminal direct 
repeats (Figure 1.3)(Cheung and Kieff, 1982). In addition, two origins of replication oriLyt and 
oriP are found within UL (Figure 1.3). EBV was the first herpesvirus to be completely cloned 
and fully sequenced using its BamHI restriction digest sites (Baer et al., 1984). The BamHI 
fragments were sequenced and open reading frames (ORFs) designated according to the order of 
direction (right or leftward) of transcription from the BamHI restriction fragment or their 
putative functions (Fields et al., 2007). More recently, the EBV wild-type (EBVwt) strain was 
created by assembling sequences of EBV strains B95.8 and Raji (de Jesus et al., 2003a). 
According to the National Center for Biotechnology Information (NCBI), the EBV type 1 (EBV-
1) genome contains 94 genes of which 94 are protein coding, including several spliced forms 
(Farrell et al., 1983). In addition, approximately 45 structural RNAs have been identified (de 





Figure 1-2 The Epstein-Barr (EBV) genome  
Diagram showing the circularised double-stranded EBV DNA episome and the location and transcription of the 
EBV latent genes Locations of the three promoters Cp, Wp and Qp within the unique long (UL) region are shown. 
The outer green arrow shows latent EBV genes transcribed from Cp or Wp whereas the red arrow shows latent 
genes transcribed from Qp. The origin of replication (oriP) is shown in orange. The terminal repeat (TR) joins the 











Figure 1-3 Schematic of the linear Epstein-Barr virus (EBV) genome 
The schematic diagram shows the linear double-stranded EBV DNA episome and location and transcription of the 
latent EBV genes. The EBV genome is split into two regions of unique sequences (UL and US), the 134kbp unique 
long sequence domain (UL), containing most of the viral coding capacity and 6kbp unique short sequence domain 
(US) and split by the presence of 3kbp internal direct repeats (IR1), and flanked by 538-bp direct terminal repeat 
regions (TRL and TRS). The plasmid origin (oriP) is contained within US and two origins of lytic replication 
(oriLyt) are contained within UL of the EBV genome. The UL region is split further into four shorter domains (U2, 
U3, U4 and U5) by the presence of three short direct repeat elements (IR2, IR3 and IR4) that transcribe EBV latent 
proteins. Adapted from Young et al. 2004. 
 
1.1.4 EBV types 1 and 2   
EBV is classified into two subtypes: EBV-1 and EBV-2 (also known as type A and B), based on 
sequence variations in genes encoding the EBV nuclear antigens (EBNA-2, EBNA-3A, EBNA-
3B and EBNA-C and EBNA-LP) (Arrand et al., 1989; Fields et al., 2007). In general, sequence 
variations are greater in EBNA-2 compared to the other EBNAs, with a 53% amino acid 
sequence identity between EBV-1 and EBV-2 (Dambaugh et al., 1984; McCann et al., 2001; 
Rowe et al., 1989; Sample et al., 1990). EBV-1 is more efficient at transforming B cells in vitro 
than EBV-2 and EBNA-2 variation is attributable to the differences in transformation efficiency 
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1.2 BIOLOGY OF EBV INFECTION 
 
1.2.1 Primary infection of EBV 
Early events of primary EBV infection include entry of EBV into the oropharyngeal epithelium, 
although whether B lymphocytes or epithelial cells are infected first is uncertain (Shannon-Lowe 
et al., 2006). EBV preferentially infects resting (naive) B cells, although epithelial cells and 
resting memory B cells are also infected (Li et al., 1992; Sixbey et al., 1984). Additionally, under 
certain circumstances T cells, natural killer cells, smooth muscle cells and monocytes can also be 
infected (Hutt-Fletcher, 2007). In general, EBV undergoes brief lytic replication in epithelial 
cells of the oropharynx (Li et al., 1992). Subsequently, EBV remains latent in memory B 
lymphocytes (Babcock et al., 1998).  
 
1.2.2 EBV entry of B lymphocytes 
EBV entry of B lymphocytes involves direct attachment to the B lymphocyte followed by 
internalisation through fusion between the viral envelope and B cell membrane. EBV uses the 
viral envelope glycoprotein gp350/220 to bind the complement receptor type 2 (CR2) also 
known as CD21 on the B lymphocyte surface (Figure 1.3). CR2 is the primary receptor for EBV. 
Eight additional glycoproteins are implicated in EBV entry, although gp350/220 is the most 
commonly used due to its high abundance on the surface of the virus particle (Hutt-Fletcher, 
2007). Once in the endosomal compartment, fusion requires interactions between the core fusion 
complex gH/gL/gB of gp42, gp85 and gp25 (Spear and Longnecker, 2003) and human leukocyte 
antigen (HLA) class II co-receptor. This interaction transforms the core fusion complex from a 
metastable to active state and requires binding of EBV envelope glycoprotein gp42 to gHgL 
  
24 
forming the complex gHgLgp42. During fusion the EBV membrane fuses with the endosomal 
lipid envelope on the B lymphocyte and the virus becomes de-enveloped (Hutt-Fletcher, 2007).  
 
1.2.3 EBV entry of epithelial cells 
Attachment of EBV to epithelial cells is less clear, since CR2 is not usually expressed in 
epithelial cells and the other ligands and receptors involved are unknown. However, when an 
epithelial cell expresses CR2, EBV can enter through interactions between CR2 and gp350, as it 
does for B lymphocytes (Borza and Hutt-Fletcher, 2002; Li et al., 1992). Interactions with other 
cell surface proteins are thought to mediate EBV attachment to CR2-negative epithelial cells, 
including gHgL and the putative receptor gHgLR (Borza and Hutt-Fletcher, 2002; Molesworth et 
al., 2000). The mechanism of fusion of EBV and epithelial cells is unclear and does not require 
gp42. Interestingly, gp42 can inhibit entry into epithelial cells (Hutt-Fletcher, 2007). Cell transfer 
of EBV to epithelial cells through the formation of B-cell-epithelial conjugates is an alternative 
route of entry. In this mechanism, EBV is not internalised but attaches to B lymphocytes through 
gp350/CD21 complexes from where they transfer efficiently to CD21-negative epithelial cells, 
enhancing infectivity by up to 10,000-fold (Shannon-Lowe et al., 2006). 
 
1.2.4 EBV cell tropism 
Cell tropism is shown in Figure 1.4. (Borza and Hutt-Fletcher, 2002).  EBV cell tropism is 
dependent on gp42 and the cell type from which EBV is produced (Borza and Hutt-Fletcher, 
2002; Farrell, 2002). Normally, gp42 forms part of the fusion complex gH/gL/gp42. However, 
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virus produced in B cells is relatively depleted of gp42 (gH/gL), due to sequestering by HLA 
Class II. As a result, gH/gL targets the HLA Class II co-receptor on other B cells less effectively 
than on HLA class II-negative epithelial cells. Conversely, in virus produced from epithelial 
cells, gp42 (gH/gL/gp42) are relatively more abundant and more efficient at targeting the HLA 




Figure 1-4  Putative models of EBV entry, infection and cell tropism  
EBV infects resting B cells through interaction of gp350/220 with CD21 on the B cells and gHgLgp42 fusion 
complex with HLA Class II co-receptor on B cells. EBV produced from B cells is depleted of gp42 (gHgL), 
increasing efficiency of infection of HLA Class II negative epithelial cells, but not B cells. EBV produced from 
epithelial cells infects B cells with increased efficiency through interaction of gHgLgp42 with HLA Class II co-
receptor on B cells. EBV mediates B cell-epithelial cell transfer through interaction of gp350/220 with CD21 on B 
cells, but no internalisation and formation of B cell-epithelial conjugates at cell synapse allowing transfer of EBV to 
epithelial cells. Adapted from Farrell et al. 2002    
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1.2.5 Post-fusion events 
Fusion of EBV from the endosomal compartment of the B lymphocyte enables the release of 
virus into the cytoplasm. EBV exists as a de-enveloped virion in the cytoplasm and the 
tegumented capsid must transfer to the nucleus, where the genome is replicated, packaged and 
released as new viral particles (Fields et al., 2007). However, the exact mechanisms for post-
fusion events in EBV are poorly understood. What is known from other herpesviruses, is that 
transfer from the cell membrane occurs in a reversal of the budding process required to produce 
the enveloped virus in the first place (Hutt-Fletcher, 2007).  
 
1.2.6 Assembly and egress 
The exact mechanism for EBV packaging and release is poorly understood and likely 
mechanisms are largely postulated from studies in other herpesviruses. During the DNA 
packaging process, the replicated genome is cleaved from branched concatemers into unit-length 
genomes that are packaged into pre-formed capsids (Tsurumi et al., 2005). 
 
1.3 EBV LATENT INFECTION 
 
1.3.1 Overview of latent EBV infection 
Like all herpesviruses, EBV can establish both latent and lytic replication during its life cycle. 
EBV can exist as a latent infection in vivo in both epithelial cells as well as B lymphocytes, 
however, B lymphocytes are the principle reservoir of latent EBV and the source of new EBV 
progeny upon EBV reactivation and infection of other EBV-naive B cells (Fields et al., 2007).  
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Following initial infection of resting primary B lymphocytes, the linear EBV genome circularises 
and persists as a closed circular DNA molecule or episome within the nucleus. Approximately 
10-100 episomes are maintained within the latently infected B lymphocyte. These episomes are 
self-replicating and are dependent on cellular DNA replication, where replication occurs only 
once per cycle. During latent infection of B lymphocytes only a restricted number of genes are 
expressed with no viral production. The latency genes are involved in functions such as 
stimulating cell proliferation, inhibition of apoptosis, blocking viral lytic replication, and 
ensuring accurate and equal partitioning of episomal viral genomes to daughter cells (Miller and 
El-Guindy, 2002). During latency, the EBV lytic genes are most likely repressed through host-
driven methylation of viral DNA (Hammerschmidt and Sugden, 1988). Moreover, during latent 
EBV infection, only a few EBV genes are expressed and there is no production of infectious 
virus (Fields et al., 2007). 
 
1.3.2 EBV latent gene expression  
EBV expresses a small subset of latent genes including six EBV nuclear antigens (EBNA’s) 1, 2, 
3A, 3B, 3C and LP and three latent membrane proteins (LMP’s) 1, 2A and 2B. Several of these 
have transforming and oncogenic properties including EBNA-2, EBNA-3A, EBNA-3C and 
LMP-1 (Hickabottom et al., 2002; Kempkes et al., 1995; Parker et al., 1996; Wang et al., 1985). 
In addition, other small non-coding RNAs are actively expressed during B cell transformation in 
vitro (Young and Rickinson, 2004), including the highly abundant non-polyadenylated and non-
coding EBV-encoded RNAs, EBER-1 and EBER-2 (EBER’s), a set of highly spliced non-coding 
BamHI A rightward transcripts (BART’s), also known as complementary strand transcripts 
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(CSTs), one small nucleolar RNA (snoRNA) (Feederle et al., 2011), as well as 44 mature 
microRNAs (miRNAs) derived from 25 precursor-miRNAs, the functions of which may control 
viral latency (Pfeffer et al., 2004; Riley et al., 2012). The functions of the latent genes and RNA 
transcripts are summarised in Table 1.2.   
 






A73 / RPMS1 splice Part of BARTs family, Unknown function; EBNA-2 homologue; negatively regulates activity of EBNA-2 and NotchIC 
BARF0 Part of BARTs family, Unknown function Interaction with Notch, putative maintenance of latency 
microRNAs Putative role in RNA silencing; proposed to target three viral transcripts (BALF5, LMP-1 and LMP-2) for degradation; control of viral latency 
EBER’s 
Small non-coding RNAs, Unknown function, putative interaction of IFN responses; role in 
tumorigenicity of BL cells, association with cellular proteins, lupus antigen (LA), EBER-
associated ribosomal protein (EAP, L22 (rpL22)), double-stranded (ds) RNA-dependent protein 
kinase (PKR) and retinoic acid inducible-gene I (RIG-I) 
EBNA-1 Essential for B-cell transformation, replication and maintenance of EBV episome, DNA binding phosphoprotein, activates promoter Qp, 
EBNA-2 
Essential for transformation, oncoprotein, transcriptional activator of EBV and cellular genes, 
Notch homologue, Activates promoter, Cp,  up-regulates LMP-1; Promotes G0-G1 transition in 
co-operation with EBNA-LP 
EBNA-3A Essential for B-cell transformation, oncoprotein Transcriptional regulator 
EBNA-3B Transcriptional regulator, not essential for B-cell transformation; growing evidence for a role in B-cell transformation 
EBNA-3C Nuclear protein, essential for B-cell transformation 
EBNA-LP Nuclear phosphoprotein, highly spliced BWRF1 ORF, 12 exons, enhances EBNA-2 transactivation; participates in B-cell transformation and B-cell growth; binds p53 and  pRb 
LMP-1 Essential for B-cell transformation, mimics CD40; key oncogene; up-regulates anti-apoptotic proteins bcl-2 and A20 and viral IL-10; recruits chemokines 
LMP-2A / 2B 
LMP-2A, interference with protein kinase signalling, gene terminal protein, essential for B-cell 
transformation; Inhibits signalling through BCR and promotes survival during B-cell 




1.3.3 EBV latency gene expression programmes 
EBV exhibits four latency gene expression programmes known as latency types 0, I, II and III, 
each of which is based largely on the expression of the EBNAs and LMPs and associated with the 
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differentiation state of host B cells (Table 1.3) (Babcock et al., 2000; Rowe et al., 1992; Rowe et 
al., 1987; Thorley-Lawson and Gross, 2004). The latency III programme (growth programme) is 
characterised by expression of the full set of latent genes, including the EBNAs, LMP-1 and 
LMP-2. In vivo, latency III is expressed in naive B cells during primary EBV infection and 
associated with B-cell proliferation and immortalisation (Farrell, 1995; Joseph et al., 2000). 
Latency III is also expressed in most B cell lymphomas in immunosuppressed patients. In vitro, 
latency III is expressed in EBV-transformed LCLs and represents an in vitro model of PTLD 
(Niedobitek et al., 1997a; Rowe et al., 1998; Young and Rickinson, 2004). The latency II 
programme (Default programme) is characterised by the expression of  EBNA-1, LMP1, LMP-2A 
and 2B genes and is expressed in nasopharyngeal carcinoma (NPC), gastric cancer, Hodgkin’s 
disease (HD) and some T and B cell lymphomas (Fahraeus et al., 1988). Latency I is 
characterised by the restricted expression of the EBNA-1 gene only, and is observed in 
proliferating memory B cells in healthy individuals (Chen et al., 1995). Latency I is found 
predominantly in Burkitt’s lymphoma (BL) and derived LCLs (Tierney et al., 2000). A fourth 
programme, latency 0 is observed in vivo in quiescent memory B cells and expresses none of the 
latent genes, enabling EBV to persist within the  peripheral memory B cell pool undetected by 
the CD8+ T cell response (Babcock et al., 1998). Moreover, latency I, II and III are expressed in 
different EBV-associated cancers, which originate from the different stages of infected B cells 










EBV genes expressed Infected B cell type Function Expression in disease 
Latency III (Growth 
programme) 
EBNA-1, 2, 3a, 3b, 3c, 
LP, LMP-1, LMP-2A 
and LMP2B, EBER’s, 
BART’s 
 
Naive Activate B cell Infectious mononucleosis, PTLD 
Latency II (Default 
programme) 
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Latency 0 None Peripheral memory Allow life time persistence 
Memory B 
lymphocytes in 
peripheral blood of 
healthy EBV 
seropositive carriers 
(Table Adapted from Thorley-Lawson et al., 2004) 
 
1.3.4 Regulation of EBV latency  
Following infection of B cells, the linear, uncoated EBV genome is transferred to the nucleus, 
where it re-circularises, leading to transcription of all the latent genes (Young and Rickinson, 
2004). The EBV transcription patterns are regulated largely through differential EBV promoter 
usage (Wp, Cp and Qp) (Figure 1.2). The BamHI W (Wp) and BamHI C (Cp) upstream 
promoters are involved in driving the expression of all the EBNA genes during latency III and 
they function in a mutually exclusive fashion (Woisetschlaeger et al., 1989). The Qp promoter 
leads to the selective expression of EBNA-1 during latency I, whereas latency II is initiated by 
transcription from Qp and LMP promoters (Rowe et al., 1992; Schaefer et al., 1991; Zetterberg 
et al., 1999) (Rowe et al., 1992; Woisetschlaeger et al., 1989; Woisetschlaeger et al., 1990). 
Infection of B cells with EBV, initially leads to exclusive use of Wp and initial expression of 
EBNA-2 and EBNA-LP, followed by an EBNA-2 autoregulated switch from Wp to Cp, leading 
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to the ordered expression of EBNA-1, EBNA-2, EBNA-3A, EBNA-3B and EBNA-3C (latency 
III) from a long 120kb Wp/Cp transcript (Schlager et al., 1996; Woisetschlaeger et al., 1991; 
Woisetschlaeger et al., 1990).  
EBNA-2 and EBNA-LP are the first EBV genes expressed early after B-cell infection (8-12 hrs) 
(Allday et al., 1989; Fields et al., 2007; Rooney et al., 1989a), transcribed from a bicistronic unit 
under exclusive transcription from Wp, located upstream of Cp (Schlager et al., 1996; Thorley-
Lawson and Gross, 2004; Woisetschlaeger et al., 1989; Woisetschlaeger et al., 1990). EBNA-2 
functions as the principle transcriptional activator of the Cp promoter of viral genes (Wang et al., 
1987; Wang et al., 1991), whereas EBNA-LP enhances EBNA-2 activation (Peng et al., 2005). 
By 36 hrs, EBNA-2 autoregulates the switch from Wp to Cp, giving rise to a long 120 kb Wp/Cp 
transcript from which all the EBNA genes (1, 2, 3A, 3B and 3C) are differentially spliced 
(Schlager et al., 1996; Woisetschlaeger et al., 1991; Woisetschlaeger et al., 1990).  At the same 
time, EBNA-LP co-activates EBNA-2 transcription of LMP-1 and LMP-2A/B from EBNA-2 
responsive promoters, and EBNA-1 from promoter Qp, leading to the default programme 
(latency II) which is essential for differentiation of latently infected B cells into memory B cells 
(Fahraeus et al., 1990; Sample et al., 1986). Transcription from the promoter, Qp (Figure 1.2), 
leads to exclusive expression of EBNA-1 (latency I) and EBV persistence (Schaefer et al., 1995; 





1.3.5 EBV latent DNA replication 
EBV persists in host B lymphocytes as a covalently closed circular DNA episome (EBNA-
1/oriP) (Young and Rickinson, 2004). These episomes are self-replicating and dependent on 
cellular DNA replication proteins and EBNA-1 for latent DNA replication. EBNA-1 has two key 
functions during latent EBV DNA replication, including genome maintenance and retention and 
partition at division (Yates et al., 1984; Yates et al., 1985). Replication of the EBV episome is 
mediated by the cellular DNA replication machinery, occurring once per cell division cycle 
(Adams, 1987) and partitioning to daughter cells during mitotic division (Kirchmaier and 
Sugden, 1995), and is initiated within the origin of DNA replication, oriP, located in the short 
unique domain (US) of the viral genome (Figure 1.0). The oriP consists of two sequence 
elements with high-affinity EBNA-1 binding sites, FR, the family of repeat element (30 bp 
repeats)(FR) and the dyad symmetry element (DS), each separated by approximately 960 base 
pairs, both required for replication (Reisman et al., 1985). EBNA-1 is essential for latent DNA 
replication that directly binds and activates oriP (Yates et al., 1985). EBNA-1 mediates genome 
replication from within oriP by first interacting with EBNA-1 binding sites within the DS 
element of oriP. Therefore, the main purpose for EBNA-1 may be to stabilise the replicated 
DNA during partition at division. To complete replication of the episome, EBNA-1 interacts 
with the FR element within oriP and tethers the viral genome to the host chromosome through 
interactions with cellular chromosome-associated protein, ensuring that EBV episomes are 
evenly partitioned upon cell division. Latent EBV DNA replication occurs once per cell cycle 





1.3.6 EBV persistence in vivo 
Following primary infection, EBV establishes a life-long latent infection in circulating resting 
memory B lymphocytes, where it persists as an episome, typically at a frequency of 1 to 50 
copies per million B lymphocytes (Babcock et al., 1998; Miyashita et al., 1997). The exact 
mechanism as to how EBV establishes persistence in the memory B cell pool is uncertain. 
According to the proposed model of EBV persistence in vivo, EBV exploits the normal B-cell 
differentiation pathway, and uses its transforming properties to specifically provide activation 
signals to newly infected naive B lymphocytes which differentiate at the germinal centre (GC) 
into resting memory B lymphocytes where they persist (Thorley-Lawson, 2001). During primary 
infection, EBV particles produced either in tonsils or that enter tonsillar tissue infect resting 
(naive) B cells. The transforming properties of the latent proteins drive the naive B cells to 
become proliferating lymphoblasts, which migrate towards follicular areas where they form 
follicles known as the GC. Within the GC, EBV expresses the more restricted pattern of gene 
expression (latency II), that provide survival signals to prevent apoptosis and enable the GC B 
lymphocytes to differentiate into long-lived resting memory B cells. These memory B cells exit 
the GC and escape immune recognition by switching to the latency I programme, and then 
latency 0, where no genes are expressed. EBV is able to persist in memory B cells since they are 
long-lived and remain undetected by the immune response (Babcock et al., 1998; Joseph et al., 
2000). Periodic reactivation of EBV, possibly from memory B cell activation within lymphoid 
tissues results in differentiation into plasma cells followed by viral replication and infection of 
naive B lymphocytes (Thorley-Lawson, 2001). Occasional reactivation of memory B cells results 
in latency III expression (Young and Rickinson, 2004). Therefore it is apparent from this model 
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that the role of the latent proteins is in establishing persistent infection and EBV uses different 












Figure 1-5 Schematic drawing of proposed models of EBV persistence and reactivation in vivo 
EBV infects naive resting B cells that are activated into lymphoblasts expressing latency III. In the presence of a 
cytotoxic T cell response these lymphoblasts proliferate and differentiate through the germinal centre where latency 
I and II is expressed, into memory B cells. After exiting the germinal centre memory B cells enter the peripheral 
blood where they persist for life. In memory B cells, all latent genes are down-regulated in latency 0. These memory 
B cells circulate in the periphery and occasionally reactivate in the tonsillar region, where they receive signals to 
undergo terminal differentiation into plasma cells, releasing newly infected virus that re-infects naive B cells and 
also lymphoblasts. In the absence of an immune response lymphoblasts can proliferate uncontrolled into PTLD. 
Rarely infection of bystander cells can also proliferate into PTLD. Adapted from (Thorley-Lawson and Allday, 
2008). 
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1.4 EBV LYTIC REPLICATION  
 
1.4.1 Overview of EBV lytic replication 
To complete the EBV life cycle, the EBV genome reactivates to enter the lytic cycle in the 
nucleus where it is transcribed into mRNA by host RNA polymerase II and progeny virus 
produced in three temporally regulated phases: (i) transcription of the viral genome, (ii) 
replication of the viral genome and (iii) assembly and egress of new progeny virus (Fields et al., 
2007). During these phases of lytic replication, three classes of genes are expressed including: 
immediate-early (IE), early (E) and late (L) genes, according to their appearance following 
activation of the lytic cascade (Takada and Ono, 1989). Over 70 EBV lytic genes are expressed 
during the lytic cycle, including two immediate-early genes, approximately 30 early genes and 
40 late genes (Fields et al., 2007). 
 
1.4.2 Immediate-Early genes 
EBV lytic replication is initiated by the expression of two IE genes BZLF1 and BRLF1, that 
encode the transcription factors BZLF1 (also known as Z, Zta, ZEBRA or EB1) (Chevallier-
Greco et al., 1986b; Countryman and Miller, 1985) and BRLF1 (also called Rta or R)(Hardwick 
et al., 1988), respectively. BZLF1 and BRLF1 are essential in activating the cascade of lytic-
cycle gene expression (Chevallier-Greco et al., 1986b; Countryman and Miller, 1985; Ragoczy 
and Miller, 1999; Rooney et al., 1989b; Takada et al., 1986; Zalani et al., 1996).  However, 
BZLF1 is the key lytic transactivator and the first gene expressed in the lytic cycle (Amon et al., 
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2004a). Rta is autoactivated by itself and Zta (Liu and Speck, 2003). Together, both co-operate 
to promote lytic cycle activation by regulating several early gene promoters (Feederle et al., 
2000b; Flemington and Speck, 1990; Hardwick et al., 1988; Kenney et al., 1989; Quinlivan et al., 
1993), leading to the activation of all early and late lytic genes and subsequently viral DNA 
replication and virion production (Inman et al., 2001). The IE genes are also expressed in the 
absence of host protein synthesis (Biggin et al., 1987; Flemington et al., 1991; Takada and Ono, 
1989).   
 
1.4.3 Zta/ZEBRA  
Zta belongs to the basic-leucine zipper (bZIP) family of transcription factors (Chang et al., 1990; 
Chen et al., 2009; Wang et al., 2005) that shares partial amino acid homology to the cellular 
activating protein 1 (AP-1) family of transcription factors, including c-Fos, Fra-1, c-Jun and Jun-
B (Chen et al., 2009; Countryman et al., 2009; Farrell et al., 1989).  Zta functions as a sequence-
specific DNA binding transcription factor (Farrell et al., 1989) activates lytic-cycle gene 
expression through the direct binding of AP-1 and AP1-1-like motifs known as Z response 
elements (ZREs) within several EBV early and cellular gene promoters (Chang et al., 1990; 
Farrell et al., 1989; Lieberman et al., 1990). Moreover, Zta can activate itself through 
interactions with ZREs within its own promoter, Zp (Flemington and Speck, 1990). Zta functions 
as a sequence-specific DNA binding phosphoprotein in vivo and requires phosphorylation within 
its carboxyl region for enhanced DNA binding and activation (Chen et al., 2009). 
Phosphorylation at serine residue 186 (Ser186) within the Zta carboxyl region results in lytic 
cycle activation following initial activation of the BRLF1 promoter, Rp (Adamson and Kenney, 
  
37 
1998; Francis et al., 1999; Francis et al., 1997) whereas phosphorylation by casein kinase II leads 
to activation of late lytic gene expression (El-Guindy and Miller, 2004). Zta and Rta also interact 
with ZREs within oriLyt domains to initiate replication of EBV DNA during the lytic cycle 
(Fixman et al., 1992). Phosphorylation at S173 within the Zta carboxyl region leads to enhanced 
Zta binding and viral replication (Chen et al., 2009; Kolman et al., 1993). The EBV genome is 
extensively methylated in latently infected cells (Ernberg et al., 1989; Minarovits et al., 1991). 
Methylation may suppress lytic gene expression, whilst preventing latent gene expression and 
maintaining EBV persistence in vivo by immune evasion (Paulson and Speck, 1999; Robertson 
and Ambinder, 1997). Zta has a high affinity for methlyated DNA and activates lytic EBV gene 
expression from the methylated EBV genome (Bhende et al., 2005), through sequence-specific 
binding to highly methylated cytosine-phosphatidyl-guanosine (CpG) motifs within ZREs 
(Bhende et al., 2005; Chen et al., 2009) located in promoter regions of several early lytic genes 
(Kalla et al., 2010), and preferentially activates methylated DNA of the  BRLF1 promoter, Rp 
(Bhende et al., 2004). Zta can regulate the expression of cellular genes including c-Fos, Fra-1, 
Jun and Jun-B through binding to the AP-1 site (Chen et al., 2009), as well as regulation of p53 
and c-myc through interactions with another domain  (Zhang et al., 1994) and the secretion of 
numerous cytokines namely IL-10, IL-8, TNFα and IFN-γ through interactions with ZREs within 
these genes (Chen et al., 2009).  
 
1.4.4 Reactivation of latency in vitro 
EBV can transform primary resting B lymphocytes in vitro and induce them indefinitely into 
proliferating B lymphocytes known as lymphoblastoid cell lines (LCLs). EBV is harboured in 
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LCLs as an extrachromosomal EBV episome. LCLs are normally characterised by the 
constitutive expression of all nine latency genes and mRNA transcripts, known as latency III, as 
well as several B-cell activation markers (Young and Rickinson, 2004). Examples of available 
LCLs include Raji, B95.8, Akata, Daudi and P3HR-1, which are characterised by mutations in 
the EBV genome and expression of the different latency programmes (Fields et al., 2007). 
Latently infected EBV can be induced into viral replication through various stimuli. A number of 
agents can reactivate the EBV lytic cycle in vitro by activating BZLF1 expression (Fields et al., 
2007). These include phorbol esters such as 12-O-tetradecanoyl phorbol-13-acetate (TPA), 
which activate the protein kinase C (PKC) pathway (Davies et al., 1991). TPA is often used in 
synergy with sodium butyrate (NaB), a histone deacetylase inhibitor (Luka et al., 1979). Other 
inducing agents include the demethylating agent azacytidine, halogenated pyrimidines such as 5-
iododeoxyuridines; nitrosamines, calcium ionophores, superinfection with P3HR1 and more 
physiologically relevant stimuli including, cytokine transforming growth factor-β (TGF-β)(di 
Renzo et al., 1994) and cross-linking of B-cell surface receptor (BCRs) with anti-
immunoglobulin (anti-IgG) antibodies of Akata cells (Fields et al., 2007; Shimizu and Takada, 
1993b; Takada, 1984).    
 
1.4.5 Phorbol ester induction of ZEBRA 
Phosphorylation is a common mechanism for regulating the function of proteins (Bhende et al., 
2005) and Zta requires phosphorylation within its carboxyl-terminal domain to enhance its DNA 
binding affinity for lytic cycle activation (Chen et al., 2009). Phorbol esters, such as TPA are 
among the most reproducible and widely used lytic cycle inducers (Davies et al., 1991) and the 
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PKC pathway has been linked to phosphorylation of Zta at serine 186 (ser186) within the C-
terminal domain, and is essential for lytic cycle activation by TPA (Baumann et al., 1998b).  
1.4.6 EBV early genes 
Approximately 30 EBV early genes are transcribed following expression of the IE transactivator 
BZLF1. The early genes are not transcribed prior to replication of the EBV genome as 
demonstrated in the presence of inhibitors of protein synthesis (Fields et al., 2007; Yuan et al., 
2006). The majority of these genes encode proteins that act as enzymes in EBV DNA replication. 
However, as summarised in Table 1.4, these genes also have roles in transcription regulation, 
RNA transport and stability, viral protein kinase activity, apoptosis, inhibition, and immune 
evasion (Fields et al., 2007).  
 
Table 1-4 EBV early genes and their proposed functions 
Gene Proposed function 
BALF1   Bcl-2 homologue, suppressor of anti-apoptosis protein BHRF1, potential role in tumorigenicity and metastasis 
BALF2 Single-strand DNA  binding protein (mDBp), part of replication fork/machinery 
BALF3 Terminase large subunit/ATPase 
BALF5 Viral  DNA  polymerase 
BaRF1 Ribonucleotide reductase 
BARF1 Binds hCSF-1, probable immunomodulation, oncogene, 
BBLF2 Part of helicase-primase complex 
BBLF3 Part of helicase-primase complex 
BBLF4 Helicase, part of helicase-primase complex 
BcRF1 Unknown function; probable TATT binding function 
BDLF4 Protein (gp115) 
BFLF1 Cytosolic zinc-binding protein, cysteine rich;Egress of capsids from nucleus; putative role in DNA packaging 
BFLF2 
Putative tegument; Nuclear localization of capsids & DNA, 
nuclear membrane phosphoprotein, part of intracellular virions, 
egress protein, complex with BFRF1 




BFRF2 Unknown function; not included in virions 
BGLF4 
Serine/threonine protein kinase (PK), Phosphorylation of 
BMRF1, EBNA-LP, translation elongation factor 1 and motifs 
recognised by cdc2 kinase, production of infectious virus, 
BGLF5 Alkaline exonuclease & Host-shutoff immune evasion 
BHRF1 Bcl-2 homologue (Anti-apoptotic activity) 
BILF1 
G-protein coupled receptor gp64; Immunoregulatory function; 
Immune evasion by targeting MHC 1 for degradation; potential 
cell transformation 
BKRF3 Uracil-DNA glycosylase 
BLLF2 Unknown function 
BLLF3 dUTP pyrophosphatase, dUTPase 
BSMLF1 (SM) 
RNA binding protein, regulates mRNA stability of viral DNA 
polymerase RNAs, processing and export of mRNA transcripts 
from nucleus to cytoplasm, enhances STAT1 expression 
BMRF1 
Viral DNA polymerase-processivity factor, early antigen protein 
(EA-D, polymerase accessory protein); transactivator of oriLyt  
and cellular gastrin promoter, replication protein 
BNLF2a Potential membrane protein; immune evasion;  TAP inhibitor 
BNLF2b Putative gp141 
BORF2 Viral dUTPase gene, deoxynucleotide metabolism 
BRRF1 Enhancement of lytic cycle induction, transcription factor 
BSLF1 Primase, subumit of the helicase-primase complex, part of the replication machinery 
BXLF1 Viral  thymidine kinase, deoxynucleotide metabolism, phosphorylation of acyclovir 
BXRF1 Nucleoprotein 
LF1 Protein LF1, contains a dUTPase like domain 
LF2 Protein LF2, contains a dUTPase like domain 
LF3 Proline-rich protein LF3, unknown function, tandem repeats, region containing oriLyt 
 
1.4.7 EBV lytic DNA replication   
EBV lytic DNA replication is initiated from the origin of lytic replication (oriLyt) and highly 
dependent on several EBV-encoded proteins (Hammerschmidt and Sugden, 1988). The EBV 
genome is amplified 100-1000 fold during the viral productive cycle (Tsurumi et al., 2005). This 
process probably occurs through a rolling circle mechanism involving the formation of long 
head-to-tail concatemers that are cleaved into unit-length DNA genomes and packaged into viral 
capsids (Daikoku et al., 2005; Zimmermann and Hammerschmidt, 1995). Lytic EBV replication 
requires seven EBV proteins including the immediate-early transactivator Zta as well as six early 
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proteins (BALF5, BMRF1, BALF2, BBLF4, BSLF1 and BBLF2/3), that function as the DNA 
polymerase, DNA polymerase processivity factor, the single-stranded DNA binding protein and 
helicase, primase and primase-associated proteins, respectively (Fixman et al., 1995). Zta is 
indispensable for initiating lytic replication by directly binding and activating ZREs within 
promoters of oriLyt (Schepers et al., 1996). Moreover, through binding to oriLyt, Zta is also 
thought to mediate and stabilise interactions between the six EBV early replication proteins to 
form a replication initiation complex at oriLyt (Gao et al., 1998; Tsurumi et al., 2005), from 
which viral replication can proceed. All replication proteins, with the exception of Zta are 
thought to participate at replication forks to synthesize leading and lagging strands of the 
concatameric EBV genome (Tsurumi, 2001).  
 
1.4.8 EBV late genes  
Approximately 40 EBV late genes are transcribed following EBV replication. Expression of 
these genes is prevented by inhibitors of DNA synthesis (Yuan et al., 2006). The late genes 
encode predominantly structural proteins, including six capsid proteins, numerous tegument 
proteins and ten envelope glycoproteins, of which gp350/220 is the most abundant (Johannsen et 
al., 2004). The EBV late proteins function largely in assembly, egress and fusion, of which five 
glycoproteins (gb, gH, gL, gM and gN) are essential, although structural proteins required for 
viral DNA packaging are poorly characterised. The EBV late genes and their functions are 




Table 1-5 EBV late structural proteins and their proposed functions   
Gene Structural protein type Proposed function 
BALF4 Envelope glycoprotein gB/gp110 Fusion 
BBLF1 Myristylated tegument protein anchored in envelope 
Alkaline exonuclease; homologue of 
herpesvirus UL11 
BBRF1 Portal capsid protein  
BBRF2 Tegument protein Unknown function 
BBRF3 Envelope glycoprotein gM Putative role in post-fusion events, part of gM/gN complex 
BcLF1 Major capsid protein Capsid assembly 
BCRF1 Viral interleukin-10  (vIL-10) homologue Protects virus from host response 
BdRF1 Scaffold protein Capsid assembly 
BDLF1 Triplex 2 Capsid assembly 
BDLF2 Putative tegument Unknown function 
BDLF3 Putative envelope glycoprotein gp150 Entry, virus lacking gp150 is more infectious for epithelial cells 
BDLF3.5 Putative tegument Unknown function 
BDRF1 Putative ATPase subunit of terminase putative DNA-packaging protein 
BFRF1A  Unknown function 
BFRF3 Small capsid protein Capsid assembly 
BGLF1 Glycoprotein gp115 DNA packaging 
BGLF2 Tegument protein MyrPBP  
BGLF3.5 Putative tegument protein; Splice Unknown function 
BGLF3 Putative tegument protein,  UL14 homologue Unknown function
 
BGRF1 DNA-packaging protein, putative ATPase subunit of terminase 
BILF2 Membrane glycoprotein gp78/55 Strucutral component 
BKRF2 Glycoprotein L precursor gL/p25 Fusion, attachment to epithelial cell co-receptor, part of gHgLgp42 
BKRF4 Putative tegument phosphoprotein Unknown function 
BLLF1a Envelope glycoprotein gp350 Attachment to complement receptor 2 (CR2, CD21) 
BLLF1b 
Envelope glycoprotein gp220, obtained 
through in-frame splicing from BLLF1   
Membrane glycoprotein gp78/55 
Attachment to complement receptor 2 (CR2, 
CD21) 
BLRF1 Membrane glycoprotein gN Putative role in post-fusion events, part of gM/gN complex 
BLRF2 Tegument  protein p23 Unknown function 
BMRF2 Multiple transmembrane  glycoprotein Unknown function, binds integrins, important for infection of epithelial cells; 
BNRF1 Major tegument protein (MTP) Viral surface protein involved in B lymphocyte binding 
BOLF1 Large tegument protein-binding protein Binding protein 
BORF1 Triplex 1 Capsid assembly 
BPLF1 Large tegument protein Debiquinating enzyme 
BRRF2 Putative tegument protein Unknown function 
BSRF1 Palmitylated tegument protein (PalmP)  
BTRF1 Putative tegument Capsid maturation 
BVLF1 Putative tegument protein Unknown function 
BVRF1 Putative DNA packaging tegument protein; capsid-associated tegument protein Seals DNA inside capsid;
 
BVRF2 Maturational protease Capsid assembly 
BWRF1 Putative tegument Unknown function 
BXLF2 Envelope glycoprotein gH/gp85 Fusion, attachment to epithelial cell co-
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receptor, part of gHgLgp42 complex, 
chaperone for gH 
BZLF2 Envelope glycoprotein gp42; Interaction with HLA Class II co-receptor on B cells, part of gHgLgp42 complex 
BVLF1 Putative tegument protein Unknown function 
 
 
1.4.9 Viral homologues  
In addition, four EBV lytic genes encode cellular homologues to assist EBV replication and 
production of infectious virus and prevent apoptosis of the infected host cell (Fields et al., 2007). 
These include viral interleukin-10 homologue (vIL-10; BCRF1), which functions to protect EBV 
from the host response, two bcl-2 homologues (BHRF1 and BALF1), which function in anti-
apoptosis and a colony stimulating factor 1 (CSF-1) homologue (BARF1) that inhibits the IFN 
alpha response, by mimicking the IFN alpha receptor (Middeldorp et al., 2003).  
 
1.5 EPIDEMIOLOGY OF EBV INFECTION 
The prevalence of EBV-1 and -2 varies depending on geographical location. Over 90% of the 
adult population are infected with EBV worldwide (Henle et al., 1969). EBV-1 is the most 
predominant subtype, particularly amongst healthy South East Asian and Caucasian individuals 
in the Western world where 80-90% are infected and the rest are infected by EBV-2. In contrast, 
EBV-2 is most predominant in equatorial Africa, except for New Guinea where both types are 
prevalent (Fields et al., 2007). In immunocompromised patients such as transplant recipients and 
HIV patients, multiple EBV-1 and -2 subtypes have been demonstrated and the pathogenesis of 
infection for both EBV subtypes is thought to be the same (Gratama and Ernberg, 1995; Rowe et 
al., 1998; Yao et al., 1998; Yao et al., 1991). 
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1.6 PATHOGENESIS OF EBV 
Up to 90% of the world’s adult population become infected by EBV during their life-time (Henle 
et al., 1979). Primary EBV infections are usually acquired following contact with infected saliva 
after which the individual remains a life-long carrier. The epidemiology of EBV is different in 
underdeveloped compared to developed countries. In underdeveloped countries, most individuals 
acquire their primary EBV infection during early childhood with up to 90% of infants infected 
by the age of two and are either asymptomatic or have non-specific symptoms. In developed 
countries where overall hygiene standards are superior, two peaks of EBV infection are seen: (i) 
in pre-school infants and children (1-6 y) and (ii) in adolescents or young adults (15-25 y) 
(Crawford et al., 2006). 
 
1.6.1 Infectious mononucleosis  
Primary EBV infection usually occurs sub-clinically during childhood. However, EBV infection 
during late adolescence or adulthood manifests itself as infectious mononucleosis in 20-75% of 
cases (Crawford, 2001; Crawford et al., 2006; McAulay et al., 2007). Infectious mononucleosis 
is an acute benign self-limiting lymphoproliferative disorder (or immunopathological disease) 
accompanied by fever, pharyngeal inflammation and cervical lymphadenopathy (Hadinoto et al., 
2008; Papesch and Watkins, 2001) and is characterised by a vigorous expansion of activated 
EBV-specific CD8+ T cells (CTLs) circulating during the acute phase (Crawford, 2001; 




1.6.2 The immune response to EBV infection 
CD8+ T cells are the main effectors of the cell-mediated immune response and responsible for 
keeping EBV infection under control, whereas CD4+ T cells are responsible for orchestrating 
virus-specific immune responses and essential for priming as well as maintenance of CD8+ T 
cells (Robertson, 2005). CD4+ T cells are classically divided into T helper (Th) cell subsets, Th1 
and Th2 that elicit Th1 and Th2 responses, respectively (Gamadia et al., 2004). Polarisation of 
CD4+ T cells determines whether a humoral  (Th2) or cell mediated response (Th1) is elicited 
(Robertson, 2005). For instance, Th1 cells secrete effector cytokines, mainly interferon-gamma 
(IFN-γ), resulting in the expansion of CD8+ T cells, effectors of a cell-mediated immune 
response that control EBV infection through cytolytic mechanisms (Maloy et al., 2000; 
Rentenaar et al., 2000). By contrast, Th2 cells are crucial for priming and maintenance of CD8+ 
T cells through secretion of interleukin (IL)-4, IL-5 and IL-6 (Constant and Bottomly, 1997). 
Infectious mononucleosis is associated with a vigorous expansion of activated EBV-specific 
CTLs, consisting primarily of CD8+ T cells directed against epitopes of EBV lytic antigens and 
to a lesser extent (2.5%), against latent epitopes (Callan et al., 1996). Moreover, the symptoms of 
infectious mononucleosis are attributable to cytokines, namely IFN-γ and IL-2 secreted by a Th1 
response (Corsi et al., 2004). Although activated during acute and persistent infection, the 
frequency of CD4+ T cells is much lower than CD8+ T cells. Moreover, CD4+ T cells target 
different latent epitopes than CD8+ T cells (Williams et al., 2004). CTLs also contain significant 
numbers (around 10%) of natural killer (NK) cells that release inflammatory cytokines during 
innate immunity and are largely responsible for the clinical symptoms associated with primary 
infection and the activated Th1 immune response (Robertson, 2005). More recently, regulatory T 
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cells (Treg) have been shown to contribute to the establishment of persistent EBV infection 
(Wingate et al., 2009). 
 
1.6.3 EBV-associated diseases 
Following a primary EBV infection in immunocompetent individuals, EBV remains as a life-
long latent infection of the B cell compartment. However, EBV has the potential to transform B 
cells and epithelial cells leading to the development of several human cancers including Burkitt’s 
lymphoma (BL), Hodgkin’s disease (HL), nasopharyngeal carcinoma (NPC), gastric carcinoma 
(GC), and AIDS-associated lymphomas (AIDS-L) in immunosuppressed individuals (Gulley et 
al., 1996; Kennedy et al., 2003; Liebowitz, 1994; MacMahon et al., 1991; Raab-Traub, 2002; 
Weiss et al., 1989). In addition, post-transplant lymphoproliferative disease (PTLD) is a serious 
complication following allograft transplantation in immunosuppressed individuals and EBV 
infection is implicated in PTLD pathogenesis (Hopwood and Crawford, 2000; Rooney et al., 
1995).   
 
1.7 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE 
 
1.7.1 Overview of PTLD 
PTLD is a B cell lymphoma that is frequently associated with an impaired T cell response in 
haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients who 
receive immunosuppressive drugs to prevent graft versus host disease (GvHD), as well as in 
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patients with acquired immunodeficiency (AIDS) caused by HIV infection (AIDS-related 
lymphoma) (Bhatia et al., 1996; Hopwood and Crawford, 2000). In HSCT, PTLD arises from the 
high dose radiation or myeloablative conditioning regimens used to either cause T-cell depletion 
or prevent graft rejection (Penn et al., 1969). In immunocompetent individuals, CTLs modulate 
the proliferation of EBV latently-infected B lymphocytes. However, in transplant recipients 
receiving immunosuppressants to prevent allograft rejection, this T cell response is impaired 
leading to uncontrolled proliferation of B lymphocytes,  hyperplasia or frank PTLD (Cohen, 
2000). 
 
1.7.2 Classification of PTLD 
PTLD represents a wide spectrum of EBV lymphoproliferative states including both hyperplastic 
and neoplastic entities and is now included in the World Health Organisation (WHO) 
classification of neoplastic diseases (Harris et al., 1997). According to these guidelines, PTLD is 
classified into four subtypes (Table 1.6) based on clinical and histological features: (i) early 
lesions, which include reactive plasmacytic hyperplasias (PH) and infectious mononucleosis-like 
illness PTLD (IM-like PTLD); (ii) polymorphic PTLD (P-PTLD) (including polymorphic 
lymphoma or polymorphic B-cell hyperplasia, which can also be a monoclonal lesion); (iii) 
monomorphic PTLD (M-PTLD) ‘Lymphomatous’ PTLD, also called immunoblastic lymphoma 
or myeloma, that include B-cell neoplasms and T-cell/NK cell neoplasms; and (iv) Hodgkin 
lymphoma (HL) and HL-like PTLD, which are very infrequent. Each type of PTLD is thought to 
represent the different stages of disease progression. Nearly all early PTLDs are polyclonal and 
associated with an EBV infection, whereas M-PTLD and P-PTLD are usually monoclonal, EBV-
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negative and associated with genetic alterations (Table 1.6) (Harris et al., 1997; Knowles et al., 
1995). Early PTLD occurs within the first two years after transplant, frequently in paediatric 
patients and are usually EBV-associated and polyclonal proliferations. Early PTLDs can be 
aggressive and fatal but usually regress in response to reduction in immunosuppression (RIS) 
(Harris et al., 1997). P-PTLD and M-PTLD may also arise soon after transplant, although M-
PTLD tends to occur late. Compared to P-PTLD, M-PTLD is frequently associated with genetic 
alterations of proto-oncogenes and tumor suppressor genes, is highly aggressive and generally 
does not respond well to RIS (Dotti et al., 2002; Harris et al., 1997; Robertson, 2005).  
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 Table 1-6 World Health Organisation Classification of PTLD  
Categories of PTLD EBV status & latency phenotype 






Time from graft  to 
PTLD Incidence Prognosis 
Early lesions Plasmacytic 
hyperplasia (PH), infectious 
mononucleosis-like lesion 
(IM) 
Always EBV positive 
(primary EBV 
infection) Latency III 
Polyclonal None Within 3 months 5% 
Aggressive, 




stage)Polymorphic B cell 
hyperplasia and 
polymorphic B cell 
lymphoma 
Always EBVpositive 
Latency II and III 
Polyclonal or 
monoclonal None Variable 15-20% 
Variable response 
to RIS 
Monomorphic B cell 
lymphomas: Diffuse large B 
cell lymphoma (DLBCL), 
Burkitt’s lymphoma or 
Burkitt’s-like lymphoma 
(BL) and myeloma or 
plasmacytoma-like lesions 
Monomorphic T-cell 











mutations in p53, Ras, 
or c-myc. 
3 months to 2 year 













positive Monoclonal None 3.5 – 7 year <5% ? 
EBV, Epstein-Barr Virus; PTLD, post-transplant lymphoproliferative disorder; ;RIS, reduction in immunosuppression; IgVH, immunoglobulin V heavy chain; TCR, T-cell  
receptor; Adapted from Harris et al. 1997 and Trappe et al. 2006
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1.7.3 EBV and PTLD 
Up to 90% of PTLD cases are EBV positive and express the latency III programme, although 
more restricted (heterogeneous) latency patterns have been found at the single cell level 
(Brink et al., 1997; Paya et al., 1999; Siemer et al., 2008; Young et al., 1989). However, cases 
(23-42%) of EBV-negative PTLDs have also been demonstrated (Leblond et al., 1998; 
Nelson et al., 2000). PTLDs are rare and usually fatal when diagnosed late. Nearly all cases 
of PTLD are of B cell origin (Allen et al., 2001). In addition, most are of recipient origin in 
SOT recipients, usually from reactivated EBV and of donor origin in HSCT recipients 
(Baumforth et al., 1999). However, in paediatric SOT recipients, in particular liver transplant 
recipients, PTLDs are usually associated with primary EBV infection acquired from the 
donor organ (Capello et al., 2009). PTLD usually develops within the first six months post 
transplant (Curtis et al., 1999). Although the reason for PTLD is unclear, it is likely that any 
factor that reduces T-cell immunity and increases B cell proliferation could precipitate the 
condition (Siemer et al., 2008).  
 
1.7.4 Origin of PTLD 
One theory for the origin of PTLD is based on the hypothetical model of latent EBV 
persistence (Figure 1.5)(Thorley-Lawson and Gross, 2004). Thorley-Lawson et al. propose 
that EBV would normally use the growth programme to differentiate into resting memory B 
cells and any B cells unable to exit the cell cycle would be targeted by EBV-specific CTLs. 
Based on the model of EBV persistence, EBV lymphomas such as PTLD would arise when 
so-called ‘by stander B cells’ (naive B cells in HD and BL) are infected by EBV and unable 
to exit the germinal centre as resting memory B cells (Robertson, 2005; Thorley-Lawson and 
Gross, 2004). EBV normally infects and activates naive or primary resting B cells to become 
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proliferating lymphoblasts that differentiate into memory cells and exit the cell cycle, without 
progression to PTLD. This is irrespective of the immune status since PTLD tumours that 
arise are not derived from naive B cells. Therefore, Thorley-Lawson et al. suggest that PTLD 
may arise when B cell types, other than naïve B cells, known as bystander cells are infected 
by EBV by chance and driven into the growth programme. An alternative theory is that B 
cells derived from the germinal centre (GC) or memory B cells could express the growth 
programme and, unable to exit the cell cycles proliferate into PTLD in the absence of an 
effective T-cell response. Moreover, EBV-seronegative recipients are at increased risk for 
PTLD since EBV DNA loads are elevated during primary EBV infection increasing the 
likelihood of EBV infection of bystander B cells (Robertson, 2005; Thorley-Lawson and 
Gross, 2004). Therefore, PTLD can arise in a rare event when EBV transforms bystander B 
cells into proliferating lymphocytes in the presence of an impaired T-cell immune response 
that cannot eliminate these rare B cells (Siemer et al., 2008).  Recently, it has been confirmed 
that PTLD, in particular late PTLD, is derived from B cells that have experienced the GC 
reaction, whose development is the result of accumulating genetic alterations of proto-
oncogenes and several tumour-suppressor genes, namely c-MYC, BCL-6 and p53 (Cesarman 
et al., 1998; Vakiani et al., 2008). The genetic alterations of proto-oncogenes involve aberrant 
somatic hypermutation (ASHM), targeting immunoglobulin variable genes (IgV) (Capello et 
al., 2003; Cerri et al., 2004; Timms et al., 2003). Moreover, ASHM is demonstrated almost 
exclusively in M-PTLD. Notably, about 50% of PTLDs express a functional surface B cell 
receptor (BCR) as a result of ASHM (Brauninger et al., 2003; Timms et al., 2003). EBV is 
thought to rescue these abnormal BCR-deficient B cells from apoptosis, by substituting two 
of its latent apoptotic proteins LMP1 and LMP2A for the BCR, enabling progression to 
PTLD (Bechtel et al., 2005).   
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1.7.5 Incidence and risk factors for PTLD  
The cumulative incidence of PTLD is much lower in HSCT recipients (0.5-1%) compared 
with SOT recipients (1-20%) and highest within the first six months post-transplant for both 
groups (Curtis et al., 1999). Risk factors for SOT include EBV serostatus pre-transplant, 
primary EBV infection, transplant type, intensity of immunosuppression, CMV co-infection, 
length of post-transplant follow-up and transplant age independent of EBV serostatus 
(Beveridge et al., 1984; Cox et al., 1995; Walker, 1995; Walker et al., 1995). Internationally, 
the incidence of PTLD varies widely according to the transplant type with highest rates 
reported for lung and small bowel (10-20%), followed by heart or heart-lung (heart 2-10%, 
lung 4-8%), and liver (2-8%) and lowest for kidney transplant recipients (2%) (Jain et al., 
2002; Leblond and Choquet, 2004; Opelz and Dohler, 2004). The incidence also varies 
according to the different immunosuppressive regimens used (Penn, 1991). In addition, 
length of time post-transplant is another risk factor; the cumulative risk of PTLD shows a 
gradual increase in the first two (10%), five (30%) and over five years (60%) post-transplant 
(Dotti et al., 2002). However, EBV seronegativity pre-transplant is considered to be the most 
important risk factor for PTLD, since patients acquire a primary EBV infection immediately 
after transplant. Paediatric patients, of which 90% are seronegative at transplant, are at 
particular risk, where PTLD accounts for 52% of cases (Ho et al., 1988; Holmes and Sokol, 
2002). The incidence of PTLD is highest in some paediatric series compared with adults (2-
3% versus 10%) (Jain et al., 2002; Leblond and Choquet, 2004). The incidence is also 
greatest in the first 3 months post-transplant (Katz et al., 2007). Moreover, primary EBV 
infection, not reactivation, is considered a greater risk factor (Allen et al., 2005; Benden et 
al., 2005; Ho et al., 1988; Scheenstra et al., 2004). Cytomegalovirus (CMV) seronegativity 
pre-transplant is also associated with an increased risk for PTLD (Manez et al., 1994). Major 
risk factors for allo-SCT recipients include T-cell depletion, age (≥50 years), specific anti-
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lymphocyte therapy for Graft versus host disease (GvHD) and human leukocyte antigen 
(HLA)  mismatch  (related and unrelated) (Baumforth et al., 1999; Curtis et al., 1999; Zutter 
et al., 1988). The incidence increases up to 22-24% when two or more risk factors are 
involved (Curtis et al., 1999; Rooney et al., 1998). In patients with no risk factors a 
cumulative incidence of 0.2% versus 8.1% for patients with three or more risk factors has 
been reported (Landgren et al., 2009). In allo-SCT recipients, the recipient’s age, EBV-
seronegative status and underlying disease are not major risk factors for PTLD, as they are 
for SOT recipient’s (Landgren et al., 2009).  
 
1.7.6 Clinical features of PTLD 
The clinical features of PTLD are often non-specific and include fever, sweats, generalised 
malaise, enlarged tonsils, and cervical lymphadenopathy or sepsis-like syndrome with rapidly 
progressing lymphoma (Shroff and Rees, 2004). In recipients who have acquired a primary 
EBV infection, the symptoms are more distinct and closely resemble infectious 
mononucleosis. PTLD may affect any organ including the central nervous system (CNS), 
bone marrow, intestine, kidneys, liver, spleen and lungs. Often diffuse disease is diagnosed 
only at autopsy in patients thought to have sepsis or GvHD (McWilliams et al., 2006). 
Therefore symptoms of PTLD appear diverse and often occur simultaneously, making an 
accurate diagnosis difficult. For this reason, histological investigations are required to 
differentiate IM from PH and other neoplasm’s (Shroff and Rees, 2004). PTLD can be 
successfully treated with reduction of immunosuppression to reconstitute the immune system. 
Other treatment options include antiviral therapy, use of anti-B-cell monoclonal antibody 
such as Rituximab®, interferon-alpha (IFN-α), radiation therapy, chemotherapy and more 
recently, cytotoxic T cell therapy is being investigated as both prophylactic and therapeutic 
measures (Loren et al., 2003). 
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1.8  DIAGNOSIS OF PTLD   
The heterogeneous and extranodal presentation of PTLD can make its diagnosis extremely 
difficult. During the early signs and symptoms of PTLD, imaging techniques are used to 
localise the tumour. In addition, B cell clonality tests, serology and, more recently, 
polymerase chain reaction (PCR) for early diagnosis further aid PTLD diagnosis (Cohen, 
2000; Gulley and Tang, 2008).   
 
1.8.1 Histology                         
Histopathological analysis of tissue biopsy for morphological features remains the principle 
method for determining a definitive diagnosis of PTLD and moreover, for distinguishing the 
different subtypes of PTLD. For histopathological analysis, light microscopy is used to 
examine infiltrates of lymphocytes for morphological changes. Moreover, 
immunohistochemistry (IHC) and in-situ hybridisation (ISH) are essential for detecting EBV 
infections, usually by EBV latent antigen expression in the tumour biopsy (Gulley and Tang, 
2008). IHC usually involves flow cytometry, western blot and enzyme-linked immunosorbent 
assays (ELISA) for detection of antibodies against LMP-1 or EBNA-2 antigens, whereas ISH 
is a highly sensitive technique that typically stains for EBV-encoded RNAs (EBERs) to 
confirm EBV-associated PTLD (Gulley and Tang, 2008; Lones et al., 1997). 
 
1.8.2 Immunophenotyping and molecular analysis 
B cell clonality tests are useful but not essential for classification of polyclonal or monoclonal 
PTLD and are based on determination of cell surface heavy and light chain Ig expression. In 
addition, abnormal cells may be positive for B-cell markers (CD19, CD20, CD21 and CD22). 
Although highly specific for PTLD diagnosis, the techniques involved are not available in all 
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transplant centres (Preiksaitis and Keay, 2001). Following the interpretation of 
histopathological, immunophenotyping and molecular analysis, patients are classified into 
one of four PTLD subtypes according to WHO criteria (Table 1.6)  (Harris, 1997).  
 
1.8.3 Serology 
Serology is performed by measuring IgG antibodies to the EBV viral capsid antigen (VCA), 
early antigen (EA) and the EBV nuclear antigen (EBNA). In immunocompetent individuals, 
primary EBV infection results in seroconversion and the detection of VCA IgM, IgG and 
early antigen (EA-D) antibodies which defines acute EBV infection. While IgM only lasts a 
few months, IgG remains for life. Antibodies to EBNA develop late in infection during 
convalescence and also persist for life. The absence of all antibodies defines no EBV 
infection and is seen in EBV-seronegative individuals. Serology has limited use in PTLD 
diagnosis for a number of reasons including the lack of detectable antibodies. For instance,  
EBNA-1 IgG is not detected during acute infection in persistently immunosuppressed 
patients (Cen et al., 1993; Preiksaitis and Keay, 2001). Further, in EBV-seropositive patients, 
declining EBNA-1 IgG correlates with elevated EBV DNA loads and PTLD development 
(Preiksaitis et al., 1992; Preiksaitis and Keay, 2001; Riddler et al., 1994). It is however the 
standard approach for diagnosis of a primary EBV infection in previously EBV-naive 
individuals, although it is useful for predicting the risk of developing PTLD, which is greatest 
in EBV-seronegative recipients. 
 
1.8.4 Early diagnosis of PTLD 
Early diagnosis of PTLD is crucial for a successful outcome by enabling prompt therapeutic 
interventions (Gulley and Tang, 2008). While PTLD is traditionally diagnosed by histology, 
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several newer approaches have been employed for the early diagnosis of PTLD including: (i) 
Detection of  IgM-related protein in serum and urine of patients with PTLD using 
monoclonal antibody tests (Badley et al., 1996); (ii) Detection of CD19+ B cells in the 
peripheral blood of PTLD versus non-PTLD patients; and (iii) more encouragingly, the use of 
polymerase chain reaction (PCR) for the serial monitoring of EBV DNA loads in clinical 
samples of patients at high risk of PTLD (Preiksaitis and Keay, 2001).  
 
1.8.4.1 Polymerase chain reaction for viral load monitoring 
EBV DNA is considered to reflect EBV-induced B-cell proliferation and EBV DNA levels in 
PBMCs, plasma or whole blood has been proposed as a means of identifying SOT or HSCT 
recipients at risk of PTLD (Baldanti et al., 2000; Thorley-Lawson and Gross, 2004). PCR is a 
highly sensitive method for quantifying viral loads and differentiating healthy low-level viral 
load carriers from high-viral load carriers at risk of disease (Gulley and Tang, 2008). A 
number of methods have been developed to quantify EBV DNA levels in peripheral blood, 
including semi-quantitative PCR (Green et al., 1998; Gustafsson et al., 2000; Lucas et al., 
1998; Riddler et al., 1994; Rowe et al., 1997; Rowe et al., 2001; Savoie et al., 1994), end-
point dilution (Kenagy et al., 1995; Riddler et al., 1994), quantitative competitive PCR (Bai 
et al., 1997; Baldanti et al., 2000; Rowe et al., 1997; Stevens et al., 2001; Stevens et al., 1999; 
Yang et al., 2000), and more recently, real-time quantitative PCR (Jabs et al., 2001; Kimura 
et al., 1999; Niesters et al., 2000; Wagner et al., 2001). Real-time PCR assays enable rapid 
virus detection in a closed system, with high sensitivity and low contamination due to 
removal of post-amplification detection procedures (Gulley and Tang, 2008).  
EBV DNA viral load monitoring is widely used in transplant centres not only for routine 
monitoring, but for early diagnosis and pre-emptive therapy before overt EBV-associated  
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PTLD develops (Holmes et al., 2002). A number of studies have demonstrated a correlation 
between high viral loads in the peripheral blood that precede the development of PTLD 
(Baldanti et al., 2000; Gartner et al., 2002; Hoshino et al., 2001; Kenagy et al., 1995; Lucas et 
al., 1998; Riddler et al., 1994; Savoie et al., 1994; Wagner et al., 2002; Wagner et al., 2001). 
However, others have previously shown that increased viral loads alone do not always 
precede PTLD (Hopwood et al., 2002; Lucas et al., 1998; Savoie et al., 1994), particularly in 
SOT recipients (Dolcetti, 2007).  In general, PTLD in the paediatric cohort is associated with 
very high viral loads in the peripheral blood that often precede onset of clinical symptoms 
(Green et al., 1998; Kenagy et al., 1995; Lucas et al., 1998; Scheenstra et al., 2004). These 
viral loads decline when PTLD regresses in response to therapy (Lee et al., 2005). 
Furthermore, recent findings from serial viral load monitoring have identified two groups of 
patients with viral loads that do not correlate with the onset of PTLD: (i) those with chronic 
high viral loads (Gotoh et al., 2010; Green and Webber, 2007; Qu et al., 2000; Rowe et al., 
1997) and (ii) those with persistently low viral loads (Green et al., 2000). In the latter study, 
persistently low viral loads within the first six months post-transplant were suggested as 
predictive markers for PTLD in paediatric intestinal transplant recipients since none of the 
recipients developed PTLD (Green et al., 2000). Therefore, although high viral loads are 
sensitive for the early diagnosis of PTLD they are not always specific (Green and Webber, 
2002). Moreover, viral loads should not be used exclusively for early diagnosis of PTLD 
(Scheenstra et al., 2004). This together with the lack of standardisation in the assays and 
extraction methods used has made comparisons between viral loads amongst transplant 
centres difficult, particularly when determining a predictive cut-off level (Dolcetti, 2007). 
Therefore alternative markers are required.  
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1.8.4.2 Alternative early predictive markers of PTLD 
Although useful in the pre-emptive management of PTLD, the use of EBV viral load alone in 
the early diagnosis of PTLD is insufficient and additional monitoring tests are required to 
improve their specificity and positive predictive value in PTLD in paediatric and adult SOT 
and HSCT recipients (Gartner and Preiksaitis, 2010). Several approaches have been 
investigated including measuring T-cell responses associated with elevated EBV viral loads 
(Clave et al., 2004; Meij et al., 2003; Sebelin-Wulf et al., 2007; Smets et al., 2002). One of 
these studies showed an association between impaired recovery of CD8+ T cells and viral 
load and risk for EBV reactivation and PTLD (Meij et al., 2003). Other markers for PTLD 
that could aid PTLD diagnosis include measuring EBV gene expression, marked 
hypergammagobulinaemia, serological measurement of responses to EBV EA, measurement 
of T cell responses such as host cytokines IL-10 and IL-6, as well as host gene 
polymorphisms (Lee et al., 2006; Randhawa et al., 1995; Tosato et al., 1993), and serum IgE.  
Further, elevated EBV DNA loads in the presence of reduced immune responses were for the 
first time, shown to be more reliable predictors for PTLD, especially within high-risk EBV 
seronegative patients (Smets et al., 2002). Given that there is no absolute correlation between 
EBV viral load and PTLD development at the moment, measuring EBV gene expression in 
association with high EBV viral loads has been suggested as a potential approach (Rowe et 
al., 1998). The role of EBV in the pathogenesis of PTLD is unclear. Latent EBV infection is 
predominant in PTLD, in particular EBV latency III patterns are frequently associated with 
PTLD biopsy tissue and known to drive B-cell proliferation (Brink et al., 1997; Thorley-
Lawson and Gross, 2004; Young et al., 1989). However, relatively little is known about the 
role of EBV lytic genes in PTLD development (Rowe et al., 1998). The demonstration of 
EBV lytic gene expression in tumour biopsies, suggests a role for EBV lytic replication and 
PTLD development (Montone et al., 1996; Niedobitek et al., 1997b; Oudejans et al., 1995; 
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Rea et al., 1994b). Therefore, analysis of host cellular gene expression together with EBV 
latent/lytic gene expression in relation to elevated EBV viral loads would provide additional 
information to help identify sensitive yet specific novel predictive markers of PTLD and 
possibly a predictive cut-off level.  
 
1.8.4.3 Early diagnosis of PTLD at King’s College Hospital 
In particular, the identification of early PTLD markers would benefit two transplantation 
cohorts at King’s College Hospital (KCH): the paediatric solid organ transplant (SOT) 
recipients and adult umbilical cord blood transplant (UCBT) recipients. KCH is a leading 
institute for transplantation in the UK and one of the largest transplant centres in Europe, 
undertaking 160 transplants each year. Around 60 paediatric liver transplants and 20 adult 
UCBT are performed a year, for the treatment of acute liver failure and haematological 
malignancies such as leukaemia, respectively. As a result, the incidence of PTLD is 
increasing and early diagnosis is highly desirable to improve patient survival and prevent 
graft loss in these cohorts. Therefore, the availability of diagnostic tests to accurately identify 





1.9 AIMS OF STUDY 
 
The aims of this study were to identify novel EBV and cellular gene markers that could be 
used to develop improved diagnostic assays for the early detection of PTLD. In order to 
identify these markers, the following three experimental approaches were undertaken:  
(i) To identify highly induced EBV genes by analysing the expression of 88 EBV 
genes during the latent-lytic switch in the Raji cell line (an in vitro model system) 
using   real-time RT-PCR with SYBR green based detection (Chapter 3) 
(ii) To identify highly differentially regulated and expressed cellular genes in response 
to the EBV lytic induction phase in Raji cells, using Affymetrix human genome 
U133 Plus 2.0 GeneChip® arrays (Chapter 4) 
(iii) To develop and validate real-time TaqMan PCR assays for the detection of EBV 
and cellular gene expression in whole blood samples from PTLD and non-PTLD 
transplant recipients, and to determine associations between gene expression levels 








2 CHAPTER 2. MATERIALS AND METHODS 
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2.1 Suppliers and Manufacturer’s 
 
American Tissue Culture Collection, LGC standards, Teddington, Middlesex, UK 
Sigma-Aldrich  Company Ltd, Dorset, England, UK 
Invitrogen Ltd, Paisley, UK 
Hettich Zentrifugen, Buckinghamshire, UK 
QIAGEN Fleming Way, Crawley, UK 
Ambion Huntingdon, Cambridgeshire, UK 
LabTech International Ltd Acorn House, The Broyle, Ringmer, East Sussex, UK 
VWR International Merck House, Poole, Dorset, UK 
Applied Biosystems Warrington, UK 
Amersham Biosciences, UK Ltd 
Metabion International AG, Lena-christ-str, Martinsried, Germany  
Advanced Biotechnologies Ltd Abgene House, Bleinhem Road, Epsom, Surrey, UK 
Bio-Rad Laboratories Ltd Bio-Rad, Hemel Hempstead, Hertfordshire, UK  
Agilent Technologies UK Ltd  Berkshire, UK 
Affymetrix UK Ltd High Wycombe, UK 
STAR LAB Ltd Milton Keynes, UK 
Sarstedt Ltd 68 Boston Road, Beaumont Leys Leicestershire 
SANYO Biomedical Europe  
 
2.2 Materials (Equipment/Reagents/Plastic ware) 
 
2.2.1 Equipment and instrumentation 
 
Agilent® 2100 Bioanalyser (Agilent) 
CO2 incubator (SANYO MCO-17AIC)    
GeneAmp® PCR system 9700 (Applied Biosystems) 
GeneChip® scanner 3000 7G (Agilent) 
Hettich Rotina 420R centrifuge (Hettich Zentrifugen, Cat. No. 4701) 
Hettich haematocrit 210 centrifuge (Hettich Zentrifugen, Cat. No. 2104) 
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HG U133 Plus 2.0 GeneChip® (Affymetrix) 
Magnetic stand-96 (Ambion P/N AM10027) 
NanoDrop ND-8000™ Spectrophotometer (LabTech) 
Perkin Elmer thermal cycler, PTC-225 (Applied Biosystems)  
Rotorgene 6000™ (Qiagen)  
Vortex mixer (STAR LAB) 
 
2.2.2 Cell culture reagents 
2-mercaptoethanol (Sigma-Aldrich Cat.No. M-7522) 
Buffer RLT lysis buffer (Qiagen Cat. No. 79216) 
Dimethyl sulphoxide (DMSO) (Sigma-Aldrich Cat. No. D2650) 
Ethanol (Sigma-Aldrich Cat. No. 200-578-6) 
Foetal Bovine Serum (FBS) (Sigma-Aldrich Cat. No. F2442-100ML) 
Hanks’ balanced salt solution (HBSS) (Sigma-Aldrich Cat. No. H9269) 
L-glutamine (Sigma-Aldrich Cat. No. G7513) 
Penicillin-Streptomycin solution (PSS) (LGC Promochem Cat. No. 30-2300) 
Phorbol 12-myristate 13-acetate (PMA/TPA) (Sigma-Aldrich Cat. No. 79350-1MG) 
Phorbol 12-myristate 13-acetate 1 mg/ml (Sigma-Aldrich Cat. No. 79346-1MG) 
Phosphate buffered salt solution pH 7.2 (Invitrogen Cat. No. 20012-027) 
Raji cell line (LGC Promochem Cat. No. ATCC-CCL-86™) 
Ramos cell line (LGC Promochem Cat. No. ATCC-1596™) 
RPMI-1640 medium 1X 500 ml (Invitrogen Cat. No. SKU#21875-091)  
Sodium butyrate (SB) ≥99.0% (Sigma-Aldrich Cat. No. 19364-250MG) 
Synth-a-Freeze® Cryopreservation Medium (Invitrogen GIBCO Cat. No. R-005-50) 
Trypan Blue 0.4% solution (Sigma-Aldrich Cat. No. T8154)  
 
2.2.3  PCR and molecular reagents 
 
1 Kbp DNA ladder (Invitrogen Cat. No. 15615-016) 
RNase-free DNase Set (DNASE70-SET) (Qiagen Cat. No. 79254) 
EBV B95.8 quantitated viral DNA control (Autogen Bioclear Cat. No. 08-926-000) 
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Ethidium bromide, 10 mg/ml (Invitrogen Cat. No. 15585-011) 
High Capacity cDNA Reverse Transcription kit (Applied Biosytems Cat. No. 4368814) 
iQ SYBR Green Supermix (Bio-Rad Cat. No. 170-8884) 
QIAshredder™ (Qiagen Cat. No. 79564) 
Molecular grade water (Sigma-Aldrich Cat.No. 95284-100ML) 
RETROSCRIPT® kit (AMBION Cat. No. AM1710) 
RNeasy® Mini kit (Qiagen Cat. No. 74104) 
Sterile RT-PCR grade RNase free water (Ambion Cat No. AM9935) 
TaqMan® Gene Expression Assays (Applied Biosystems)  
TaqMan® Gene Expression Master Mix (Applied Biosystems Cat.No. 4369016) 
Tris-ethylamine diamine (TE) buffer solution pH 8.0(Sigma-Aldrich Cat.No. 93283) 
Tris-borate Ethylamine (TBE) buffer 10X concentrate (Sigma-Aldrich Cat.No. T4415-1L) 
Whole blood RNA extraction kit (Qiagen Cat.No. 52304) 
UltraPure™Agarose (Invitrogen Cat.No. 16500-500) 
QIAamp® RNA Blood Mini Kit (Qiagen Cat. No. 52304) 
Message AmpTM Premier RNA amplification kit (Ambion, Cat.No. AM1792) 




Conical tubes 15 ml; Conical tubes 50 ml (Ambion Cat.No.AM12500 ; Cat.No. AM12501) 
Freezing-container Nalgene® Mr.Frosty (Sigma-Aldrich Cat.No. C1562) 
Hemocytometer (VWR International Cat.No.720-0585) 
Nuclease-free filter tips (STAR LAB UK Ltd Cat.Nos.S1121-3810 (0.1-10µl); S1120-1810 (1-20µl); 
S1120-8810 (1-200µl); S1122-1830 (101-1000µl) 
Nunc® cryo tube vials (Sigma-Aldrich Cat.No. V7384-ICS) 
RNase free microfuge tubes (Ambion Cat.No. AM12400) 
Rotor-gene PCR tubes 0.1 ml (Qiagen Cat.No. 981103) 
Sarstedt polypropylene microcentrifuge tubes 1.5 ml (Sigma-Aldrich Cat.No.72692) 
Serological pipette sterile 10 ml, Ind. Wrapped 200 (STAR LAB Cat.No. E4860-1011) 
Sterile graduated Pasteur pipettes 3 ml (VWR International Cat.No. 612-1747) 
Tissue culture flasks T75 cm3 (VWR Cat.No. 202-0200) 
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2.3 EBV GENE EXPRESSION ANALYSIS 
 
2.3.1 Cell culture   
 
2.3.1.1 Cell lines 
Raji is an EBV-positive human B-cell line derived from Burkitt’s lymphoma cells following 
infection of peripheral blood mononuclear cells (PBMCs), and is defective for DNA 
replication and late antigen expression (Pulvertaft, 1964). Ramos is an EBV-negative 
Burkitt’s lymphoma cell line that is frequently used as a negative control. Cell lines were 
obtained from the American Tissue Culture Collection (ATCC). Raji (ATCC; CCL-86) and 
Ramos (ATCC; CCL-1596) cell lines were cultured in RPMI 1640 (Sigma-Aldrich) 
supplemented with L-glutamine 2 mM, 10% heat-inactivated foetal calf serum (Sigma-
Aldrich) and 100 International Units (IU) penicillin/ml and maintained in a 5% CO2 
incubator at 37ºC. Cell lines were maintained in 75 cm3 tissue culture flasks (VWR 
International) at a density of 3.5 x 105 cells/ml. Cells were split every 2-3 days at dilutions of 
1/3. Cell viability was assessed using trypan blue (Sigma-Aldrich) exclusion as described in 
section 2.3.1.2. 
 
2.3.1.2 Cell counts using Trypan Blue exclusion 
Cell counts were performed using the trypan blue exclusion method described in ‘‘Cell 
Culture Manual’’ (Sigma-Aldrich). Briefly, cell suspensions were prepared by mixing 200 µl 
of cell culture, 300 µl of Hank’s buffered salt solution (HBSS) and 500 µl of 0.4% trypan 
blue w/v (Sigma-Aldrich) and allowed to stand for 15 minutes before transfer to both 
chambers of the hemocytometer (VWR). The average number of cells in all five counting 
chambers was counted and multiplied by a dilution factor of five to determine (i) the number 
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of cells counted per ml of cell culture and (ii) the total number of cells in a 10 ml tissue 
culture volume.  
 
2.3.1.3 Cryopreservation of cells 
Cell stocks for Raji and Ramos cells were cryopreserved for later use. Cells were first 
counted using trypan blue exclusion (see section 2.3.1.2) and reseeded to a density of 3 x 105 
cells per ml of cell culture. Cells were centrifuged at 500 x g for 5 min and re-suspended in 1 
ml freezing media (10% dimethyl sulphoxide (DMSO) and 90% v/v foetal calf serum (FCS); 
(Sigma-Aldrich) prior to transfer into pre-cooled 2 ml cryovial tubes. Cryovials were 
transferred immediately to -80ºC for overnight storage and transferred to liquid nitrogen for 
long-term storage.  
 
2.3.1.4 Lytic cycle induction 
For lytic cycle induction, Raji and Ramos cells were reseeded on day 1 at densities of 5x105 
cells per ml and induced 24 hrs later at a density of 1x106 cells per ml with 12-O-
tetradecanoyl-13-phorbol acetate (TPA) (Sigma-Aldrich) and sodium butyrate (NaB) (Sigma-
Aldrich) at final concentrations of 30 ng/ml and 2mM, respectively. Duplicate cell culture 
flasks were set up for induced Raji and Ramos cultures, harvested at 0, 2, 6, 24 and 48 hrs 
post-induction. Duplicate flasks were also set-up for uninduced Raji and Ramos cells at the 
same time-points.   
 
2.3.1.5 Cell harvesting 
Cells were harvested at 0, 2, 6, 24 and 48 hrs. Briefly, 10 ml of cell culture was transferred 
using sterile 10 ml pipettes (StarLab) from each tissue culture flask into sterile RNase-free 15 
ml centrifuge tubes (Ambion). Cell cultures were centrifuged at 500 x g for 5 min and cell 
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pellets re-suspended in 600 µl of RLT buffer (Qiagen) with 10% v/v 2-mercaptoethanol 
(Sigma-Aldrich) and the cell lysate vortexed for a minimum of 15 s or until the cell pellet 
was no longer visible. Cell lysates were transferred immediately to -80ºC for up to 1 month 
until RNA extraction.  
 
2.4 Molecular Methods 
 
2.4.1 Total RNA Extraction   
Total RNA was prepared from induced and uninduced Raji and Ramos cells at the various 
time-points: 0, 2, 6, 24 and 48 hrs and extracted using the RNeasy® Mini Kit (Qiagen), 
according to manufacturer’s instructions. Briefly, frozen cell lysates were thawed during 5 
minute incubation in a 37°C water bath prior to cell homogenisation and RNA extraction. 
Cells lysates were transferred to QiaShredder columns (Qiagen) and centrifuged at 22,130 x g 
for 2 min. Total RNA was extracted from the homogenised lysates using the RNeasy® Mini 
extraction kit (Qiagen), according to the manufacturer’s instructions. Briefly, equal volumes 
(600 µl) of 70% ethanol (Sigma-Aldrich) were added to the homogenised lysates and mixed 
well by pipetting. Six hundred microlitres of the lysate was transferred to QIAamp mini spin 
columns and centrifuged at 11,290 x g for 1 min and the supernatant discarded. The 
remaining 600 µl was transferred to the same QIAamp mini spin column, re-centrifuged as 
before and the supernatant discarded. Six hundred microlitres of RW1 wash buffer was 
applied to the spin column and the spin column centrifuged at 11,290 x g for 1 min and the 
collected supernatant discarded. Contaminating genomic DNA was eliminated by an on-
column DNase digestion after the first RW1 wash and prior to the first RPE elution step using 
the RNase-free DNase Set (Qiagen). Briefly, 70 µl of DNase I buffer (Qiagen) was mixed 
with 10 µl of DNase I stock (Qiagen) and 80 µl of the DNase mixture applied to the QIAamp 
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mini spin column for on-column DNAse digestion during a 15 min incubation at room 
temperature. Residual DNase I was then eliminated from the column following a second 
RW1 wash step by centrifugation at 11,290 x g for 1 min and the supernatant discarded. An 
additional centrifugation step at 22,130 x g was performed prior to the first elution step to 
remove all residual RW1 wash buffer. Next 60 µl of RPE elution buffer was applied to the 
spin column and centrifuged for 11,290 x g and total RNA eluted into new RNase free 
collection tubes and aliquots transferred immediately to -80ºC for storage prior to reverse-
transcription. 
 
2.4.2 Quantification of total RNA 
The concentration (ng/µl) and purity of total RNA was determined at an absorbance of 
260/280 nm using a NanoDrop ND-8000™ spectrophotometer (LabTech International).   
 
2.4.3 Reverse Transcription 
 
Two micrograms of total RNA was reverse-transcribed into cDNA using the RETROscript® 
Kit (Ambion) according to the manufacturer’s instructions. Briefly, prior to reverse 
transcription, 12 µl reactions were set-up consisting of 2 µg total RNA and 2 µl of random 
decamers (50 μM) and the mixture heat-denatured at 75 ºC for 3 minutes in a water bath. The 
reaction mix was transferred immediately to ice for 5 min, centrifuged briefly and returned to 
ice. Following heat denaturation of RNA,  8 µl reaction mixes were set-up on ice consisting 
of 10X RT buffer, dNTP mix (2.5 mM each dNTP), 10 U/µl RNase inhibitor (RNase I) and 
100 U/µl of Moloney-murine leukaemia virus reverse transcriptase (MMLV-RT) and applied 
to the previous 12 µl reaction mix. Reverse transcription was carried out in 20 µl reactions in 
a water bath at 42ºC for 1 hr and reverse transcriptase inactivated with a final incubation at 
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92ºC for 10 min. All cDNAs were diluted 1/10 with sterile nuclease free water (Qiagen) and 
cDNA aliquots transferred immediately for storage at -20ºC until real-time  PCR analysis. 
 
2.4.4 Quality controls for total RNA 
The presence of residual genomic DNA in the total RNA extract was evaluated by 
performing a minus RT-reaction (minus M-MLV RT) as described in section 2.4.3 with the 
RT-enzyme substituted by sterile RNase-free water (Ambion), followed by PCR 
amplification using the programme described in section 2.4.7. All ‘minus RT’ controls were 
carried out with 2 µg total RNA.   
 
2.4.5 Primer sequences for real-time PCR gene expression analysis 
Eighty-nine EBV genes of known open reading frames (ORFs), were investigated for gene 
expression analysis and cDNAs derived from these genes amplified by real-time PCR. Of the 
89 genes, seven were splice variants (BBLF2/BBLF3, BGRF1/BDRF1, EBNA3B/3C and 
BWRF1. PCR primer sequences for 78 of 89 transcripts including the single copy 
housekeeping gene, Beta-actin (ACTB) were obtained from the literature (Pan et al., 2005). 
Three of the 89 published primer sets LMP-2A (previously LMP-2); BKRF2 (previously 
gp25) and (BSMLF1) (previously BSLF1 and BMLF1) were redesigned using the Invitrogen 
Oligo Perfect™ Designer software (Invitrogen, UK) for newly available GenBank sequences 
of the EBV-1 genome (Accession number NC_007605) found at the National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nih.gov). PCR primers were 
subsequently designed using the Invitrogen design software for a further seven genes 
(A73/RPMS1, BDLF3.5, BFRF1A, BGLF3.5, LF1, LF2 and LF3) and an additional primer set 
for BARF0 was published (Kienzle et al., 1998) to encompass the entire EBV-1 genome 
(Accession number NC_007665). Criteria for primer design consisted of: Tm of 58-60 °C, 
 70 
18-30 bp length, and 20-80% GC content. Primer sequences for all 89 EBV genes and ACTB 
are shown in Table 2.1. The product length (bp) ranges from 57-289 bp. All primer sequences 
were obtained from Metabion International. Of note, BERF1 (also known as EBNA-3A) was 
subsequently excluded from gene expression analysis. In addition, primer pairs for the fifteen 
overlapping genes were excluded from further analysis. 
 
2.4.6 Real-time PCR for validation of primer specificity 
All 89 primer pairs were validated for EBV amplification by PCR as described below using 
control DNA from the EBV strain B95-8 (Advanced Biotechnologies, Cat. No. 08-702-000), 
cDNA from induced Raji cells and gDNA from induced EBV-negative Ramos cells. PCR 
was carried out using the following PCR reaction and PCR programme described below. 
Real-time PCR analysis was performed using a Rotor-Gene 6000TM real-time instrument 
(Qiagen). Amplification of cDNA (1/10 dilution) and genomic DNA (gDNA) template was 
performed in triplicate using the iQ™ SYBR Green I Supermix (BioRad) with 1 µl of each 
cDNA template amplified in each 25 µl reaction volume:  
For a single reaction: 
iQ™ SYBR Green I 2X Supermix (BioRad)    12.5 µl   
Primer detection mix (10 pmols F/R)          2 µl  
Sterile nuclease-free water         9.5 µl 
cDNA template                1 µl 







Real-time PCR was performed using the following programme:  
95ºC for 10 min (hold) 
50 cycles of: 
95ºC for 10 sec (denaturation) 
57ºC for 20 sec (annealing) 
72ºC for 20 sec (extension)  
Final extension: 
72ºC for 1 min (hold)  
Melt-curve analysis: 
 Ramp from 72ºC to 99ºC 
 Rising by 1ºC pre-melt to 5ºC 
Fluorescence data was acquired during the extension step for 5 sec, when SYBR green I dye 
is released from the amplified double-stranded DNA and fluoresces. Melt-curve analysis was 
also used to verify primer specificity by the detection of single peaks. Real-time PCR with 
SYBR Green I detection is just as specific and sensitive as detection with probes. However, 
SYBR Green hybridises to all double-stranded DNA, resulting in the potential detection of 
non-specific amplicons (Qiagen, UK). 
 
2.4.7 Agarose gel analysis of EBV specific PCR products   
All 89 PCR products were analysed by 2% agarose gel electrophoresis. Agarose gels were 
prepared by melting 2g agarose powder (Invitrogen) in 100 ml of 1 X Tris-Borate-EDTA 
(TBE) buffer (Sigma-Aldrich) for 2 min at maximum power in a microwave. The melted 
agarose was cooled for 2 minutes before the addition of 5 µl of 10 mg/ml ethidium bromide 
(EtBr) (Sigma-Aldrich) and then swirled gently to distribute the EtBr before being poured 
into casting plates and allowed to set for 20 minutes before samples were loaded. Briefly, 10 
µl of PCR products were mixed with 3 µl orange G gel loading dye and loaded onto agarose 
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gels. Twenty microlitres of 1 Kbp DNA ladder (Invitrogen) was loaded into the first well of 
each gel to enable comparative estimates of PCR product size. PCR products were separated 
by electrophoresis at 100 V for approximately 1 hr until the loading dye reached the end of 
the gel. PCR products were then visualised under ultra-violet (UV) illumination. 
 
2.4.8 Validation of real-time PCR  
Real-time PCR was performed on cDNA diluted at 1/2, 1/5, 1/10 and 1/20 dilutions in 
nuclease free water to assess the sensitivity of detection of the cDNA using PCR programme 
described in section 2.4.6. PCR amplification was tested on all cDNAs using primer sets 
(Shown in Table 2.1) for the immediate-early gene BZLF1, and the reference control ACTB.  
 
2.4.8.1 PCR controls 
PCR controls included 1 µl of cDNA from EBV-negative Ramos cells (negative control), 1 
µl of control DNA from the EBV strain B95-8 (Advanced Biotech Cat.No. 08-702-000), and 
1 µl of sterile nuclease free water as a non-template background control.  
 
2.4.9 Analysis of real-time PCR data 
 
2.4.9.1 Threshold cycle   
The threshold cycle (Ct) is the cycle number at which the fluorescence generated within a 
reaction crosses the threshold line, usually set sufficiently above background fluorescence 
(Applied Biosystems). The Ct is a relative measure of the concentration of target in the PCR 
reaction; high Ct indicates low concentration of template, whereas low Ct indicates high 
concentration of target molecules in the sample (Bustin and Nolan, 2004).  
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2.4.9.2  Comparative quantitation (ΔΔCt) 
Relative expression was quantified using the ‘Comparative Quantitation’ method or 2-ΔΔCt 
method  (Schmittgen and Livak, 2008), similar to the previously published ΔΔCt method 
(Livak and Schmittgen, 2001) supplied on the Rotorgene software (version 5.0). ΔΔCt 
enables the dynamic amplification efficiency of each run to be determined by taking into 
account the take-off point, similar to the Ct (ΔΔCt) (Applied Biosystems). The Rotorgene 
software automatically calculates the take-off point for each amplified target. Relative 
expression was quantified as follows: 
 
2.4.9.2.1 Calculation of relative expression levels to ACTB   
To calculate the ΔCt value or normalised value (i.e., relative expression to ACTB), the means 
of triplicate Ct values for ACTB were subtracted from the means of triplicate Ct values for 
each target using the formula: ΔCt = Ct TARGET – Ct ACTB.  
 
2.4.9.2.2 Calculation of fold-change   
To calculate the ΔΔCt value (or fold-change), the ΔCt value for induced sample was divided 
by the ΔCt for uninduced sample using GraphPad Prism 5.0 software (Graphpad Prism, La 
Jolla, CA).  
 
2.4.10 Statistical analysis 
Data analysis including statistics and graphs were performed in GraphPad Prism. The 
statistical significance of fold-change was calculated using the student’s pair wise t test. A P-
value of less than 0.05 was considered statistically significant.   
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Table 2-1 Primer sequences used for real-time PCR analysis of EBV gene expression  
Target gene Sequence Amplicon size (bp)  Reference 
A73/RPMS1 5’-AGACACTCGATATCGAAGGCCAG-3’ 5’-TCACCTTTGGCTGGTACAGC-3’ 154 In-house 
BALF1 5’-CTGTGCTACACAGTGGTGTT-3’ 5’-GCAAACCAGAGTCTGCGATA-3’ 116 Pan et al. 2005 
BALF2 5’-AAACTACGCTGTGGAGCA-3’ 5’-AACTGCAGGTAGTAGG-3’ 81 Pan et al. 2005 
BALF3 5'-CATCCTCCTTCCCCGTTT-3' 5'-GGCCTCTCTCGAGTTCTC-3' 94 Pan et al. 2005 
BALF4 (gp110) 5'-GGGCCTGTTGATGGTGTT-3' 5'-CGCGTACCAGCCATTGTA-3' 106 Pan et al. 2005 
BALF5 5’-CAGCAGGCCTACTTCTA-3’ 5’-AGGGTGATCTTGTGGTAGTC-3’ 182 Pan et al. 2005 
BaRF1 5’-CGCTGCCTCCCTGTTATACA-3’ 5'-TCCACGAGCCTCGATGAA-3' 121 Pan et al. 2005 
BARF1 5'-GCTGTCACCGCTTTCTTG-3' 5'-GTGGTGCATGCGCCCAAT-3' 138 Pan et al. 2005 
BARF0 5’-CCATATCAGGGAAGTCAGGA-3’ 5’-CTGTTTACCCAGACCCTGAG-3’ 250 (Kienzle et al., 1998) 
BBLF1 5'-TGCCGACGACGAGTCAAC-3' 5'-TCGAGCCCCTCGTTGGTT-3' 146 Pan et al. 2005 
BBLF2 5'-TCGACTACCGAACTCAAC-3' 5'-CGGTCTCGGGTTCTAAAT-3' 125 Pan et al. 2005 
BBLF3 5'-GAGACCCGAGGCAGACAA-3' 5'-ACACGTGGCTTCCAGAGA-3’ 173 Pan et al. 2005 
BBLF4 5’-AGAGCACCAGCGTTAG-3’ 5’-ATAGACGGTTGGGCAGTA-3’ 132 Pan et al. 2005 
BBRF1 5'-GATCTGCCAGCTCCTGAA-3' 5'-CAGGTTGTTGGAGGCATC-3' 220 Pan et al. 2005 
BBRF2 5’-GCCCTGCTCTCGATGATTGA-3’ 5’-TCCTCCAGGTCGTGGTACTT-3’ 173 Pan et al. 2005 
BBRF3 5’-CCTCATCCTGCCCATCTTCT-3’ 5'-CTTGGCGGAGACAAAGAC-3' 154 Pan et al. 2005 
BcLF1 5'-CAGCGGACATTCATTGTG-3' 5’-CCACGTACTCTGCGTACT-3’ 130 Pan et al. 2005 
BcRF1 5’-GAGATGCCCAGGGATTCACA-3’ 170 Pan et al. 2005 
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5’-CACGGCAGACGTGGCTTATT-3’ 
BCRF1 5'-TCTCCGCAGACCCCATTT-3' 5'-TCCCTCCGCCGTTACTCT-3' 104 Pan et al. 2005 
BDLF1 5’-ATTTGGACGAGAGCATGCCA-3’ 5’-CAGGAGAATCTTCTGCAGCA-3’ 112 Pan et al. 2005 
BDLF2 5'-GCCTCCACGCTGTTTCAT-3' 5'-CCCCACCGGCATAAAGCT-3' 121 Pan et al. 2005 
BDLF3 5'-GACTAGCGCCCCTATAAC-3' 5'-GGTGGATGCGTTGGAAGT-3' 110 Pan et al. 2005 
BDLF3.5 5’-TCAGAGACCTCCTGCTCAA-3’ 5’-CGGATGCTCTGAAAGACAG-3’ 151 In-house 
BDLF4 5'-GCGAGTACCACGTATGTG-3' 5'-GGTCCTGTGTGTCTTGTC–3’ 
 
150 Pan et al. 2005 
BDRF1 5’-TTCGTGCACACCAAGGACAAGA-3’ 5’-GCGTAGATGAGCCTCTCAAA-3’ 93 Pan et al. 2005 
BdRF1 5’-CCCTCTACCGCAAGGACATA-3’ 5’-GACGTATCTGGGCACTTCGT-3’ 197 Pan et al. 2005 
BERF1 5’-ACGGCACAGGCTTGGAAT-3’ 5’-TCGTTTGCCCGCTCTCAT-3’ 246 
 
Pan et al. 2005 
BFLF1 5'- TACGAGTCCCTCTCTCCA-3' 5'-GCCTGTGATGAGGCTAGA -3' 162 
 
Pan et al. 2005 
BFLF2 5’-CTTTCCCAACCCAGCCTTCT-3’ 5’-CAAGCAGGTCTCTGGGATGT-3’ 150 Pan et al. 2005 
BFRF1 5’-CGGACGACGATGCAGTTTCT-3’ 5'-GACTTGACCAGACCGAGA-3' 111 Pan et al. 2005 
BFRF1A 5’-GTTTCTCGCCTATGATCCAC-3’ 5’-AAATAAGACCTCACGCTGGA-3’ 156 In-house 
BFRF2 5’-CTTGTCCCTTTCAGTGGTCA-3’ 5’-CAGGCAGCTATTCTATCGGA-3’ 126 Pan et al. 2005 
BFRF3 5'-GGTGCTCATGCACACCTT-3' 5'-CCGGAGGCTGCTAATAGA-3' 154 Pan et al. 2005 
BGLF1 5'-TCGAGAACCCCAGCAACA-3' 5'-AATGGCCCGACGGGTCTT-3' 140 Pan et al. 2005 
BGLF2 5'-GCGGTGCCTGTGGAGATT-3' 5'-GTCCCAGTGGGATGATCT-3' 142 Pan et al. 2005 
BGLF3 5'-AATTGCGCTGGCCTGGAA-3' 5'-CACGCACGTCCAAGTACA-3' 290 Pan et al. 2005 
BGLF3.5 5’-CCGCTCTAGCTGCTTGTAGT-3’ 5’-AAGAGCCTCGGTAGAAAAGAG-3’ 224 In-house 
BGLF4 5'-GATCCGACCCGCTCTACTTT-3' 5'-GGTCAGGCCCATGTCTAAGT-3' 101 Pan et al. 2005 
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BGLF5 5’-TCCACGGCACAACTACTTCT-3’ 5’-AGAAGGCCGTCACAATGTTC-3’ 128 Pan et al. 2005 
BGRF1 5'-ACCCTCTGGTGGGCACAA-3' 5'-AGGGCTCGCACCGAACAT-3' 131 Pan et al. 2005 
BHRF1 5’-CTGCAGGACATTGTGTTGTAA-3’ 5’-TCAGTCCAGCAAGAAACAAA-3’ 189 Pan et al. 2005 
BILF1 5'-GCTCTGGGTGCTGGGAAA-3' 5'-CGCCATACCCAAGTGAGT-3' 118 Pan et al. 2005 
BILF2 5’-CCTGCAGCGTTCCTAGCA-3’ 5’-ACGGCCAAGGGCAGTTGT-3’ 88 Pan et al. 2005 
BKRF2 5’-TGCTGTTGGTGTATTTCTGG-3’ 5’-GTTGCTCCCATTCTTAGGTG-3’ 212 In-house 
BKRF3 5’-TTGGCTGGGCGTGGTTTACT-3’ 5'-AGAGGTCAGAACCAGATG-3' 140 Pan et al. 2005 
BKRF4 5'-GGACGTGAGTGACACTGA–3 5'-GCTCTCGCTGTAGTCAGA-3' 157 Pan et al. 2005 




5’-GGCTGGTGTCACCTGTGTTA-3’ 212 Pan et al. 2005 
BLLF2 5’-ACAGATTACGGCGGTGATTC-3’ 5’-TAACCGGTGGGCTCGTAAAAGT-3’ 118 Pan et al. 2005 
BLLF3 5’-CACCACAGGCCGACAATCTT-3’ 5’-AAGGAGGTGAGGTGGTGCTT-3’ 188 Pan et al. 2005 
BLRF1 5'-CGCTTCCAGTCCCACAAA-3' 5'-CTAATCCGTCAGCAGCGT-3' 218 Pan et al. 2005 
BLRF2 5’-CTCGCCTGGAGTCTGAGAAT-3’ 5’-CCGTGGCCTGCGTAATCATT-3’ 150 Pan et al. 2005 
BMRF1 5’-GGATCTCTACGTCACCACGT-3’ 5'-GCCAGACCTGTAAAACCT-3' 235 Pan et al. 2005 
BMRF2 5’-TCTGGCTTTGGGCTCTGGAA-3’ 5'-ATGGAGGGTCTCCTTCAG-3' 133 Pan et al. 2005 
BNLF2a 5'-ATGGTACACGTCCTGGAG-3' 5'-TTAGATGAGGAGCAGGCA-3' 182 Pan et al. 2005 
BNLF2b 5’-GCGACTGATCCGCAGAAA-3’ 5'-TTATCCACACCATCCCAA–3’ 154 Pan et al. 2005 
BNRF1 5’-AGTGACCATCACTATGCC-3’ 5’-GTGCTCTGCAAACATCTC-3’ 58 Pan et al. 2005 
BOLF1 5’-GAGAATGGCCGCGAGTTT-3’ 5’-TGGACCTAAATCCGGAACA-3’ 188 Pan et al. 2005 
BORF1 5'-TACACGCCAGCTCCTTCAAC-3' 5'-CGGCCGTGATTCATTAGG-3' 133 Pan et al. 2005 
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BORF2 5'-TGACCCAGGCCCTCTATA-3' 5'-TCTCCGGCAGCTTCGTTT-3’ 134 Pan et al. 2005 
BPLF1 5’-GCTAATAAGG.AGTAGGGACCGA-3’ 5’-AGTTCGGAAGTGAGCAGTTG-3’ 117 Pan et al. 2005 
BRLF1 5’-AAACTCCTATCCTCGTGTCC-3’ 5’-CGGGAGACTTTCGAGTTCAT-3’ 140 Pan et al. 2005 
BRRF1 5’-GCTGTTCCTGGCAAGAGTCT-3’ 5’-GGCGATGTCACGCTGTTCAT-3’ 145 Pan et al. 2005 
BRRF2 5'-TTGCTCCGGGCTATCGTG-3' 5'-AGGACACGGGCGTCGTAT-3' 233 Pan et al. 2005 
BSLF1 5’-TTCTCTCGTGGAACTGCAGCTT-3’ 5’-TCTAGGTAGGTGGATAGAC-3’ 159 Pan et al. 2005 
BSMLF1 5’-CAACCAACAAGGACACATGG-3’ 5’-CTCGCGTGTTAGGAAGGAAG-3’ 238 In-house 
BSRF1 5'-TGCGGGCTCTGGCTCTTT-3' 5'-GCCCATCGTCTGCTCATT-3' 162 Pan et al. 2005 
BTRF1 5’-CGCACCATCCGGGATATT-3’ 5’-CTGTCGCCCGATGTCGTG-3’ 168 Pan et al. 2005 
BVLF1 5’-CAGTATTCATCCGGCACCTT-3’ 5’-TTTTGCACCTATCCCTGACC-3’ 128 Pan et al. 2005 
BVRF1 5’-CATGTCGGCTAATGCCAT-3’ 5’-CACTTCTGTCATCAGC-3’ 101 Pan et al. 2005 
BVRF2 5'-CCAGCTCCCTCTGAAGAA-3' 5'-TCGAGGCTGCGCTAAAGA-3' 115 Pan et al. 2005 
BXLF1 5’-GCCGTGACATCTAATACT-3’ 5’-AGTAGGCTTTTGGTGTG-3’ 108 Pan et al. 2005 
BXLF2 (gp85) 5’-CGTCTATGCTTAACCGCTAC-3’ 5’-ATTCAGGCCGCTAATGACTC-3’ 152 Pan et al. 2005 
BXRF1 5’-CCAACCCGCAAAGCGTTA-3’ 5’-CTCAGGGATCGCTGGTTT-3’ 160 Pan et al. 2005 
BWRF1 5’-TCTGTCCTTCAGAGGAACCA-3’ 5’-CCTCACTTTACAGACAGTGCAC-3’ 120 Pan et al. 2005 
BZLF1 5’-AGCCTGCTCCTGAGAATGCT-3’ 5’-CCACTGCTGCTGCTGTTTGA-3’ 150 Pan et al. 2005 
BZLF2 (gp42) 5'-GCCATCGCACTTGTTATT-3' 5’-ACCGGCCAGACCTCTACATT-3’ 125 Pan et al. 2005 
EBER1 5’-AGGACCTACGCTGCCCTAGA-3’ 5’-AAAACATGCGGACCACCAGC-3’ 168 Pan et al. 2005 
EBNA-1 5’-GACAAAGCCCGCTCCTACCT-3’ 5’-AGCCCCTTCCACCATAGGTG-3’ 99 Pan et al. 2005 
EBNA-2 5’-AAGGGCAAGTCCAGGGACAA-3’ 5’-CATTGGATGGGCCAGGAGTT-3’ 154 Pan et al. 2005 
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EBNA-3A 5’-GCCCTGGATGACAACATGGA-3’ 5’-CAGGTGGGCATCTTCTGCTT-3’ 138 Pan et al. 2005 
EBNA-3B 5’-CCCTTGCGGATGCAGCCAAT-3’ 5’-GGCTGATATGGAATG.TGCCC-3’ 124 Pan et al. 2005 
EBNA-3C 5’-CACCCAGTGAAGCGCACAAA-3’ 5’-GCTCCACGGTCACTGATGAT-3’ 112 Pan et al. 2005 
EBNA-LP 5’-CCTCGGACAGCTCCTAAGAA-3’ 5’-ACCGCTTACCACCTCCTCTT-3’ 115 Pan et al. 2005 
LF1 5’-TCTAGGATAGCCGCACCTAC-3’ 5’-GAACTCTGCCCTTCAGTGTC-3’ 178 In-house 
LF2 5’-AGAGGTAGGGGTTCTTGACC-3’ 5’-CTACTTTACGGTCGCGTTTT-3’ 189 In-house 
LF3 5’-CAGAATAACAGGGGAAGCAA-3’ 5’-GGGCATTGGTGTAACAATAAA-3’ 157 In-house 
LMP-1 5’-CTCCTCTTGGCGCTACTGTT-3’ 5’-GGCTCCAAGTGGACAGAGAA-3’ 153 Pan et al. 2005 
LMP-2A 5’-CTCTCACTTCTACTCTTGGCAG-3’ 5’-AGTCAAACGGCGCCATCTCCTT-3’ 255 In-house 
bp, base pairs 
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2.5 AFFYMETRIX HUMAN GENOME MICROARRAY ANALYSIS 
 
2.5.1 Microarray procedures 
 
2.5.1.1 Total RNA extraction and integrity analysis 
Total RNA was extracted from duplicate flasks of induced and uninduced Raji and 
Ramos cells, harvested at 24 hr time-points using the RNeasy® Mini Kit (Qiagen) 
according to manufacturer’s instructions as described in section 2.4.1. The 
concentration of total RNA extract was measured on the NanoDrop ND-8000™ 
Spectrophotometer (LabTech International) as described in section 2.4.2 and the 
quality of total RNA was assessed further using an RNA 6000 Nano assay chip with 
the Agilent RNA LabChip Kit and run on an Agilent® 2100 Bioanalyser (Agilent), 
according to manufacturer’s instructions. Total RNA from the duplicate culture flasks 
representing induced and uninduced cells was pooled, standardised to 100 ng/µl total 
RNA and heat-denatured by incubation at 70°C for 2 min prior to first-strand cDNA 
synthesis.  
 
2.5.1.2 Reverse transcription to synthesise first-strand cDNA   
Antisense RNA (aRNA) was generated from total RNA in two steps: a first-strand 
cDNA synthesis followed by second-strand cDNA synthesis to generate double-
stranded cDNA template that was subjected to T7 in-vitro transcription (IVT) to 
produce biotin-labelled antisense RNA (aRNA). First-strand cDNA was synthesised 
from 100 ng of total RNA with the Message AmpTM Premier RNA amplification Kit 
(Ambion) according to manufacturer’s instructions. Briefly, oligo-dTs were used to 
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generate first-strand cDNA by addition of 5 µl of standardised total RNA (500 ng) to 
the following first-strand reaction mix:  
First-strand reaction mix for a single reaction:     
First-strand buffer mix          4 µl 
First strand enzyme mix         1 µl 
Total volume            5 µl 
The first-strand reaction mix was set-up on ice and all reagents added in the order 
listed above. The reaction was mixed well by vortexing and centrifuged briefly. Next 
5 µl of the reaction mix was transferred to PCR tubes to which 5 µl of total RNA was 
added, giving a total reaction volume of 10 µl. The reaction mix was mixed once 
more by vortexing, centrifuged briefly and returned to ice. The reaction tubes were 
transferred to a Perkin Elmer thermal cycler (Applied Biosystems) and first-strand 
synthesis carried out at 42°C for 2 hrs with a final hold at 4°C. Following incubation, 
reaction tubes were centrifuged briefly and placed immediately on ice prior to second-
strand cDNA synthesis.  
 
2.5.1.3 Second-strand cDNA synthesis  
First-strand cDNA was used directly in a second reaction to generate double-stranded 
DNA (dsDNA) template for IVT. The second-strand reaction mix was set-up on ice in 
the following reaction: 
Second-strand reaction mix for a single reaction: 
Nuclease-free water      13 µl 
Second-strand buffer mix         5 µl  
Second strand enzyme mix         2 µl 
Total reaction volume     20 µl 
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The second-strand master mix was mixed thoroughly by gentle vortexing, centrifuged 
briefly and placed on ice. Next, 20 µl of the reaction mix was transferred to PCR 
tubes containing 10 µl of the first-strand cDNA samples. The reaction mix (30 µl) was 
mixed well by vortexing, centrifuged briefly and returned to ice. Second-strand cDNA 
synthesis was carried out in a pre-cooled Perkin Elmer thermal cycler for 1 hr at 16°C 
followed by 10 min at 65°C. After this incubation step, the reaction tubes were 
centrifuged briefly and transferred immediately to –20°C for overnight storage prior 
to IVT the following day.  
 
2.5.1.4 In vitro transcription to synthesise biotin-labelled aRNA    
The following day, double-stranded cDNA template was subjected to IVT to generate 
biotin-labelled aRNA using Message AmpTM Premier RNA Amplification Kit 
(Ambion) according to the manufacturer’s instructions. All reaction mixtures for the 
IVT were set-up at room temperature (RT). The T7 IVT master mix was set-up in the 
following reaction: 
T7 IVT master mix for a single reaction: 
Nuclease-free water      4 µl 
T7 Biotin IVT mix    20 µl 
T7 enzyme mix      6 µl 
Total reaction volume   30 µl 
The IVT master mix reagents were added in the order listed above. The reaction was 
mixed thoroughly by gently vortexing and centrifuged briefly. Next, 30 µl of the T7 
master mix was transferred to PCR tubes containing the double-stranded cDNA 
template synthesised the previous evening (30 µl). The entire reaction was mixed 
thoroughly by gently vortexing, centrifuged briefly and immediately transferred to a 
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thermal cycler. The IVT reaction was carried out overnight for 16 hrs at 40°C. After 
incubation, the reaction was placed on ice prior to the aRNA purification step.   
 
2.5.1.5 Purification of biotin-labelled aRNA 
For the first step of the aRNA purification, 40 µl of nuclease-free water (heated to 50-
60°C for a minimum of 10 min) was added to each biotin-labelled aRNA resulting in 
a total reaction volume of 100 µl. The reaction mix was mixed thoroughly by 
vortexing, centrifuged briefly and transferred to a new nuclease-free 1.5 ml sarstedt 
tube. Next, 60 µl of aRNA binding buffer was added to each aRNA sample and the 
entire sample transferred to the wells of a U-bottom plate. Immediately after transfer, 
120 µl of 100% ethanol was added to each aRNA sample, the reaction mixed by 
pipetting up and down three times, and the entire plate shaken for 3 min at 5,000 x g. 
Purification of aRNA involved two washing steps. For the first wash step, the 96-well 
plate was placed on a magnet for 5 min. After 5 min, the supernatant was discarded 
and the beads re-suspended in 100 µl of wash buffer, and shaken for 1 min at 6,000 x 
g and returned to the magnet for 5 min. The supernatant was discarded and the wash 
step repeated (shake for 1 min, magnet for 5 min). After the second wash, the 
supernatant was discarded and the plate removed from the magnet. A final shake was 
performed for 1 min at full speed to remove all traces of ethanol. The final step in the 
purification involved an elution step. In this step, 50 µl of aRNA elution buffer (pre-
heated to 50-60°C) was added to the 96-well plate and the reaction mixed by gently 
pipetting up and down 2-3 times and shaken vigorously for 3 min at full speed. The 
plate was transferred to a magnetic stand for 5 min and the supernatant 
(approximately 50 µl) transferred to a second 96-well plate for fragmentation of 
aRNA. 
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2.5.1.6 Fragmentation of biotin-labelled aRNA  
Prior to fragmentation, the quality of aRNA was assessed with the Agilent bioanalyser 
as described in section 2.5.1.1. The aRNA fragmentation reaction mix was set-up in 
the following reaction: 
30 µl reaction volume (15.51 µg in 31 µl*) 
Sample (µg/µl) for 
15.5 µg Sample volume (µl) Volum H20 (µl) 
5X array 
fragmentation buffer 
1.54 10.05 14.75 6.2 µl 
2.16 7.16 17.64 6.2 µl 
1.05 14.66 10.14 6.2 µl 
2.10 7.38 17.42 6.2 µl 
0.99 15.57 9.23 6.2 µl 
*1 µl was used in the bioanalyser 
 
The aRNA was fragmented by incubating the fragmentation reaction at 94ºC for 35 
min. After the incubation, the reaction mix was immediately placed on ice ready to 
hybridise to the array. The fragmented aRNA was next analysed on the Agilent 
bioanalyser. Briefly, 1 µl of fragmented aRNA was heat-denatured at 70ºC for 2 min 
and run on the bioanalyser (Figure 4.2).  
 
2.5.1.7 Hybridisation of fragmented aRNA  
The fragmented aRNA was used immediately in the following hybridisation reaction: 
Hybridisation master mix for a single reaction:   
Fragmented biotinylated aRNA       25 µl      
Control oligo B2 (3 nM)       4.2 µl      
20X hybridisation controls                12.5 µl    
2X hybridisation mix        125 µl      
DMSO           25 µl      
H20                    58.3 µl     
Total reaction volume       250 µl 
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Twenty-five microlitres of hybridisation mix was added to 25 µl of the fragmented 
aRNA and immediately transferred to -80ºC until hybridisation to the arrays. 
Fragmented aRNA from duplicate replicates of induced and uninduced Raji and 
Ramos cells were hybridised to a total of eight Affymetrix (HG-U133 Plus 2.0 
GeneChips® and signal intensity measured.  
 
2.5.2 Microarray Data Analysis 
 
2.5.2.1 Affymetrix data acquisition 
Following aRNA hybridisation, each HG U133 Plus 2.0 GeneChip® was scanned by 
laser using the GeneChip® scanner 3000 7G and the fluorescence signal recorded. 
Raw signal intensity data (CEL.file) captured from the scanner was analysed using the 
microarray suite 5.0 (MAS 5.0) algorithm (Affymetrix Suite v5.0) built into the 
Affymetrix GeneChip® operating software (GCOS). Using MAS 5.0, several 
processing steps were undertaken to transform the raw data (in the form of probe set 
intensities) into expression levels in an absolute analysis, followed by several filtering 
steps to identify highly differentially expressed genes in a pair-wise comparison of 
induced and uninduced conditions.  
Affymetrix arrays consist of thousands of probe sets (Figure 2.1). The HG U133 Plus 
2.0 GeneChip® contains 54,675 probe sets (Figure 2.1) that interrogate 38,500 genes 
(Irizarry et al., 2003; Lipshutz et al., 1999). Each probe set consists of 11-20 short 
(25-mer) oligonucleotide pairs that span different sections of the gene, with some 
genes being detected by multiple probe sets. Each probe pair consists of a perfect-
match (PM) oligonucleotide and its mismatch (MM). The MM probe is identical to 
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the PM probe except for a single substitution (13th base) of the 25-mer oligo and 
serves to measure non-specific hybridisation (Irizarry et al., 2003). In order to 
measure the expression levels of a particular mRNA transcript, the signal intensity for 
each probe set (11-20) is summarised and the mean signal intensity calculated for the 
gene. The use of pairs of PM and MM probe sets provides accurate and reproducible 




Figure 2-1  Affymetrix probe-set 
Example of 11-20 short (25-mer) perfect match (PM) and mismatch probe (MM) set used to interrogate 
gene transcripts in the Affymetrix HG U133 Plus 2.0 GeneChip®. Each probe set typically contains 11-
20 pairs of perfect match (PM) and mismatch (MM) probe pairs. The mismatch has a mutation at the 
13th base and serves to detect non-specific hybridisation. Signal intensities of the summarised probe 
pairs are generated to provide a single gene expression level for each probe set and hence for the gene 
transcript. Each gene can be interrogated by multiple probe sets. Taken from the MAS 5.0 algorithm 
 
2.5.2.2 Affymetrix calibration for absolute analysis of single arrays 
Data pre-processing is required to transform raw signal intensities for each probe-set 
(Figure 2.0) into single gene expression measurements or signal value (i.e. the 
absolute data) through removal of non-specific hybridization signals and control for 
sample variation. Typically, three pre-processing steps are required: (i) Background 
correction (ii) Normalisation and (iii) Expression summary, although not necessarily 
in that order (Harrison et al., 2007). The processed data is saved as a CHP.file for 
comparative analysis of baseline and experimental arrays.  
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2.5.2.2.1 Background correction  
Background correction or perfect match (PM) correction refers to the adjustment of 
PM signal intensities to account for non-specific hybridisation signals. Negative 
values are excluded when the MM intensity exceeds the PM signal (MM ≥ PM = 
exclude negative values). MAS 5.0 assigns each probe set a detection call of present 
(P), marginal (M) or absent (A) that indicates how reliably each transcript is detected 
(Liu et al., 2002). MAS 5.0 uses probe pair (PM-MM) intensities to produce detection 
P-values for the detection calls (Pepper et al., 2007). 
 
2.5.2.2.2 Normalisation 
Normalisation of each array is necessary before the array can be compared alongside 
other arrays by correcting for differences in overall mRNA levels and technical 
variations such as differences in processing of arrays (Bolstad et al., 2003). 
Normalisation of each HG-U133 Plus 2.0 array was performed by global scaling so 
that the average signal of each array equalled arbitrary target signal intensities (TGT) 
of 100 to enable signal comparisons between each array. Global scaling was 
performed by scaling the signal intensities for all probe sets and taking the average 
signal as the trimmed mean (i.e., mean of the middle 96% of the ranked data, ignoring 






2.5.2.2.3 Expression summary  
Expression summary is required to transform signal intensity from each probe set into 
a measure of relative mRNA abundance (Harrison et al., 2007), reflected in the signal 
value. The real signal value is determined by calculating the mean signal intensity for 
each probe pair  by taking the log of the PM after subtraction of the MM probe value: 
Real Signal = log (PM-MM). Signal values refer to the absolute data (.CHP file) and 
were used to perform comparative analyses between experimental and baseline 
GeneChips® arrays (Hubbell et al., 2002; Irizarry et al., 2003).  
 
2.5.2.3 Pair-wise comparison analysis  
Following data pre-processing, comparison analysis was performed between induced 
and uninduced arrays to estimate differential gene expression changes between the 
two conditions. Comparison analysis requires several filtering steps to identify lists of 
highly differentially regulated and expressed probe sets. The purpose of filtering is to 
bias towards selecting probe sets that are most significantly and highly expressed by 
excluding those probe sets that are not reliably expressed or low expressed and thus 
uninformative (Hackstadt and Hess, 2009). Therefore, the MAS 5.0 algorithm was 
required to filter data by: (i) detection call and (ii) change call and (iii) signal change. 
A subsequent analysis step was performed to bias for the top 250 most highly 
differentially expressed probe sets. The tiered filtering approach is illustrated in 




2.5.2.3.1 Filtering on all probe sets called absent  
Filter 1 removed all probe sets called absent during pre-processing, leaving only probe 
sets that were present in at least one array. By filtering on absent calls, all probe sets 
with low signal intensity and not highly expressed were removed. 
 
2.5.2.3.2 Filtering on probe sets not changing  
Filter 2 removed all probe sets showing no change (NC) between induced and 
uninduced arrays. Change call refers to the direction of gene expression. Five 
possibilities for the change include: increase (I), marginal increase (MI), no change 
(NC), decrease (D) and marginal decrease (MD). By filtering out all probe sets called 
NC, only probe sets that were definitely changed (i.e., I or D) between the induced 
and uninduced array were selected.    
 
2.5.2.3.3  Filtering on probe sets changing by less than two-fold 
Filter 3 removed all probe sets whose expression did not change by 2-fold. The signal 
log ratio (SLR) refers to the magnitude in gene expression and represents the ratio 
between two samples for each probe sets, expressed as the log2 ratio, where a SLR of 
1.0 indicates a 2-fold change. Hence, a SLR of +1.0 indicates a 2-fold increase and a 
SLR of -1.0 indicates a 2-fold decrease. By removing all probe sets with a SLR ≥1.0 
(2-fold increase) and ≤1.0 (2-fold decrease), only probe sets that changed by at least 




2.5.2.3.4  Ranking to bias selection of highly differentially expressed probe sets 
In summary, we have filtered on the basis of probe sets being absent in samples, probe 
sets not changing between both samples and also probe sets changing by less than a 2-
fold cut-off (Figure 2.2). The remaining list also contains probe sets that have low 
signal values for both samples, but an apparently high SLR. We felt that these probe 
sets should be removed from further analysis because it was likely that the observed 
SLR was due to experimental noise. Therefore, to bias for probe sets with a higher 
overall signal, by removing probe sets that displayed high SLR but low signal values 
(low overall signal), the following formula was applied to the data: Sum signals 
(Signal(induced) +  Signal(uninduced)) x  magnitude of SLR. For example, two probe sets 
(Probe set A and B) have the same SLR (6) but different signal values; Probe set A 
has a signal of 1.0 (induced) and 0.01 (uninduced), whereas Probe set B has a signal 
of 100 (induced) and 1.0 (uninduced). By applying the formula for Probe set A: Sum 
(1.0(induced) +0.01(uninduced)) x6, the resulting signal is 6.06, known as ‘sum signals x 
SLR’, whereas for Probe set B: Sum (100(induced) +1.0(uninduced)) x6, the resulting signal 
is 606, representing a 100-fold difference in signal value between Probe set A and 
Probe set B.  Therefore, by using this formula, genes with the same SLR can be 
distinguished. This formula (unpublished) was performed by Dr Matt Arno at the 
Genomics Centre, KCL in lieu of statistical analysis using ANOVA, since only 
duplicate, not triplicate arrays were analysed. The result of this selection is a set of 
highly differentially expressed probe sets (Figure 2.1). In order to focus on a small 
group of highly differentially expressed genes, the top 250 most commonly modulated 
probe sets were selected from the ranked ‘sum signals x SLR’values of an overlap 
between two duplicate induced arrays (Figure 2.2).   
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2.5.2.3.5 Calculating fold change from signal log ratio 
The fold change for each probe set was determined by taking the average SLR for 
each probe set from experiment 1 and 2 (induced versus uninduced SLR), and then 
calculating the fold-change where a SLR of +1.0 and -1.0 equals a 2-fold increase or 
decrease. Probe sets (Table 4.1) were identified using the Affymetrix NetAffyxTM 
Analysis Centre found at www.netaffyx.com. 
 
Figure 2-2  Filtering steps to identify highly differentially expressed probe sets  
Pre-processing steps including (i) Background correction; (ii) Normalisation and (iii) Expression 
summary were performed for absolute analysis on each single induced and uninduced array.  Three 
filters were performed during comparison analysis of duplicate induced and uninduced arrays. Filter 1 
removes all absent probe sets on both arrays, leaving only present probe-sets, filter 2 removes all 
probe-sets not changing between the comparison, leaving only increased or decreased probe sets and 
filter 3 removes all probe sets changing less than 2-fold, leaving probe sets changing by 2-fold or more. 
Two final analysis steps were performed to distinguish between genes with a high SLR but low signal 
value and select the top 250 most differentially expressed and regulated probe sets 
Pre-processing steps for ‘absolute 
analysis’ of each array  
Background correction, Normalisation 
and Expression summary 
 
Filter 1 – filtering by detection call   
Removal of probe sets deemed absent 
on both arrays of each comparison, 
leaving only present probe sets on at 
least one array 
Filter 2 – filtering by change call 
Removal of probe sets not changed 
between induced and uninduced arrays, 
leaving probe sets that were either 
increased or decreased 
Ranking – probe sets with high SLR 
Ranking to distinguish between probe 
sets with a high SLR but low signal value 
between comparisons using the formula 
‘Sum Signals x SLR’ 
Top 250 differentially expressed probe 
sets  
Selection of the top most highly 
differentially expressed and regulated 
probe sets from ranked probe sets 
Filter 3 – filtering by signal change 
Removal of probe sets that are 
expressed less than the 2-fold between 
induced and uninduced arrays, leaving 
probe sets changed by 2-fold     
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2.5.3 Molecular Methods 
 
2.5.3.1 Validation of Affymetrix data by real-time PCR 
After the array analyses, 22 candidate genes (Table 4.) were selected for further 
validation according to the following criteria: (i) not regulated in response to lytic 
cycle inducers (TPA/NaB); (ii) known regulation in EBV-associated PTLD and/or 
EBV infection; (iii) highly regulated with a biological function of interest, and (iv) 
highly represented within Gene Ontology. However, in this study, 17 of 22 genes 
were investigated, since cDNA template was limiting. Real-time PCR (described in 
section 2.4.6) was run in triplicate on cDNA (diluted 1/100) derived from the same 
total RNA extracted from duplicate induced and uninduced Raji cells and hybridized 
onto HG-U133 Plus 2.0 GeneChip® arrays. Briefly, 4 μl of cDNA was mixed with 
2X TaqMan® Gene Expression Master Mix (Applied Biosystems) and 20X 
TaqMan® Gene Expression Assays (final 2X concentration) made up to a final 
volume of 20 µl with sterile nuclease-free water (Ambion). Each reaction mixture was 
set up as follows:  
PCR mix for a single reaction: 
Applied Biosystems TaqMan® Gene Expression Master Mix  10 µl 
Applied Biosystems TaqMan® Gene Expression Assays (20X)    1 µl 
cDNA template (1-100 ng)         4 µl  
Ambion Nuclease-free water         5 µl 
Total reaction volume       20 µl 
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Microarray validation was performed in triplicate for each of the 22 cellular candidate 
genes using the same real-time PCR programme described in section 2.4.6, omitting 
melt curve analysis:  
95ºC for 10 min (hold) 
50 cycles of: 
95ºC for 10 sec (denaturation) 
57ºC for 20 sec (annealing/extension) 
 
TaqMan® gene expression assays for 17 host cellular candidate genes are listed in 
Table 2.2. All candidate genes were normalised to the endogenous control ACTB 
(Hs99999903_m1) listed in Table 2.2 and relative expression levels, fold change and 
significance of fold change calculated as described in sections 2.4.9. 
 
Table 2-2 TaqMan gene expression assays for real-time PCR  



















Reference control*   
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2.5.3.2 TaqMan gene expression assays 
Primers specific for the cellular genes were selected from an assortment of optimised 
TaqMan® gene expression assays provided by Applied Biosystems (Listed in Table 
2.2). Selection criteria for the TaqMan® gene expression assays included (i) where 
possible, assays must span an exon-exon junction to avoid detection from 
contaminating chromosomal DNA (ending with suffix_m1) (ii) identification of the 
most mRNAs including those spotted on the HG-U133 Plus 2.0 array, and (iii) 
inventoried.   
2.5.4 Bioinformatics Analysis 
  
2.5.4.1 Functional network and pathway analysis using Metacore 
MetaCore (GeneGo bioinformatics software, Inc., St. Joseph, MI) is an integrated 
software suite, based on a manually curated database of human protein-protein 
interactions, protein-DNA interactions, and transcriptional factors, metabolic and 
signaling pathways for identification of Gene Ontology processes (Nikolsky et al., 
2005). Affymetrix data sets (6,517 and 5,437 probe sets) (from the pair wise 
comparison) were uploaded as their Affymetrix probe set IDs, SLR and P-values for 
SLR into GeneGo MetaCore™ (GeneGo bioinformatics software, Inc) for 
identification of three biological processes: (i) biological process (ii) and canonical 
pathway analysis (iii) disease biomarkers and then ranked according to their P-value. 
Probe sets that were up- and down-regulated 1.5 fold with a significance of P<0.05 
were first uploaded into MetaCore™ and an enrichment workflow analysis performed 
that provides the ten most highly represented gene networks shown as significant 
enrichment analysis histograms. For network and pathway analysis, the data sets were 
uploaded into MetaCore and biological networks constructed.  
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2.6 GENE EXPRESSION ANALYSIS IN WHOLE BLOOD 
  
2.6.1 Study design 
A case-control study was undertaken in the Virology department at King’s College 
Hospital, to identify viral and cellular genes that could be used as diagnostic 
marker(s) for early detection of PTLD. Ethical approval was not applicable for the 
study.  
 
2.6.2 Study groups 
Twenty-one paediatric transplant recipients who underwent solid organ transplant 
(SOT) between 2000 – 2009 and two adult umbilical cord blood transplant (UCBT) 
recipients who underwent transplantation for haematological malignancies between 
2008 between and 2010 were investigated. From these, seven cases of PTLD were 
diagnosed during the period of 2008 – 2010. The demographic and clinical details of 
all available patients and unmatched controls are shown in Tables 2.3 and 2.4. 
Therefore the study groups consisted of:  
(i) Paediatric transplant recipients who developed PTLD following liver and 
small bowel transplant (Table 2.3). These patients were transplanted primarily 
for the treatment of acute liver failure (ALF), and small intestinal bowel 
transplantation for acute intestinal failure. Altogether, five cases of PTLD 
were available for investigation during the period of 2009 – 2010. Two of the 
five patients were orthotopic liver transplant (OLT) recipients and the 
remainder were small bowel transplant recipients. Transplant dates were 
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known for 4/5 patients. The median age of patients at transplant was 72 
months (Range: 1-192 months). Three cases were female and two were male.  
(ii)  Adult transplant recipients one of which developed PTLD and a second 
who remained at high risk (non-PTLD). Both patients were diagnosed as 
having haematological malignancies, primarily acute myeloid leukaemia 
(AML) and subsequently underwent UCBT. Two of 13 UCBT recipients were 
available for investigation during the period of 2009 – 2010 (Table 2.4). 
Multiple samples were available for each patient. The median age of the 
patients at transplant was 29.5 years (Range 28 – 31 years). Both cases were 
female. 
(iii) ‘Unmatched’ paediatric controls – The control group consisted of 16 
paediatric SOT recipients who were not diagnosed with PTLD (denoted: non-
PTLD) (Table 2.3). Controls were selected based on viral loads since 
matching by age and sex was limited by the small population to draw from in 
our laboratory. Transplant dates were not known for 14/16 controls. All 
controls were evaluated for analysis of EBV gene expression patterns. 
However, for the cellular gene expression analysis, 5 closely matched 
controls, based on sampling times post-transplant (≤12 months), were selected 
as controls for the cellular gene expression analysis. Controls were matched 
1:1 with PTLD cases. The median age of these five controls at transplantation 
was 12 months (range 0.4 –144 months).  
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Table 2.3  Clinical details from paediatric PTLD cases and controls 
Variables Cases (n = 5) Controls (n = 5) 





VCA IgG negative (n = 4)/VCA 
IgG indeterminate (n = 1) 
VCA IgG negative (n = 3)/VCA IgG 
indeterminate (n = 1)/EBV-seronegative (n = 
1) 
Age at transplant 
(months) 
(median, ranges) 
(median 72, range 1 – 192 
months) (median 12, range 0.4 – 144 months) 
PTLD, post-transplant lymphoproliferative disorder; VCA, viral capsid antigen; IgG, immunoglobulin; 
-, not diagnosed; F, female; M, male 
 
Table 2.4   Clinical details of the single adult PTLD case and control 
Variables Cases (n = 1) Controls (n = 1) 
Sex (F:M)  female  female 
EBV pre-transplant serostatus VCA IgG positive  VCA IgG positive 
Age at transplant (months) 
(median, ranges) (median 0, 336 months) 
 
(median 0, 360 months) 
 
PTLD, post-transplant lymphoproliferative disorder; VCA, viral capsid antigen; IgG, immunoglobulin; 
-, not diagnosed; F, female 
 
2.6.3 Virological laboratory data 
All patients were monitored routinely for EBV DNA loads by real-time quantitative 
PCR amplification during the first year following transplant using an in-house EBV 
assay based on the method described previously by Jabs et al., 2001 (Wagner et al., 
2001). Viral loads ≤10 genome copies/ml and ≥10 copies/ml were considered 
negative and positive, respectively. Serology was performed to determine pre-
transplant EBV status using an ELISA (DiaSorin). EBV recipient status was available 
for all patients however the donor status was not. Of the 20 paediatric patients 
investigated, at the time of transplant, 8 patients were EBV-seropositive, 3 VCA-IgG 
indeterminate and nine EBV-seronegative, whereas post-transplant, five developed 
PTLD, 16 remained PTLD negative (non-PTLD), one remained EBV seronegative 
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with no EBV viraemia (≤10 copies/ml) and four had primary EBV infection based on 
development of an EBV viraemia, including 2 PTLD and 2 non-PTLD patients. All 
adult patients were EBV-seropositive pre-transplant, whereas post-transplant only one 
patient developed PTLD. PTLD was diagnosed by histological analysis and EBV 
confirmed in biopsy tissue by EBER in-situ hybridisation.    
 
2.6.4 Whole blood samples 
Overall, 299 fresh whole blood samples were collected prospectively from paediatric 
and adult transplant recipients during a six month period between October 2009 and 
April 2010 and subjected to isolation of the non-red blood cell (non-RBC) fraction, 
followed by total RNA extraction. Clinical samples consisted of consecutive samples 
of EDTA-treated whole blood collected weekly or fortnightly for each patient. 
However, of the 299 samples, preference was given to samples with ≥30 ng/µl total 
RNA and of varying viral loads to ensure sufficient total RNA for real-time PCR 
analysis.  In this study, 33 samples of different viral loads (ranging from ≤10 
copies/ml to 197,629 copies/ml) from 20 patients were subject to gene expression 
analysis, including 15 samples from 5 paediatric PTLD patients and 18 from 16 non-
PTLD patients (Figure 2.3). An additional 12 samples (ranging from ≤10 copies/ml to 
477,642 copies/ml) were analysed from two adult patients, including 6 samples each 





Figure 2-3 Schematic diagram showing the patient study cohort 
 
2.6.4.1 Isolation of the non-RBC fraction  
The non-RBC fraction was isolated within 24 hrs of collection using the QIAamp 
RNA Blood Mini Kit (Qiagen). Briefly, whole blood samples were transferred from 
collection tubes into 15 ml RNase-free centrifuge tubes (Ambion) using sterile 3 ml 
pipettes (VWR International). Where possible, 1.5 ml of whole blood was used. Next, 
five volumes of erythrocyte lysis (EL) buffer was added to whole blood samples: 7.5 
EL buffer: 1.5 ml whole blood or 2.5 ml EL buffer: 0.5 ml whole blood. The whole 
blood: EL lysate was mixed briefly by gentle vortexing and incubated on ice for 15 
minutes, with two additional vortexes during incubation. Whole blood:EL samples 
were centrifuged at 400 x g  for 10 min in a 4ºC centrifuge, the supernatant discarded 
and the cell pellets re-suspended by pipetting in 1 volume of EL buffer (3 ml EL 
buffer: 1.5 ml whole blood and 1 ml EL buffer: 0.5 ml whole blood) prior to 5 min 
incubation on ice. The re-suspension was centrifuged at 400 x g for 10 min followed 
by complete removal of supernatant and the cell pellets re-suspended in 600 µl of 
RLT buffer containing 10 µl/ml 2-mercaptoethanol (Sigma-Aldrich) and the sample 
vortexed for 15 s to mix or longer until no visible pellet remained. Cell lysates were 





 Samples (n=15) 
Non-PTLD (n=16) 
Samples (n=18) 
2 adults  
(n=12 samples) 
PTLD (n=1)  
Samples (n=6) 
Non-PTLD (n=1)  
Samples (n=6) 
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2.6.5 Molecular Methods 
 
2.6.5.1 Total RNA extraction from white blood cell lysates  
Total RNA was isolated from homogenized lysates using the QIAamp® RNA Blood 
Mini Kit (Qiagen) according to manufacturer’s instructions. Briefly, prior to RNA 
extraction, white blood cell lysates were thawed by incubating for 5 min at 37ºC in a 
water-bath. Lysates were homogenized by transferring the lysates to shredder spin 
columns and centrifuging at 22,130 x g for 2 min. Next, the homogenized lysate was 
mixed with 600 µl of 70% ethanol by pipetting up and down 5-6 times. Next, 600 µl 
of the ethanol: lysate mixture was transferred to a mini spin column and centrifuged 
for 1 min at 11,290 x g. The supernatant was discarded and the remaining 
ethanol:lysate was transferred to the same spin column with new collection tube and 
re-centrifuged for 1 min at 11,290 x g. For the first wash step, the supernatant was 
discarded, a new collection tube added and 350 µl of RW1 wash buffer added to each 
spin column, and centrifuged for 1 min at 11,290 x g. On-column DNase digestion 
was performed using the RNase-free DNase Set kit (Qiagen) as described in section 
2.4.1.  For the second wash step, 350 µl of RW1 wash buffer was added to each spin 
column and centrifuged at 11,290 x g for 1 min. The supernatant was discarded and a 
new spin column added. Next, 500 µl of RPE wash buffer was added to each spin 
column, centrifuged for 1 min at 11,290 x g, the supernatant discarded and a new 
collection tube provided. A final wash step was performed with 500 µl of RPE, this 
time centrifuged at 22,130 x g for 3 min. Next, new collection tubes were provided 
and each spin column centrifuged at full speed for 1 min to remove residual wash 
buffer. For the elution step, 30 µl of RNase-free water was added to the centre of each 
spin column and incubated for 1 min at room temperature. Total RNA was eluted by 
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centrifuging at 11,290 x g for 1 min. An additional 30 µl of RNase-free water was 
added to the spin column, incubated for 1 min at room-temperature and centrifuged 
for 1 min at 11,290 x g, leaving a total elution volume of 60 µl total RNA. The 
concentration and quality of total RNA extract was determined immediately on the 
NanoDrop™ ND-8000 instrument (LabTech International) as described previously in 
section 2.4.2. Subsequently, total RNA was transferred immediately for long-term 
storage at -80°C, prior to RT.  
 
2.6.5.2 Reverse-transcription 
Reverse transcription of total RNA derived from whole blood samples was performed 
from 300 ng of total RNA (standardised to 30 ng/µl) using the High-Capacity 
Reverse-Transcription kit (Applied Biosystems), according to manufacturer’s 
instructions. Briefly, reverse-transcription was carried out on 10 µl of total RNA with 
random primers, reverse-transcription buffer (RT buffer), dNTPs and 125 U 
Multiscribe™ reverse transcriptase. Each RT was carried out on ice in a final volume 
of 20 µl and set-up in 0.2 ml PCR tubes (Qiagen) in the following order: 
RT mix for a single reaction: 
RT buffer   4 µl 
dNTPs    2 µl 
RNAse inhibitor   1 µl 
Reverse-transcriptase   1 µl 
Sterile RNAse-free water 2 µl 
Total RNA template  10 µl    
Total reaction volume  20 µl 
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The reverse-transcription master mix (minus total RNA) was set-up on ice in the order 
listed above, mixed by gently pipetting 2-3 times and centrifuged briefly.  Next, 10 µl 
of total RNA was added to the reaction mix, and the reaction mix mixed 2-3 times by 
pipetting, centrifuged briefly and placed in a pre-programmed thermal cycler (Applied 
Biosystems). Reverse-transcription was carried out at 37ºC for 2 hrs and an indefinite 
hold at 4ºC. All cDNAs were diluted 1/3 in sterile PCR grade water and transferred 
immediately to -20ºC prior to real-time PCR.  
 
2.6.5.3 Primers and probes used for PCR gene expression analysis 
TaqMan MGB probe sequences were designed for 17 EBV gene targets using the 
Invitrogen design software ‘software oligo3 primer output’ (Invitrogen, UK). All 
probes were synthesized by Applied Biosystems and were 5’-labeled with FAM. All 
primers were synthesised previously by Metabion as described in section 2.4.5 and 
shown in Table 2.1. All 17 primer and corresponding probe sequences used for EBV 
gene expression profiling are listed in Table 2.3. For detection of host cellular gene 
targets, 17 TaqMan® gene expression assays shown in Table 2.2 were selected from a  
Collection of Applied Biosystem gene expression assays 
(www.appliedbiosystems.com) as described previously in section 2.5.3.2. 
 
2.6.5.4 Real-time TaqMan PCR for gene expression profiling 
Gene expression profiles were analysed using the same real-time PCR programme as 
described in section 2.5.3.1.  Briefly, real-time PCR was performed on cDNAs 
(diluted 1/3) using the Applied Biosystems Gene Expression Master Mix (Applied 
Biosystems). PCR was conducted in a total volume of 20 µl consisting of 2X Gene 
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Expression Master Mix, 20X TaqMan® gene expression assays and/or EBV detection 
mix and sterile nuclease-free water. For detection of EBV gene targets, primer/probe 
detection mixes were prepared, containing 10 pmol of each forward/reverse primer 
and 5 pmol of each TaqMan probe in a total volume of 100 µl and 1 µl used per 
reaction. The PCR master-mix was set-up on ice as follows: 
 
PCR mix for a single reaction: 
2X Gene Expression Master mix        10 µl 
TaqMan® Gene expression assay (20X)/EBV detection mix       1 µl  
Sterile DNAse/RNase-free water            5 µl 
cDNA template (100 ng)            4 µl 
Total reaction volume          20 µl 
 
The PCR reaction mix was mixed gently by inverting 2-3 times and then centrifuged 
briefly.  16 µl of master mix was added to 0.1 ml PCR tubes (Qiagen) with 4 µl 
diluted cDNA added to each reaction mix. All PCR reactions were performed in 
triplicate for each target in 0.2 ml tubes as described in section 2.5.3.1. Relative 
quantification was determined using the comparative quantitation method described in 
section 2.4.9.  
 
2.6.6 Statistical analysis  
All graphs and statistical analyses were performed using GraphPad Prism v5.0 
software (GraphPad Prism, La Jolla, California, USA). The Mann-Whitney U-test was 
used to compare the relative expression levels between PTLD and non-PTLD groups. 
P-values <0.05 were considered statistically significant.  
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Table 2-3 Primer and probe sequences for clinical validation by using real-time PCR 
Gene name Primer sequence (5’ – 3’) TaqMan probe sequence (5’ – 3’) 
EBNA1 5’-GACAAAGCCCGCTCCTACCT-3’ 5’-AGCCCCTTCCACCATAGGTG-3’ 6FAM-CTG TGT GCA GCT TTG ACG AT-MGBNFQ 
EBNA2 5’-AAGGGCAAGTCCAGGGACAA-3’ 5’-CATTGGATGGGCCAGGAGTT-3’ 6FAM-CTT GGA GAC CAG AGC CAA AC-MGBNFQ 
EBNA3A 5’-GCCCTGGATGACAACATGGA-3’ 5’-CAGGTGGGCATCTTCTGCTT-3’ 6FAM-ATC TAC CTC GGT TGT GCA GG-MGBNFQ 
EBNA3B 5’-CCCTTGCGGATGCAGCCAAT-3’ 5’-GGCTGATATGGAATG.TGCCC-3’ 6FAM-TTA ATC ATC CAG TGG GAC CC-MGBNFQ 
EBNA3C 5’-CACCCAGTGAAGCGCACAAA-3’ 5’-GCTCCACGGTCACTGATGAT-3’ 6FAM-TAA GGC AGA AGC ACA AAG CA-MGBNFQ 
EBNALP 5’-CCTCGGACAGCTCCTAAGAA-3’ 5’-ACCGCTTACCACCTCCTCTT-3’ 6FAM-ACC CAG ACG AGT CCG TAG AA-MGBNFQ 
LMP1 5’-CTCCTCTTGGCGCTACTGTT-3’ 5’-GGCTCCAAGTGGACAGAGAA-3’ 6FAM-TGA GTG ACT GGA CTG GAG GA-MGBNFQ 
LMP2 5’-CTCTCACTTCTACTCTTGGCAG-3’ 5’-AGTCAAACGGCGCCATCTCCTT-3’ 6FAM-TTC TGG TGA TGC TTG TGC TC-MGBNFQ 
BALF5 5’-CAGCAGGCCTACTTCTA-3’ 5’-AGGGTGATCTTGTGGTAGTC-3’ 6FAM-CAG GCC TAC TTC TAC GCC AG-MGBNFQ 
BDLF4 5'-GCGAGTACCACGTATGTG-3' 5'-GGTCCTGTGTGTCTTGTC–3’ 6FAM-TTT CCT TTG TGT TCC CTT GC-MGBNFQ 
BGLF4 5'-GATCCGACCCGCTCTACTTT-3' 5'-GGTCAGGCCCATGTCTAAGT-3' 6FAM-TGT CGC AGA TGT GGA ACC T-MGBNFQ 
BMRF1 5’-GGATCTCTACGTCACCACGT-3’ 5'-GCCAGACCTGTAAAACCT-3' 6FAM-CTC TGA GTG TGG GGC CAT AC-MGBNFQ 
BPLF1 5’-GCTAATAAGG.AGTAGGGACCGA-3’ 5’-AGTTCGGAAGTGAGCAGTTG-3’ 6FAM-TCT TAA AGG ACT GGT CGG GA-MGBNFQ 
BRRF1 5’-GCTGTTCCTGGCAAGAGTCT-3’ 5’-GGCGATGTCACGCTGTTCAT-3’ 6FAM-CCA TCG TCC CCA AGA TCT TA-MGBNFQ 
BVRF1 5’-CATGTCGGCTAATGCCAT-3’ 5’-CACTTCTGTCATCAGC-3’ 6FAM-AAC CTG AAC TTT ACC AAC TC-MGBNFQ 
BXLF1 5’-GCCGTGACATCTAATACT-3’ 5’-AGTAGGCTTTTGGTGTG-3’ 6FAM-ATC CTG CCC CTT TAC CCT AC-MGBNFQ 






3 CHAPTER 3. REAL-TIME RT-PCR ANALYSIS OF EBV 
GENE EXPRESSION DURING THE EBV LYTIC INDUCTION 







In the immunocompetent host, expansion of EBV-transformed B lymphocytes is kept 
in check by a functional host CTL response. In immunosuppressed transplant patients 
there is uncontrolled expansion of EBV-latently infected B lymphocytes leading to 
PTLD, often as a result of EBV reactivation. EBV can transform B cells in vitro into 
LCLs (Young and Rickinson, 2004) that express latency III, which has also been 
noted in EBV-positive B cells in PTLD tumour biopsies (Brink et al., 1997). While 
the EBV latent genes, in particular LMP-1 and EBNA-2, are known to be expressed in 
PTLD and have pathogenic roles, the role of the EBV lytic genes and therefore viral 
replication is less clear (Fields et al., 2007; Rowe et al., 1998). The latent-lytic switch 
has significant implications for pathogenesis. While latency is the most predominant 
phase found in PTLD, the virus must replicate lytically to enable transmission 
between cells and individuals (Countryman et al., 2009). EBV replication has been 
detected in PTLD biopsies and non-malignant oral hairy leukoplakia (OHL) (Montone 
et al., 1996; Walling et al., 2003). Further, several lytic genes have emerged as having 
transforming properties, including BARF1 and BILF1, suggesting a role in the 
development of EBV-associated diseases such as PTLD (Lyngaa et al., 2010; Sheng 
et al., 2003). Since specific predictive markers for PTLD are lacking, we wanted to 
identify highly regulated EBV latent and lytic genes that could serve as potential 
markers for the early detection of this disease. A suitable experimental model for 
measuring EBV gene expression during the latent-lytic switch is the EBV-
transformed Burkitt’s lymphoma nonproducer Raji cell line, a Burkitt’s lymphoma 
cell line (Pulvertaft, 1965). Raji cells are defective for EBV DNA lytic replication and 
as a consequence, late lytic gene expression is not detected (Chevallier-Greco et al., 
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1986a; Decaussin et al., 1995; Laux et al., 1988). EBV-negative Ramos cells served 
as controls. The latent-lytic switch can be induced in Raji cells following treatment 
with TPA (Zur Hausen et al., 1978) a protein kinase agonist which activates the PKC 
pathway (Gradoville et al., 2002), in synergy with NaB, which functions as a histone 
deacetylase inhibitor (Luka et al., 1979). Moreover, Raji cells exhibit a latency III 
pattern of EBV gene expression. This is significant since latency III patterns have 
been associated with PTLD, making this a suitable model system for investigating 
EBV gene expression upon lytic induction in the context of PTLD (Brink et al., 1997). 
 
3.1.1 Objectives of Chapter 3 
EBV gene expression profiles were analysed in induced and uninduced Raji cells at 0, 
2, 6, 24 and 48 hr time-points by real-time PCR with SYBR Green I chemistry.   
The aims of the experiments described in this chapter were three-fold: 
(i) To validate the real-time PCR assays for evaluation of EBV gene 
expression profiling in whole blood samples from PTLD and non-PTLD 
patients.  
(ii)   To examine the changes in relative expression of all 88 EBV genes 
during the latent-lytic switch. 
(iii)  To identify any highly induced EBV latent or lytic genes in order to 






3.2.1 Analytical validation of primer specificity using EBV B95-8 genomic DNA 
Prior to the expression analysis, a commercially purchased stock of genomic DNA 
(gDNA) extracted from B95-8 cells was used to confirm the specificity of the EBV 
primer sets. EBV B95-8 gDNA was used as template in real-time PCR assays, where 
each primer set was evaluated for single peaks by melting curve analysis. To confirm 
the amplification of single products, PCR products from each PCR reaction were 
analysed on 2% agarose gels. Melt curve analysis and visualisation of PCR products 
demonstrated single products of the expected size for all primer sets (Panels A-E, 
Figure 3.1), with the exception of BOLF1, which showed non-specific amplicons 
(Lane 2, Panel D, Figure 3.1). Following validation of primer specificity, three 
deletions (LF1, LF2 and LF3) from the B95-8 EBV genome were confirmed by the 
absence of specific amplicons of the expected size  (Panel E, Figure 3.1) (Parker et al., 
1990). The absence of these PCR products gives further confidence for the specificity 














Figure 3-1 Specificity of EBV primers using EBV B95-8 gDNA   
Agarose gel electrophoresis of 89 PCR products amplified using control DNA from EBV strain B95-8 
(AbGene) as template. PCR amplification was performed using B95.8 control gDNA (Abgene). Real-
time PCR was performed on gDNA using the BioRad iQ Sybr Green supermix with primers specific 
for the 89 EBV genes shown. Ten microlitres of double-stranded DNA PCR product was analysed by 
2% agarose gel electrophoresis. The DNA was stained with Ethidium bromide prior to electrophoresis. 
(A-E) PCR products for the various EBV genes (bp); Lane 1, 1 Kbp molecular weight marker (M) 
(Invitrogen) and Lane 90, endogenous control ACTB. Asterisk indicates deletions from the B95.8 EBV 





3.2.2 Quality control of extracted total RNA for real-time PCR 
Total RNA was extracted from induced Raji and Ramos cells, treated with DNase and 
reverse-transcribed into cDNA for gene expression analysis by real-time PCR. To 
confirm the absence of residual gDNA in the total RNA extract, a no reverse 
transcriptase (RTase) control was carried out and analysed by real-time PCR 
alongside other samples. Elimination of ‘detectable’ gDNA was demonstrated by the 
absence of an amplification curve following real-time PCR (details not shown). 
Additionally, no EBV gene expression could be detected in the no-RTase controls.   
3.2.3 Analytical validation of primer specificity in cDNA from Raji cells 
To confirm the ability of all 89 EBV primer sets to amplify EBV gene expression 
products, total RNA was extracted from TPA/NaB induced Raji cells at 24 hrs 
following lytic induction. It has been shown previously that most EBV gene products 
are expressed within 24 hrs following TPA/NaB induction (Pan et al., 2005). Total 
RNA was converted into cDNA and subjected to real-time PCR with all 89 EBV 
primer sets. Of the 89 primer sets, 85 gave single peaks in melting curve analysis as 
well as single PCR products of the expected size when analysed on 2% agarose gels 
(Panels A-E, Figure 3.2).  Three genes (BALF1, BZLF2 and BARF1) are deleted from 
the Raji EBV genome (Hatfull et al., 1988), along with two truncations (BALF2, and 
EBNA-3C) (Hatfull et al., 1988). PCR products were not detected for all four deletions 
confirming the two deletions in the Raji EBV genome (Panels A-E, Figure 3.2). 
However, BALF2 showed low-level amplification in cDNA from induced Raji cells 
(Lane 3, Panel A, Figure 3.2). As expected, PCR products were detected for all five 
genes following amplification with genomic DNA from wild type B95-8 cells (Panels 
A-E, Figure 3.1). However, a weakly intense band was detected for BALF2 (Lane 3, 









         
Figure 3-2  Specificity of EBV primers using Raji cDNA 
Agarose gel electrophoresis of 89 PCR products amplified from Raji cDNA. Real-time PCR was 
performed using cDNA derived from total RNA from Raji cells stimulated with TPA/NaB and 
harvested at 24 hr time-points. Real-time PCR was performed on gDNA using the BioRad iQ Sybr 
Green supermix with primers specific for the 89 EBV genes shown. Ten microlitres of double-stranded 
DNA PCR product was analysed by 2% agarose gel electrophoresis. The DNA was stained with 
Ethidium bromide prior to electrophoresis. (A-E) PCR products for the various EBV genes (bp); Lane 
1, 1 Kbp molecular weight marker (M) (Invitrogen) and Lane 90 show the endogenous control ACTB. 

















































3.2.4 Analytical validation of primer specificity using EBV-negative Ramos  
To confirm that amplification of single products from EBV B95.8 virus and Raji cells 
was not due to host cellular gDNA and gene expression, respectively, gDNA from the 
EBV negative Ramos cell line was tested by real-time PCR. The PCR products from 
B95-8 and Raji cells (Panels A-E, Figure 3.1 and 3.2) were compared to those 
amplified from Ramos (Panels A-E, Figure 3.3). No specific single peaks were 
detected by melt-curve analysis on gDNA from Ramos cells. The lack of specific 
products was confirmed further by the absence of PCR products of the expected size 
following PCR amplification of gDNA from Ramos cells. In all of our subsequent 












Figure 3-3  Specificity of EBV primers using gDNA from EBV-negative Ramos cells  
Agarose gel electrophoresis of 89 PCR products amplified from Ramos gDNA. Real-time PCR was 
performed using cDNA derived from total RNA from Ramos cells stimulated with TPA/NaB and 
harvested at 24 hr time-points. Real-time PCR was performed using gDNA isolated from 2 x 106 
Ramos cells using the Qiagen DNeasy extraction kit. Real-time PCR was performed on gDNA using 
the BioRad iQ Sybr Green supermix with primers specific for the 89 EBV genes shown. Ten 
microlitres of double-stranded DNA PCR product was analysed by 2% agarose gel electrophoresis. The 
DNA was stained with Ethidium bromide prior to electrophoresis. (A-E) PCR products for the various 






3.2.5 Validation of real-time PCR assay sensitivity  
To demonstrate that sufficient cDNA would be available for the entire EBV gene 
expression analysis, a small-scale sensitivity study was carried out. Dilutions (1/2-
1/20) of cDNA were tested using primers specific to BZLF1 and ACTB and the Ct 
values for the differing amounts of templates compared. Both targets were detectable 
in all the dilutions (Panels A and B, Figures 3.4). From these experiments, 1/10 





Figure  3-4  Sensitivity of detection of ACTB and BZLF1 from induced Raji cells 
Raji cells were stimulated with 30 ng/ml TPA and 3mM NaB and harvested at 24 hr time-points. Total 
RNA was isolated from the harvested cells using the Qiagen RNeasy Mini Extraction Kit and 2 µg total 
RNA reverse-transcribed into cDNA using the RetroScript kit. Serial dilutions (1/2 – 1/20) of cDNA 
template was prepared and amplified by real-time PCR for ACTB (A) and BZLF1 (B) by amplification 
with primers specific for ACTB AND BZLF1. Arrows indicate the serial dilutions for the cDNA 






























































3.2.6 Analysis of fold-changes in EBV gene expression at 0-48 hrs 
To examine the expression of 88 of the 89 EBV genes (BERF1 omitted) during the 
latent-lytic switch, gene expression was measured following TPA/NaB induction of 
Raji cells compared with uninduced Raji cells. Relative expression levels of all 88 
EBV genes (11 latent, 2 immediate-early (IE), 33 early and 42 late genes) (Table 3.2) 
were analysed in a single biological replicate tested in triplicate at 0, 2, 6, 24 and 48 
hr time-points after lytic induction. For the early time-points (0, 2 and 6 hrs), 
induction levels were below 2-fold (Table 7.1). Relative expression levels were 
calculated using the delta Ct method as described previously. Because of the relatively 
small changes in expression levels in the early time-points, subsequent analyses were 
carried out only on samples from the 24 and 48 hr inductions.  
 
3.2.6.1  Fold-changes of the immediate-early genes at 24-48 hrs   
Evidence of EBV lytic induction was demonstrated at 24 hrs after TPA/NaB induction 
by the expression of the IE gene BZLF1 with a 19-fold and 156-fold induction above 
uninduced levels at 24 and 48 hrs, respectively (Figure 3.5; Table 3.1). In contrast, the 
IE gene BRLF1 was induced from 3-fold at 24 hrs up to 60-fold at 48 hrs (Figure 3.5).  
The mean of the variation was low for both BZLF1 and BRLF1 (Table 3.1). Hence 
error bars were not visible (Figure 3.5).  
 
 Table 3-1 Summary of fold-changes of the immediate-early genes  
Gene (n=2) Mean fold-change at 24 hrs (±SD) 
Mean fold-change at 48 hrs 
(±SD) 
BRLF1 3.69 (±0.01) 60.33(±1.16) 
BZLF1 19.38 (±1.07) 156.00(±10.39) 


































Figure 3-5  Fold-changes in expression of the EBV immediate-early genes at 24-48 
hrs following TPA/NaB induction of Raji cells  
Fold-changes in expression of two immediate-early EBV genes in induced versus uninduced Raji cells. 
Raji cells were stimulated with TPA/NaB to induce the EBV lytic phase and cells harvested at 24 and 
48 hr time-points. Uninduced Raji cells served as the control. After 24 hrs of induction, total RNA was 
extracted from three biological replicates of induced and uninduced Raji cells using the Qiagen RNeasy 
mini extraction kit. cDNA was generated from 2 µg total RNA using the Ambion RETROscript™ kit. 
Real-time PCR was performed on cDNA from three technical replicates using the BioRad iQ SYBR 
Green supermix with primers specific for the EBV genes shown. ΔCt values were calculated for each 
gene using the ACTB gene as reference according to the comparative quantitation method (ΔΔCt) 
(Livak and Schmittgen, 2001), provided on the Rotorgene™ software (Qiagen, UK). Relative 
expression values were converted to fold-change values for each of the replicates (ΔCt Induced/Uninduced) 
using Prism (GraphPad Prism, USA). Data represents the mean fold-change relative to uninduced ±SD 
of one experiment performed in triplicate.  
 
3.2.6.2 Fold-changes of the EBV early genes at 24-48 hrs  
Fold-induction levels were determined for all of the 33 EBV early genes and are 
summarised in Table 3.2. With the exception of the two deletions discussed 
previously (BALF1 and BARF1), expression was detected in all genes (31/33 
[93.94%]) (Panel A, Figure 3.6). This includes the truncation in BALF2; induced at 
10-fold and 7-fold at 24 hrs and 48 hrs, respectively (Panel A, Figure 3.6).  
At the 24 hr time-point, 16/33 (48.48%) early genes were induced above 10-fold 
(Table 3.5), including 13/33 (39.39%) early genes (BALF2, BALF3, BALF5, BBLF2, 
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BBLF3, BBLF4, BDLF4, BFLF2, BFRF1, BFRF2, BILF1, BMRF1, BSLF1, BORF2 
and BXRF1) that were induced between 10-100-fold (Panels A-D, Figure 3.6; Table 
3.2) and 3/33 (9.09%) early genes (BcRF1, BGLF4, BXLF1) that were induced over 
100-fold at 104-, 114- and 153-fold, respectively (Panels B and D, Figure 3.6, Table 
3.2). Noticeably, 8/33 (24.24%) genes (BALF2, BALF3, BALF5, BBLF2, BBLF3, 
BBLF4, BcRF1 and BGLF4) were induced higher at 24 versus 48 hrs (Panels A-C, 
Figure 3.6; Table 3.2).  
At the 48 hr time-point, 25/33 (75.76%) early genes were induced above 10-fold 
(Table 3.4), including 16/33 (48.48%) genes (BALF3, BaRF1, BBLF2, BcRF1, 
BGLF4, BGLF5, BHRF1, BILF1, BKRF3, BLLF3, BRRF1, BSLF1, BSMLF1, BXRF1, 
LF1, LF2 and LF3) that were induced between 10-100-fold and 8/33 (24.24%) genes 
(BDLF4, BFLF2, BFRF1, BFRF2, BILF1, BMRF1, BORF2 and BXLF1) that were 
induced over 100-fold (Panels B-D, Figure 3.6 Table 3.2). Notably, two genes BFRF2 
and BMRF1 were induced over 1000-fold from 24 to 48 hrs (Panels B and C, Figure 









Table 3-2 Summary of fold-changes in expression of the EBV early genes  
Gene (n=33) Mean fold-change at 24 hrs (±SD) Mean fold-change at 48 hrs (±SD) 
BALF1* - - 
BALF2 10.64 (±3.43) 7.47 (±1.45) 
BALF3 26.47 (±11.43) 15.69 (±0.00) 
BALF5 14.15 (±1.20) 6.23 (±0.34) 
BaRF1 3.42 (±2.23) 59.88 (±1.87) 
BARF1* - - 
BBLF2 87.60 (±1.49) 21.77 (±1.16) 
BBLF3 34.10 (±5.56) 7.80 (±0.00) 
BBLF4 54.99 (±33.12) 9.80 (±2.39) 
BcRF1 104.44 (±91.38) 63.67 (±2.01) 
BDLF4 12.30 (±11.04) 141.33 (±7.35) 
BFLF1 5.37 (±1.30) 38.67 (±3.06) 
BFLF2 11.59 (±0.72) 114.93 (±99.64) 
BFRF1 19.11 (±1.14) 597.33 (±18.48) 
BFRF2 29.66 (±1.56) 1406.67 (±1219.59) 
BGLF5 3.22 (±0.10) 39.00 (±2.00) 
BGLF4 114.17 (±7.11) 38.58 (±1.20) 
BHRF1 0.45 (±0.11) 11.77 (±1.37) 
BILF1 12.13 (±1.34) 106.28 (±5.56) 
BKRF3 5.12 (±0.29) 90.33 (±4.51) 
BLLF2 9.49 (±1.12) 102 (±11.53) 
BLLF3 2.61 (±0.55) 35.33 (±30.75) 
BMRF1 90.17 (±10.51) 1323.67 (±343.52) 
BNLF2a 2.15 (±0.21) 5.50 (±0.17) 
BNLF2b 2.10 (±0.12) 3.67 (±0.40) 
BORF2 20.25 (±1.23) 166.00 (±5.20) 
BRRF1 7.19 (±1.00)  73.33 (±5.86) 
BSLF1 7.08 (±0.40) 28.33 (±24.95) 
BSMLF1 8.30 (±0.00) 20.33 (±1.16) 
BXLF1 153.00 (±9.88) 624.00 (±34.00) 
LF1 7.04 (±1.88) 11.67 (±1.16) 
LF2 3.62 (±0.20) 11.33 (±0.58) 
LF3 5.53 (±0.00) 59.00 (±6.00) 























































































































































































































Figure 3-6 Fold-changes in expression of the EBV early genes at 24-48 hrs following 
TPA/NaB induction of Raji cells  
Fold-changes in expression of 33 EBV early genes in induced versus uninduced Raji cells (A-D). Raji 
cells were stimulated with TPA/NaB to induce the EBV lytic phase and cells harvested at 24 and 48 hr 
time-points. Uninduced Raji cells served as the control. After 24 hrs of induction, total RNA was 
extracted from three biological replicates of induced and uninduced Raji cells using the Qiagen RNeasy 
mini extraction kit. cDNA was generated from 2 µg total RNA using the Ambion RETROscript™ kit. 
Real-time PCR was performed on cDNA from three technical replicates using the BioRad iQ SYBR 
Green supermix with primers specific for the EBV genes shown. ΔCt values were calculated for each 
gene using the ACTB gene as reference according to the comparative quantitation method (ΔΔCt) 
(Livak and Schmittgen, 2001), provided on the Rotorgene™ software (Qiagen, UK). Relative 
expression values were converted to fold change values for each of the replicates (ΔCt  Induced/Uninduced)   
using Prism (GraphPad Prism, USA). Asterisks indicate deletions from the Raji EBV genome. Data 
represents the mean fold-change relative to uninduced ±SD of one experiment performed in triplicate.  
 
3.2.6.3  Fold-changes of the EBV late genes at 24-48 hrs  
Fold-induction levels were also determined for 42 EBV late genes (Table 3.3), with 
the exception of deletion BZLF2 (Panel D, Figure 3.7). Unexpectedly, At the 24 hr 
time-point, 20/42 (47.62%) genes were induced above 10-fold (Table 3.5), including 
18/42 (42.86%) genes (BBLF1, BBRF2, BcLF1, BDLF2, BDRF1, BdRF1, BFRF1A, 
BFRF3, BGLF1, BILF2, BKRF4, BOLF1, BPLF1, BTRF1, BVLF1, BVRF2, BWRF1 
and BXLF2) induced between 10-100-fold (Panels A-D, Figure 3.7) and 2/42 (4.76%) 
genes (BMRF2  and BXLF2) that were induced over 100-fold at 117- and 103-fold, 
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respectively (Panels C and D, Figure 3.7). However, despite measuring 11- and 53-
fold-induction level at 24 hrs and 48 hrs, respectively for BWRF1, this gene is not 
known to be expressed (Jenson et al., 1987).  
At the 48 hr time-point, 33/42 (78.57%) genes were induced above 10-fold (Table 
3.5), including 19/42 (45.24%)  genes  that were induced between 10-100 fold and 
13/42 (30.95%) genes (BDLF3, BDRF1, BdRF1, BFRF1A, BFRF3, BILF2, BKRF4, 
BMRF2, BOLF1, BORF1, BPLF1, BVRF1 and BXLF2) that were induced over 100-
fold, of which three genes (BdRF1, BOLF1 and BXLF2) were induced over >1000-
fold (Panels B, C and D, Figure 3.7; Table 3.3).  Moreover, of the 13 genes induced 
over 100-fold, only two genes (BMRF2 and BXLF2) were induced highly from >100-
fold (117- and 103-fold) at 24 hrs to >800-fold (826- and 1365-fold) at 48 hrs (Panels 
C and D, Figure 3.7; Table 3.3). In contrast, the other 10 genes were induced from 
<100-fold at 24 hrs to >100-fold at 48 hr (Table 3.3). Overall, in comparison to the 
early genes, most late gene expression was increased at 48 hrs following TPA/NaB 
induction in Raji cells (Table 3.5).  
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Table 3-3 Summary of fold-changes in expression of the EBV late genes  
Gene  (n=42) Mean fold-induction at 24 hrs (±SD) 
Mean fold-induction at 48 hrs 
(±SD) 
BALF4 2.38 (±0.20)   7.01 (±0.23) 
BBLF1 3.5 (±0.56)   20.79 (±1.75) 
BBRF1 6.70  (±5.81) 1.68 (±1.07) 
BBRF2 34.74  (±2.05) 62.50 (±4.44) 
BBRF3 4.35 (±1.45)   1.49 (±0.84) 
BcLF1 32.37 (±5.12) 41.81 (±4.65) 
BCRF1 6.92  (±0.62) 76.61 (±8.34) 
BDLF1 3.48 (±0.22) 28.99 (±0.77) 
BDLF2 23.42 (±0.72) 45.44 (±39.54) 
BDLF3.5 2.85 (±0.57) 91.06 (±2.76) 
BDLF3 3.50 (±0.56) 313.15 (±19.88) 
BDRF1 17.25 (±0.21) 900.60 (±393.44) 
BdRF1 27.33 (±2.29) 1693.23 (±155.22) 
BFRF1A 21.99 (±1.18) 736.67 (±390.29) 
BFRF3 13.31 (±11.71) 158.33 (±30.07) 
BGLF1 10.41 (±1.19) 38.84 (±2.92) 
BGLF2 1.49 (±1.31) 25.33(±1.16) 
BGLF3.5 1.06 (±0.17) 8.58 (±0.72) 
BGLF3 4.15 (±0.51) 6.30 (±0.70) 
BGRF1 0.35 (±0.22) 4.03 (±0.31) 
BILF2 23.76 (±3.12) 254.33 (±16.17) 
BKRF2 0.56 (±0.11) 12.00 (±1.00) 
BKRF4 12.50 (±1.01) 251.33 (±41.04) 
BLLF1a 2.63 (±0.29) 5.67 (±4.93) 
BLLF1b 2.85 (±0.40) 13.33 (±0.58) 
BLRF1 2.70 (±0.52) 24.67 (±2.08) 
BLRF2 3.18 (±0.52) 29.33 (±2.08) 
BMRF2 117.01 (±16.58) 826.33 (±71.91) 
BNRF1 4.37 (±0.99) 59.00 (±51.16) 
BOLF1 58.0 (±3.46) 1331.33 (±15555.01) 
BORF1 1.45 (±0.24) 245.33 (±30.60) 
BPLF1 32.73 (±2.70) 569.80 (±99.98) 
BRRF2 3.48 (±0.41) 17.67 (±1.53) 
BSRF1 5.16 (±1.27) 70.33 (±5.69) 
BTRF1 12.03 (±1.31) 28.33 (±2.08) 
BVLF1 8.94 (±4.16) 70 (±4.00) 
BVRF1 27.55 (±3.54) 219.67 (±17.24) 
BVRF2 21.40 (±2.76) 53.33 (±8.51) 
BWRF1 11.16 (±1.01) 53.00 (±9.54) 
BXLF2 103.19 (±5.62) 1365.67 (±657.03) 
BXRF1 43.81 (±3.62) 70.68 (±14.98) 
BZLF2* - - 


























































































































































































































































Figure 3-7  Fold-changes in expression of the EBV late genes at 24-48 hrs following 
TPA/NaB induction of Raji cells 
Fold-changes in expression of 42 EBV late genes in induced versus uninduced Raji cells (A-D). Raji 
cells were stimulated with TPA/NaB to induce the EBV lytic phase and cells harvested at 24 and 48 hr 
time-points. Uninduced Raji cells served as the control. After 24 hours of induction, total RNA was 
extracted from three biological replicates of induced and uninduced Raji cells using the Qiagen RNeasy 
mini extraction kit. cDNA was generated from 2 µg total RNA using the Ambion RETROscript™ kit. 
Real-time PCR was performed on cDNA from three technical replicates using the BioRad iQ SYBR 
Green supermix with primers specific for the EBV genes shown. ΔCt values were calculated for each 
EBV gene using the ACTB gene as reference according to the comparative quantitation method (ΔΔCt) 
(Livak and Schmittgen, 2001), provided on the RotorGene™ software (Qiagen, UK). ΔCt values were 
converted to fold-change values for each of the replicates (ΔCt  Induced/Uninduced) using Prism (GraphPad 
Prism, USA). Asterisks indicate deletions from the Raji EBV genome. Data represents the mean fold-
change relative to uninduced ±SD of one experiment performed in triplicate. 
 
3.2.6.4 Fold-changes of the EBV latent genes at 24-48 hrs   
Fold-changes were also analysed for 11 latent genes, with the exception of the 
deletion EBNA-3C (Figure 3.8). At the 24 hr time-point, the fold-change for the latent 
genes was below 2-fold, with the exception of A73/RPMS1 and BARF0 which were 
induced to 2- and 11-fold, respectively (Table 3.4). At the 48 hr time-point, five genes 
were induced below 2-fold and the remaining induced below 10-fold, with the 
exception of EBNA-3A which was induced over 15-fold (Table 3.4).  
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Table 3-4 Summary of fold-changes in the expression of the EBV latent genes  
Gene  (n=11) Fold-change at 24 hrs (±SD) Fold-change at 48 hrs (±SD) 
A73/RPMS1 2.17 (±0.04) 5.63(±0.10) 
BARF0 11.00 (±1.29) 2.69(±0.16) 
EBER1 1.43 (±0.11) 3.73(±0.07) 
EBNA-1 0.67 (±0.03) 2.87(±0.74) 
EBNA-2 0.18 (±0.01) 0.28(±0.02) 
EBNA-3A 0.72 (±0.06) 15.33(±0.67) 
EBNA-3B 1.77 (±0.27) 0.42(±0.25) 
EBNA-3C* - - 
EBNA-LP 0.26 (±0.01) 0.18(±0.03) 
LMP1 1.65 (±0.13) 0.71(±0.06) 
LMP2A 1.25(±0.08) 1.68(±0.14) 





























































Figure 3-8  Fold-changes in expression of the EBV latent genes at 24-48 hrs 
following TPA/NaB induction of Raji cells 
Fold-change in expression of 11 EBV latent genes in induced versus uninduced Raji cells. Raji cells 
were stimulated with TPA/NaB to induce EBV lytic activation and cells harvested at 24 and 48 hr time-
points. Uninduced Raji cells served as the control. After 24 hours of induction, total RNA was 
extracted from three biological replicates of induced and uninduced Raji cells using the Qiagen RNeasy 
mini extraction kit. cDNA was generated from 2 µg total RNA using the Ambion RETROscript™ kit. 
Real-time PCR was performed on cDNA from three technical replicates using the BioRad iQ SYBR 
Green supermix with primers specific for the EBV genes shown. ΔCt values were calculated for each 
EBV gene using the ACTB gene as reference according to the comparative quantitation method (ΔΔCt) 
(Livak and Schmittgen, 2001), provided on the RotorGene™ software (Qiagen, UK). ΔCt values were 
converted to fold change values for each of the replicates (ΔCt  Induced/Uninduced) using Prism (GraphPad 
Prism, USA). Asterisks indicate deletions from the Raji EBV genome. Data represents the mean fold 
change relative to uninduced ±SD of one experiment performed in triplicate. 
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Table 3-5 Summary of fold-changes in expression of the EBV early and late genes 
at 24 and 48 hr time-points following lytic induction in Raji cells 
 Early genes  (n=33) 
Late genes 
 (n=42) 
 ≤10-fold ≥10–100-fold ≥100-fold ≤10-fold ≥10–100-fold ≥100-fold 








(42.86%) 2/42 (4.76%) 
















In this study real-time PCR assays were developed and used to quantify relative expression 
levels of 88 EBV genes, following induction of the EBV latent-lytic switch in Raji LCLs. In 
the first instance, the EBV-encoded microRNAs were not examined since we were restricted 
by the number of targets we could investigate. Future work will involve the analysis of these 
transcripts. Confidence in the specificity of our assay was determined in three ways. First, all 
89 primer sets were validated for EBV analytical specificity with our real-time PCR assays. 
BERF1 (also known as EBNA-3A) was excluded from further investigation following 
analytical validation, resulting in 88/89 genes being analysed, of which fifteen were 
overlapping in the EBV genome. Seventy-eight of the 89 primer sets were published 
previously, and primer specificity was validated on amplicons derived from B95-8 genomic 
DNA template by melt-curve analysis and agarose gel electrophoresis (Pan et al., 2005). In 
this study, commercially available gDNA derived from the EBV-positive B95.8 cell line was 
used as PCR template to amplify 89 EBV gene specific primer sets, since the Raji EBV 
genome contains two deletions (Hatfull et al., 1988). Analysis of the 89 amplicons using 
Melt-curve analysis and agarose gel electrophoresis yielded both single peaks and bands of 
the expected sizes.  
Second, the 89 primer sets were also assessed for specificity to DNA and RNA present in the 
cells. The Raji cell line has been used extensively to examine EBV gene expression (Biggin 
et al., 1987; Gargouri et al., 2011a; Gargouri et al., 2011b; Guo et al., 2010a; Ohashi et al., 
2007; Rek et al., 2010). In this study, we validated the detection of EBV specific mRNA, 
using total RNA extracted from TPA/NaB induced Raji cells. Our results confirmed single 
products by melt-curve analysis and visualisation of amplification products analysed by 
agarose gel electrophoresis for 85 of the 89 primers tested. We showed that all primer sets 
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were specific for the EBV gene targets. Further, we also we detected an amplicon of the 
expected size for BWRF1, which is not known to be expressed (Jenson et al., 1987). Further 
work is required to determine whether this transcript is translated into a functional protein. 
Lastly, our EBV primer sets were tested against total RNA extracted from TPA/NaB-induced 
EBV-negative Ramos cells. Ramos is an EBV-negative Burkitt’s lymphoma cell line that is 
frequently used as an EBV-negative control, particularly for Raji LCLs where an EBV-
negative counterpart is not available. This validated the specificity of our assay, since only 
non-specific amplification was detected by melt-curve analysis and agarose gel 
electrophoresis of the 89 amplicons. These non-specific products are likely to reflect genomic 
DNA since SYBR Green I binds non-specifically to all double stranded DNA (Qiagen, UK). 
Further, no amplification traces were detected during the PCR runs when Ramos cDNA was 
used as a control and amplified with EBV-specific primers. The sensitivity of our assay was 
assessed by a titration of cDNA template derived from induced Raji cells, and a 1/10 dilution 
yielded Ct values of 24 and 16, for BZLF1 and ACTB genes, respectively providing sensitive 
detection and enough cDNA material for the analysis of all 89 gene targets tested in triplicate. 
 
Validation of primer specificity for overlapping EBV transcripts 
Many EBV lytic mRNAs are overlapping in the EBV genome (Baer et al., 1984; de Jesus et 
al., 2003b), sharing 3’-polyadenylation sites. As a result, primers in overlapping sequence 
regions may amplify more than one transcript, and not all transcripts can be detected 
uniquely. For instance, primers for shorter mRNAs that are completely contained within 
another mRNA will certainly amplify one or more mRNA transcripts. Of the 89 amplicons, 
15 fell into regions that overlap with multiple transcripts (BFLF2/BFLF1, BFRF1/BFRF2, 
BORF1/BORF2, BSMLF1/BSLF1, BLRF1/BLRF2, BLLF1/BLLF2, BKRF2/BKRF3, 
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BBRF1/BBRF2, BXRF1/BVRF1, BVRF2/BdRF1, BaRF1/BMRF1/BMRF2, 
BBLF1/BGLF5/BGLF4, BGRF1/BGLF2/BGLF1/BDLF4, BDLF3/BDLF2/BDLF1 and 
BNLF2a/BNLF2b/BNLF1/LMP1), including seven late lytic transcripts (underscored). The 
mRNAs of BFLF2, BORF2, BMRF1, BMRF2, BSMLF1, BLRF2, BLLF2, BKRF4, BBRF2, 
BBLF1, BGLF5, BGRF1, BGLF2, BGLF1, BDLF3, BDLF2, BVRF1, BdRF1 and 
BNLF2a/BNLF2b/LMP-1 are completely contained within the longer transcripts, as 
illustrated in the EBV transcription map 
(http://www1.imperial.ac.uk/departmentofmedicine/divisions/infectiousdiseases/viro/epsteinb
arr/ebvmap/). For these genes, our measures of transcription will therefore be a combination 
of the overlapping mRNAs. Thus, the fold-induction levels (Tables 3.2-3.3) may be over-
estimated.  
 
A potentially more accurate measurement should be found for the nine (BFLF2, BFRF1, 
BORF1, BSLF1, BLRF1, BLLF1, BKRF2, BBRF1, BXRF1, BVRF2, BaRF1, BGLF4, 
BDLF4, BDLF1 and LMP-1) partially overlapping longer transcripts, the exact 
measurements of these genes can be resolved by subtraction from the longer mRNAs. But, a 
number of variables could result in measurements that are not accurate, including differences 
in expression of the transcripts and variations in RT efficiency. Varying levels of a genes 
transcription can also arise depending on the proximity from the 3’-poly A sites when 
priming with oligo-dTs. This should not be a factor since we used random primers. In some 
cases, overlaps of early and late transcripts exist and the early/late distinction is obscured. 
Therefore, given that our RT-PCR is measuring more than one transcript, the overlapping 




Confirmation of deletions in the Raji EBV genome 
Two major deletions are found within the BamHI A region of the Raji EBV genome, 
resulting in three deletions (BALF1, BARF1, BZLF2) and two  truncations (BALF2 and 
EBNA-3C) (Hatfull et al., 1988). The first deletion is the 2.9kb sequence, in a region of 
BamHI A adjacent to the BARF1 oncogene, resulting in a 679-bp deletion of the whole 
BARF1 sequence (165496 to 166192 bp), encoding a 33-kDa protein capable of transforming 
rodent fibroblasts (Wei et al., 1994; Wei and Ooka, 1989), and a 256-bp sequence in the 
BALF2 reading frame (from position 163979 to 164235 bp), encoding a 135-kDa single 
single-stranded DNA binding protein (mDBP) (Tsurumi et al., 1996). The BALF1 gene, 
encoding a Bcl-2 homologue, with potential roles in cell survival, tumour formation and 
metastasis is also deleted in the BamHI A fragment of the Raji EBV genome (Hsu et al., 
2012). The second deletion is a 3.5-kbp sequence covering the entire region of the EBNA3C 
reading frame, resulting in a truncated protein crucial for B-lymphocyte transformation 
(Tomkinson et al., 1993), and the deletion of the BZLF2 fragment, encoding a type II 
membrane protein crucial for entry of B cells (Rowe et al., 2011). 
While EBNA3C is essential for B-cell immortalisation, BALF2 is essential for lytic DNA 
replication (Decaussin et al., 1995). Indeed, the deletion of the promoter region leads to the 
transcription of a truncated protein, with limited or partial function (Baer et al., 1984). As a 
consequence, the Raji EBV genome is incompetent for transformation, lytic DNA replication 
and crucially, late lytic gene expression, which is dependent of viral DNA synthesis 
(Chevallier-Greco et al., 1986a; Decaussin et al., 1995; Laux et al., 1988). Raji can be 
rescued for replication by providing the BALF2 cDNA in trans following super-infection 
with the EBV strain P3HR-1 (Biggin et al., 1987), and also for transformation, by rescuing 
the EBNA3C deletion by recombination, which incorporates the wild-type EBNA3C gene 
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from an overlapping genomic DNA fragment (Robertson et al., 1996). This recombination 
event renders the resulting virus competent for B-lymphocyte transformation.  
We confirmed all five deletions in the induced Raji cDNA. The specificity of our assay was 
validated further by the detection of these deletions in B95.8 genomic DNA (Figure 3.2 vs. 
3.1). Therefore, a major unexpected finding was the detection of late lytic gene expression, as 
will be discussed here. One of the aims of this study was to identify EBV genes, which were 
induced after EBV lytic induction, and that could serve as potential markers of PTLD. 
Overall, at the 24 hr time-point, 9.09% of EBV early genes were induced over 100-fold. By 
comparison, 4.76% of late genes were also induced above 100-fold. At the 48 hr time-point, 
24.24% of the early genes were induced above 100-fold as compared to 30.95% induced 
above 100-fold. Therefore, while the numbers of highly induced (>100-fold) early genes 
increased from 9.09% to 24.24% at 24 to 48 hrs, the numbers of ‘late genes’ also induced 
over 100-fold from 24 to 48 hrs increased from 4.76% to 30.95%, indicating higher induction 
of the early genes at an early stage after lytic induction and a ‘supposedly’ higher induction 
of the late genes at a later stage after lytic induction (i.e., 48 hrs).  
 
Detection of immediate-early gene expression 
Evidence for efficient induction of the EBV latent to lytic switch was demonstrated as early 
as 24 hrs by the expression of the IE gene BZLF1, the first gene to be expressed in the lytic 
cycle (Amon et al., 2004b) with a 19-fold and 156-fold induction at 24 hrs and 48 hrs, 
respectively. The IE gene BRLF1 was induced from 3-fold up to 60-fold at 24 and 48 hr time-
points, respectively (Figure 3.5). BZLF1 is known to autoregulate its expression (Feederle et 
al., 2000b). Therefore, the higher levels of BZLF1 expression compared to BRLF1 could be 
attributable to BZLF1 autoregulation. EBV replication is regulated by two immediate-early 
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genes BZLF1 and BRLF1 that encode transcriptional activators Zta and Rta of the latent-lytic 
switch (Chevallier-Greco et al., 1986b; Hardwick et al., 1988; Miller and El-Guindy, 2002; 
Ragoczy et al., 1998; Ragoczy and Miller, 1999; Speck et al., 1997). Zta binds ZREs in 
promoters of EBV early genes and cellular genes activating viral DNA replication and 
packaging and release of infectious virus (Chang et al., 1990; Chen et al., 2009; Farrell et al., 
1989). Rta also interacts with numerous cellular proteins and affects the activities of host 
cells to facilitate lytic replication (Bentz et al., 2010). Together, Zta and Rta are known to 
promote G0/G1 in Raji cells, indicating their increased expression in this system 
(Countryman et al., 2009).  
 
Detection of early lytic gene expression 
The EBV early genes are classically defined as genes expressed following lytic cycle 
activation, prior to lytic replication, and are expressed in the presence of agents that inhibit 
viral DNA replication (Robertson, 2005). Of the early genes, three (BcRF1, BGLF4 and 
BXLF1) were induced to a high level (>100-fold) at 24 hrs. Moreover, two of these genes 
(BcRF1 and BGLF4) demonstrated peak expression above 100-fold at 24 hrs rather than 48 
hrs (Table 3.2). An additional two genes (BBLF2 and BMRF1) were induced over 80-fold at 
24 hrs (Table 3.2). Seven genes (BDLF4, BFLF2, BFRF1, BFRF2, BILF2 BORF2 and 
BXLF1) were induced further (to expression levels above 100-fold) at 48 hrs. Indeed, BXLF1 
induction levels were 153-fold and 634-fold at 24 and 48hrs, respectively.  Notably, several 
genes (BGLF4, BcRF1, BGLF4, BMRF1, BDLF4, BFLF2 and BORF2) are overlapping in the 
EBV genome, three of which (BMRF1, BFLF2 and BORF2) are fully contained in the 
overlaps. Therefore, it is highly likely that the fold-induction levels are for these shorter 
overlapping genes. 
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Detection of late lytic cycle gene expression  
Regulation of the late lytic genes is less well understood than for the IE and early genes, but 
is known to be coupled to viral DNA replication (Gruffat et al., 2012; Robertson, 2005). The 
late lytic genes are classically defined as genes expressed after the activation of viral DNA 
replication, and are blocked at the protein level and steady state mRNA levels (Amon et al., 
2006b; Serio et al., 1997a). As a consequence, late gene expression is sensitive to the same 
agents (phosphonoacetic acid, PAA and acyclovir, ACV), that prevent lytic replication (Katz 
et al., 1989; Rickinson et al., 1978; Summers and Klein, 1976), by targeting the viral DNA 
polymerase, BALF5 (Lin et al., 1991), suggesting a dependence on this protein and viral lytic 
DNA replication. In addition, Raji has two major deletions and is defective for viral lytic 
DNA replication, resulting in the lack of late lytic cycle gene expression (Decaussin et al., 
1995; Hatfull et al., 1988). Since we measured the relative expression of 89 genes from the 
EBV genome, we also measured late gene expression at the 24 and 48 hr time-points, 
however in the absence of inhibitors of lytic replication. Therefore, an unexpected finding 
was the detection of late lytic gene expression in the model system. For instance, 14 late 
genes were induced over 100-fold at 48 hrs (Table 3.3), of which two, BMRF2 and BXLF2, 
were also induced over 100-fold at 24 hrs, both of which participate in viral entry (Heineman 
et al., 1988; Kurilla et al., 1995; Tugizov et al., 2003).  
The reasons for the detection of late lytic gene products of the expected size was unclear, 
since we validated for the analytical specificity of the primers and potential contamination 
with EBV LCLs or wild-type EBV B95.8 gDNA by the following: (i) detection of EBV 
deletions in the Raji genome and deletions of the B95.8 genome (LF1, LF2 and LF3), 
confirming the absence of B95-8 gDNA contamination; (ii) absence of products of the 
expected size in Ramos gDNA, (iii) absence of EBV gene expression in a no-RTase control 
confirming absence of contaminating Raji gDNA and/or Raji LCLs, and (iv) use of Ramos 
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gDNA and no-template controls during the PCRs, assessing potential gDNA contamination. 
Therefore, possible explanations for the demonstrated results are likely to be biological rather 
than technical, two of which are discussed here. Firstly, we did not use inhibitors of lytic 
DNA replication, such as ACV or PAA in our model system which blocks not only viral lytic 
DNA replication, but also late lytic gene expression.  Therefore, the levels of late lytic gene 
expression found is very likely to be due to the measurement of ‘read-through transcription’ 
from the early lytic genes, including some overlapping mRNAs, into downstream late 
regions. This would arise from the continual priming of the RNA polymerase through the 
EBV genome beyond the normal termination signal. As a result, the distinction between 
early/late lytic cycles is also unclear. Secondly, we measured gene expression in total cellular 
RNA, not mature cytoplasmic mRNA. Therefore, the likelihood of background cellular 
mRNA is high, and we could potentially be measuring non-specific amplification of cellular 
mRNAs. It is not clear what products have been amplified in the results demonstrated, but 
those detected on agarose gels are likely to represent short specific regions of the cellular 
RNAs amplified by the primer pairs.  
While the regulation of IE and early gene expression is well understood in EBV, the 
mechanisms regulating late gene expression were poorly understood until recently (Gruffat et 
al., 2012). Several mechanisms for late gene expression were proposed previously. Serio et 
al. showed that activation of some late gene promoters (BcLF1 and BFRF3) could be 
observed on transiently transfected reporter plasmids even if the reporter plasmids did not 
have the OriLyt sequence in cis  i.e.,  in a replication-independent manner (Serio et al., 
1998b; Serio et al., 1997b). Similarly, studies performed in Z and R-deleted viruses suggested 
that viral replication in cis was not required for activation of EBV late promoters (Feederle et 
al., 2000a; Ragoczy and Miller, 1999). By contrast, Amon et al. showed that late lytic gene 
expression required viral replication in cis (Amon et al., 2004a). Notably, ori lyt was shown 
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to be required for the production of virus replication compartments associated with 
promyelocytic leukaemia protein nuclear bodies (PML-NBs) (Amon et al., 2006a). Taken 
together, these studies suggested both viral proteins and trans-acting factors were involved. 
Viral proteins have been implicated as regulators of late gene promoters but are poorly 
understood in other herpesviruses. In the case of HSV-1, several viral proteins (ICP4, ICP8 
and ICP27) have been shown to be necessary for the efficient expression of late genes (Gao 
and Knipe, 1991; Kim et al., 2002; Lester and DeLuca, 2011; Rice and Knipe, 1990; Tang et 
al., 2003). In murine herpesvirus 68 (MHV-68) and cytomegalovirus (CMV), several viral 
proteins, namely ORF18, ORF24 and ORF34, respectively have also been shown to be 
necessary for the expression of late genes. EBV also encodes three homologues (ORF18, 
ORF24 and ORF34) found in MHV-68 and CMV, including BVLF1.5, BcRF1 and BGLF3 
(Arumugaswami et al., 2006; Wong et al., 2007; Wu et al., 2009). Of these proteins, only 
BcRF1 has a putative function as a homolog to the TATT-binding protein (TBP) (Wyrwicz 
and Rychlewski, 2007a), and was previously implicated in regulation of late gene expression 
(Serio et al., 1998a). The role of BcRF1 has recently been characterised during the EBV 
productive cycle using recombinant assays and to function as a TBP-like protein crucial for 
EBV late gene expression (Gruffat et al., 2012). Three significant findings were identified in 
the study: (i) cells only produce virions when transfected with BcRF1; (ii) BcRF1 is critical 
for the accumulation of late viral transcription but not for viral DNA synthesis and (iii) 
BcRF1 interacts specifically with TATT sequences present  within late gene promoters. 
Therefore, BcRF1 has been shown to form complexes with TATT motifs within late gene 
promoters, following DNA replication only, once the viral genome is methylated (Gruffat et 
al., 2012). These interactions involve viral proteins and are also likely to occur in trans with 
the assistance of other cellular factors (Gruffat et al., 2012). Exactly how BcRF1 forms 
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complexes with the TATT sequence is under investigation. Taken together, the mechanism 
proposed supports the findings of the earlier studies (Amon et al., 2004a; Serio et al., 1997b).  
Owing to the difficulties discussed previously associated with determining late lytic gene 
expression, our preliminary analysis focused on EBV early lytic genes with high fold-
induction levels at either 24 or 48 hrs. Initially twenty-four genes were identified for further 
analysis by the criterion of a more than 100-fold induction at either time-point (Tables 3.6 
and 3.7). Of these 24 genes, nine were selected for further analysis, since only limited 
amounts of cDNA material was available for testing (Table 3.6). We focused on these genes 
since they were highly regulated among the candidate genes and had interesting biological 
properties. Two genes (BALF5 and BRRF1) were selected based on their biological properties 
rather than fold-change alone. In addition, three of the 24 candidate genes (BcRF1, BFRF1 
and BILF1) were early genes with longer overlaps and were selected for future analysis 
(Table 3.7). Altogether, nine genes were selected for further analysis (Table 3.6). However, 
following preliminary evaluation in clinical samples (chapter 5), data was presented for only 
six of the nine genes, since three genes (BMRF1, BPLF1, and BVRF1) were realised to be 
either short overlaps and/or late lytic genes with fold-induction levels that are not likely to be 
accurate for the explanations described earlier. 
Table 3.6 EBV candidate genes selected for preliminary clinical validation  
EBV genes Overlapping genes (Long/Short) Class 
Mean fold-change 
(24 hrs) 
Mean fold-change  
(48 hrs) 
BALF5 - E 14.15 6.23 
BDLF4* Long E 12.30 141.33 
BGLF4* Long E 114 38.58 
BMRF1* Short E 90.17 1323.67 
BPLF1 - L 32.73 569.80 
BRRF1 - E 7.19 73.33 
BVRF1* Short L 27.55 219.67 
BXLF1* Long E 153 624 
BZLF1 - IE 19 156 
IE, immediate-early genes; E, early genes; L, late genes; *overlapping genes; excluded from analysis (bold) 
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Table 3.7 EBV candidate genes selected for future clinical validation 
EBV genes Overlapping genes (Long/Short) Class 
Mean fold-change 
(24 hrs) 
Mean fold-change  
(48 hrs) 
BcRF1* Long E 104.44 63.67 
BDLF3 - L 3.50 313.15 
BDRF1 - L 17.25 900.60 
BdRF1* Long L 27.33 1693.23 
BFRF1A - L 21.99 736.67 
BFRF1* Long E 19.11 597.33 
BFRF2* Short E 29.66 1406.67 
BFRF3 - L 13.31 158.33 
BILF1 - E 12.13 106.28 
BILF2 - L 23.76 254.33 
BKRF4 - L 12.50 251.33 
BMRF2* Short L 117.01 826.33 
BOLF1 - L 58 1331.3 
BORF1* Long L 1.45 245.33 
BXLF2 - L 103.19 1365.67 
IE, immediate-early genes; E, early genes; L, late genes; *overlapping genes; selected candidate genes 
highlighted in bold. 
 
EBV early candidate genes and their biological properties 
The majority of early genes function in viral DNA replication (Fields, 2002). Overall, at the 
24 hr time-point, 9.09% of the early genes were induced over 100-fold (Table 3.5). Of 
interest, 7/32 (21.88%) early genes (BALF2, BALF5, BBLF2, BBLF3, BBLF4, BcRF1, and 
BGLF4), including BALF5 that encodes the viral DNA polymerase, demonstrated maximal 
expression at 24 hrs versus 48 hrs. This implies that EBV lytic replication is occurring at 
early stages of the lytic cycle since the majority of the early EBV gene products function in 
viral lytic DNA replication (Tsurumi et al., 2005).  
The majority of other early genes (BaRF1, BDLF4, BFLF1, BFLF2, BFRF1, BFRF2, 
BGLF5, BHRF1, BILF1, BKRF3, BLLF2, BLLF3, BNLF2a, BNLF2b, BORF2, BRRF1, 
BSLF1, BSMLF1, LF1, LF2 and LF3) exhibited delayed induction with higher fold-change at 
48 hrs versus 24 hrs. Most of these genes were involved in functions other than EBV 
replication, including some unknown functions (Table 1.4). We also identified six genes 
(BFLF2, BFRF1, BFRF2, BILF1, BMRF1 and BXLF1) that showed increased expression 
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(>100-fold) over time (24-48 hrs), of which two (BILF1 and BXLF1) are not overlapping. 
Our findings reveal ten highly induced (>70-fold) early genes (BcRF1, BDLF4, BFLF2, 
BFRF1, BFRF2, BGLF4, BILF1, BMRF1 BRRF1 and BXLF1) at 24 hrs or 48 hrs that could 
serve as potential early markers of PTLD (Tables 3.6 and 3.7). However, in the first instance, 
six genes (BALF5, BDLF4, BGLF4, BMRF1, BRRF1 and BXLF1) were selected for further 
analysis (Table 3.6). We focused on these genes among the highly regulated early candidate 
genes since they were biologically interesting. However, three genes (BDLF4, BGLF4 and 
BMRF1) are overlapping, of which BMRF1 is contained within the longer mRNA transcript, 
and its expression levels may be overestimated.  
A brief summary of the proposed functions of all of the EBV early genes is presented in 
Table 1.4. Further details on the functions of the identified candidate PTLD genes are 
described here. EBV lytic gene expression has been demonstrated in PTLD alongside latent 
gene expression (Brink et al., 1997; Rea et al., 1994b). It is presumed that EBV reactivation 
during immunosuppression can lead to an increase in viral replication that contributes to the 
development of PTLD (Hopwood et al., 2002). However, the role of the EBV lytic genes and 
their contribution to PTLD is less clear (Rowe et al., 1998). Examining the gene expression 
patterns of selected EBV genes may provide an understanding of their involvement in PTLD. 
The BALF5 gene functions as the viral DNA polymerase, essential for EBV lytic DNA 
replication (Tsurumi, 1991). The BGLF4 gene encodes the nuclear serine/threonine protein 
kinase (PK), a virion tegument component that phosphorylates several EBV proteins 
(Feederle et al., 2009; Johannsen et al., 2004), including BMRF1 (Chen et al., 2000), BZLF1 
(Asai et al., 2006; Asai et al., 2009), EBNA-LP (Kato et al., 2003) and EBNA-2 (Yue et al., 
2005) as well as numerous cellular proteins including elongation factors (Kawaguchi et al., 
2003). BRRF1, encodes a transcription factor that enhances lytic cycle induction via the IE 
protein BRLF1 (Hong et al., 2004; Segouffin-Cariou et al., 2000), whereas BXLF1 encodes 
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the viral thymidine kinase (TK) that phosphorylates targets (Littler et al., 1986). Therefore, as 
mentioned earlier, these genes could contribute to PTLD through an increase in the level of 
viral replication during an immunosuppressed state. 
Additional candidate genes whose functions are unknown include BDLF4, which encodes 
envelope glycoprotein 115 (gp115) (Boeckmann et al., 2003) and BcRF1, for which a role as 
a TATA-binding protein (TBP), important for transcriptional regulation has been proposed 
(Wyrwicz and Rychlewski, 2007b). Furthermore, the BcRF1 protein has very recently been 
shown to be essential for activation of late gene expression via interactions with TATT motifs 
within the promoters of these genes (Gruffat et al., 2012). Interestingly, we detected maximal 
fold-induction levels of BcRF1 at 24 hrs (104-fold vs. 66-fold), reflecting its early 
requirements during the viral life cycle. Therefore, it would be interesting to investigate this 
gene further as a potential biomarker of PTLD. BDLF4 is up-regulated by the early gene 
BSMLF1 (also known as SM) which encodes the RNA export protein BSMLF1, essential for 
EBV lytic DNA replication. This suggests that BDLF4 is a BSMLF1-dependent protein and a 
clear marker of EBV replication (Han et al., 2007).   
 
EBV late genes and their biological properties 
The majority of EBV late genes encode structural components of the EBV virion involved in 
viral assembly and egress (Fields et al., 2007). Studies have shown that the EBV late genes 
are demonstrated less frequently in PTLD as compared to the early genes, suggesting that 
productive infection does not always occur (Rea et al., 1994b). Since the detection of late 
lytic gene expression was unclear we chose to investigate the early lytic genes only. 
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EBV latent gene expression 
In vitro, latency III is demonstrated by expression of all latent genes including EBV-encoded 
RNAs (EBERs) and BamHI A rightward transcripts (BARTs) (Young and Rickinson, 2004). 
We also detected latent gene expression in Raji LCLs following activation of the lytic cycle, 
although full latency III was not observed. At the 24 hr time-point, 2/11 (18%) latent RNAs 
(A73/RPMS1 and BARF0), were induced over 2-fold, both of which were BART RNAs 
(Kusano and Raab-Traub, 2001; Smith et al., 2000; Zhang et al., 2001). BARF0 was induced 
maximally to 11-fold at 24 hrs. Although the exact function of BARF0 in vivo is uncertain, its 
expression has been demonstrated in biopsy tissue of several malignancies, including PTLD, 
where it is presumed to participate in maintenance of latency, however, not B-cell 
transformation (van Beek et al., 2003). The remaining nine latent genes were down-regulated, 
confirming disruption of latency.  
At the 48 hr time-point, increased latent gene expression (induced >2-fold) was detected in 
5/11 (45.45%) latent genes (A73/RPMS1, BARF0, EBER-1, EBNA-1 and EBNA-3A) (Table 
3.4). EBNA3A was induced over 13-fold at 48 hrs. EBNA-3A functions as a transcriptional 
regulator of gene expression during latency (Hertle et al., 2009). In addition, EBNA-3A has 
been shown to co-operate with EBNA-2 to induce anti-apoptosis, a process likely to 
contribute to malignancies such as PTLD (Anderton et al., 2008).  
Our findings are in keeping with other studies where latent (but not latency III), gene 
expression was detected during lytic cycle activation (Yuan et al., 2006). In particular, 
expression of the EBNA3s was detected during lytic cycle activation (Yuan et al., 2006).  
Other studies have demonstrated increasing latent gene expression including expression of 
EBNA1, EBNA2 and LMP1 during lytic cycle reactivation (Rowe et al., 1992). Similarly, Lu 
and colleagues showed detection of EBNA2, EBNA3A and EBNA3C during lytic replication 
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(Lu et al., 2006). Further, concomitant increases in latent gene expression with early lytic 
gene expression have also been detected (Bernasconi et al., 2006). The co-expression of 
latency III during EBV lytic replication could facilitate EBV replication (Chen et al., 2009; 
Yuan et al., 2006). Latency III has been implicated with PTLD (Brink et al., 1997). In order 
to gain a better understanding of the functions of the EBV latent gene products and their 
contribution to PTLD, all eight EBV latent genes (EBNA-1, EBNA-2, EBNA3A, EBNA-3B, 
EBNA-3C, EBNA-LP, LMP-1 and LMP-2) were chosen for further analysis.     
 
Comparison with EBV gene expression in TPA induced B95.8 cells   
In the present study, we used real-time PCR to analyse relative expression levels of 88 EBV 
genes, including six spliced forms following TPA/NaB induction of Raji cells at 24 and 48 
hrs. Seventy-eight of the 88 primer sets were published previously and used to investigate 
EBV gene expression following TPA induction in B95.8 cells at 24 and 48 hrs (Pan et al., 
2005). Consistent with our study, lytic activation was demonstrated following the induction 
of BZLF1 and BRLF1. Overall, they showed that the majority of EBV genes were induced 
following TPA induction, with 12 of the 80 (15%) genes and a further 20 genes (25%) 
induced highly at 24 and 48 hrs, respectively. Notably BILF2, BBLF4, BFRF2, BSLF1 (now 
BSMLF1), EBER1 and EBNA-3A were induced highly in their study, consistent with ours. In 
comparison to their study, we detected much stronger fold-induction levels in our model 
system. However, following manual calculation of the ddCt (fold-change) for the dCt values 
of the genes in their study, we detected higher levels of induction than described in their 
study. This made it difficult to compare fold-induction levels for these genes. One possible 
explanation for the higher levels of fold induction detected in our system could be the 
synergistic effect of TPA/NaB versus TPA alone in their study, which results in enhanced 
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lytic induction. Despite the demonstration of latent and lytic gene expression, these findings 
suggest variations in the levels of EBV gene expression between different systems.   
 
Limitations of study 
Two major limitations are associated with the study.  Firstly, the choice of cell line in which 
we measured EBV gene expression was not optimal since Raji has two major deletions and is 
defective for late lytic gene expression (Decaussin et al., 1995). Therefore, expression levels 
of the entire EBV genome were not assessed. Further, the mechanism of lytic induction using 
the phorbol ester, TPA is uncertain (Baumann et al., 1998a). Alternative cell lines could 
provide more suitable models for measuring EBV gene expression, such as the Akata cells 
line, which is induced to enter the lytic phase by IgG cross-linking, offering a more specific 
and physiological method for lytic activation (Amon et al., 2004a; Shimizu and Takada, 
1993a). Secondly, a control for inhibition of viral lytic DNA replication, such as PAA or 
ACV was not included in the model system. In summary, in the model system used here, we 
detected highly induced EBV early and unexpectedly, late genes at 24 and 48 hrs, 
respectively. The demonstration of late lytic gene expression is likely to be due to ‘run 
through’ transcription from either early genes into late regions’ or non-specific amplification 
of background cellular mRNAs, since total RNA was used. Profound expression of the 
majority of the early genes at the 48 hr time-point was likely to be due to prolonged 
TPA/NaB treatment (Pan et al., 2005). Notably, induction over 1000-fold was detected for 
2/33 (6%) early genes (BMRF1 and BXLF1) and 3/42 (7%) late genes (BdRF1, BOLF1 and 
BXLF2), of which three (BMRF1, BdRF1 and BXLF2) were overlapping and excluded from 
further analysis. In addition, we detected concomitant latent gene expression in lytic induced 
Raji cells, which could facilitate viral replication (Chen et al., 2009; Yuan et al., 2006). We 
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also demonstrated the real-time PCR assays evaluated here to be a sensitive, specific and 
rapid approach for EBV gene expression analyses in LCLs, and in doing so validated the 
primer pairs for this purpose. Using these assays, the majority of EBV genes were detectable 
and we were able to identify highly induced EBV lytic candidate genes. Owing to limited 
amounts of cDNA material, only 14 genes (six lytic, eight latent) were selected for further 
analysis. In order to evaluate the contribution of the EBV lytic genes to PTLD, the remaining 
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In the previous chapter, EBV gene expression profiles were analysed in TPA/NaB induced 
Raji cells using real-time PCR. A number of highly induced EBV candidate genes were 
identified, indicating successful EBV lytic induction in the model system. As reliable 
predictive markers of PTLD are lacking, and EBV lytic genes, such as BZLF1 are known to 
regulate cellular gene expression, our aim was to identify additional cellular genes regulated 
by EBV during the lytic induction phase that could serve as potential markers for PTLD 
(Carter et al., 2002; Chang et al., 2006; Hahn et al., 2005; Morrison and Kenney, 2004; 
Morrison et al., 2004). Several studies have sucessfully used DNA microarrays to analyse 
cellular gene regulation in response to EBV lytic replication, EBV infection, EBV-associated 
PTLD in biopsy tissue, and EBNA-2 induction in in vitro systems (Allen et al., 2009; Baran-
Marszak et al., 2002; Broderick et al., 2009; Craig et al., 2007; Spender et al., 2002; Spender 
et al., 2006; Yuan et al., 2006). Therefore, we chose to use this technique to investigate the 
cellular response to the early phase of the EBV lytic cycle.  
DNA Microarray technology is a widely used technique to measure global changes in gene 
expression levels following the simultaneous expression of thousands of genes in a given 
sample under a number of different biological conditions. Consequently, widely used 
applications for microarray gene expression profiling include the identification of genes that 
could serve as potential diagnostic markers of disease or disease progression, by screening 
patient samples (Davis and Staudt, 2002). The principle of microarray technology is to 
generate a signal intensity that reflects the abundance of gene expression in a given sample 
under a particular condition compared to its control. In order to achieve this, DNA 
microarrays consist of an array of thousands to tens of thousands of DNA fragments or 
probes (either synthetic oligonucleotides, cDNAs or PCR amplicons) spotted onto their 
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surface, each of which represents a gene transcript. Following hybridisation of fluorescently 
labelled cDNA or aRNA to the immobilised probes, a fluorescent signal is emitted, which is 
proportional to the amount of cDNA hybridised to the probe and present in the original 
sample. It is this measurement that determines the differential expression of a gene, by 
comparing signal intensities with other reference genes from the organism under 
investigation. DNA microarrays can be either a glass slide or silicon chip, also known as a 
gene chip although earlier arrays were based on nylon membrane technology.  
Affymetrix GeneChip® arrays are the most popular type of high density oligonucleotide 
arrays available and are used widely by many researchers (Irizarry et al., 2003; Lipshutz et 
al., 1999).  As mentioned previously, the Affymetrix HG U133 Plus 2.0 GeneChip® contains 
54,675 probe-sets that interrogate 38,500 genes (Irizarry et al., 2003; Lipshutz et al., 1999). 
We chose this chip since it covers the whole human genome and allowed us to interrogate all 
cellular genes as candidate markers. In this study, we used HG U133 Plus 2.0 GeneChips® to 
analyse host cellular gene expression profiles in cDNA derived from TPA/NaB induced Raji 
and Ramos cells at 24 hrs post-induction, since the early genes were highly induced at this 
time-point. Microarray analysis was performed in duplicate and a pair-wise comparison 
performed on four arrays (induced and uninduced Raji cells). The duplicate experiments 
represent two biological replicates, one of which demonstrated high lytic gene expression as 
described in chapter 3.  A second pair-wise analysis was performed on four arrays (induced 
and uninduced EBV-negative Ramos cells) to eliminate any background host gene expression 
due to the effects of the induction stimulus alone (TPA/NaB). Therefore a total of eight arrays 




4.1.1 Objectives of chapter 
 
The aims of the experiments described in this chapter were three-fold: 
(i) To identify cellular genes which are highly differentially expressed and regulated 
in response to the EBV lytic induction phase following TPA/NaB treatment  
(ii) To identify the overall representative Gene Ontology of cellular genes regulated in 
response to the EBV lytic induction phase 
(iii) Using the data generated in (i) and (ii) to identify cellular candidate genes as 















4.2.1 Validation of RNA integrity 
Total RNA was extracted from two independent experiments with induced and uninduced 
Raji and Ramos cells. The quality of the total RNA was assessed on the Agilent® 2100 
Bioanalyser (Figure 4.1). Antisense RNA (aRNA) and fragmented aRNA derived from this 
total RNA were also analysed using the Agilent® 2100 Bioanalyser to ensure successful 
fragmentation (Figure 4.2). The RNA integrity for total RNA, aRNA and fragmented aRNA 
was high as demonstrated by the 2:1 ratio of 28S and 18S ribosomal RNA (rRNA), and  
broad profiles (fragmented aRNA)(Figure 4.2, panel B). The same process was used to 
confirm the integrity of total RNA extracted from the induced and uninduced Ramos cells. 
Total RNA was reverse-transcribed into cDNA as described previously (section 2.4.3) and 
the fragmented cRNA finally analysed on the DNA arrays. 
 
    
   
Figure 4-1 Validation of total RNA integrity 
Gel image and Bioanalyser electropherogram for total RNA derived from the Raji cell line induced for the EBV 
lytic cycle with TPA/NaB. Total RNA was isolated from duplicate biological replicates of TPA/NaB induced 
and uninduced Raji cells. Total RNA was analysed on an Agilent® Bioanalyser RNA 6000 Nano chip. (A) 
Panel A shows the gel image. (B)  Panel B shows traces of intact RNA representing 2:1 ratios for the 28S (right 
trace) and the 18S (left trace) rRNAs. The far left trace likely represents 5S RNA. The 2:1 ratio represents high-
integrity total RNA. The y-axis represents the fluorescence units (FU) and the x-axis the nucleotide (nt) length. 











        
 
Figure 4-2 Validation of aRNA fragmentation  
Gel image and Bioanalyser electropherogram for total RNA derived from pooled duplicate biological replicates 
of TPA/NaB induced Raji cells. Approximately 200 ng total RNA was amplified into aRNA using the 
MessageAmp™ Premier RNA amplification kit (Ambion) followed by aRNA fragmentation. The quality of 
fragmented aRNA (A) and unfragmented aRNA (B) was analysed on an Agilent Bioanalyser RNA 6000 Nano 
chip. The broad peaks shown in panel A represent successful fragmentation of aRNA. Marker = RNA 6000 
Ladder (P/N#am7152) 
  
4.2.2 Identification of differentially expressed probe sets regulated over 2-fold  
Affymetrix MAS 5.0 analysis was performed on aRNA derived from induced and uninduced 
Raji cells at 24 hrs post-induction. In order to identify highly differentially expressed and 
regulated cellular genes, several filtering steps were applied to all probe sets on the arrays 
(Figure 2.2), as described (section 2.5.2.3). In the third filtering step, a minimum 2-fold cut-
off threshold was used leaving 6,517 and 5,437 probe sets in replicates a and b, respectively. 
From the overlap of the 6,517 and 5,437 probe sets, a total of 3,884 probe sets were identified 
that were commonly modulated in both biological replicates (Figure 4.3). These probe sets 





4.2.3 Identification of the top most highly differentially expressed probe sets 
A sub-set of probe sets was selected from the overlap of 3,884 probe sets, by using the 
method ‘sum (signals) x SLR’, described previously (section 2.5.2.3.4), to remove genes with    
high SLR but low signal values that represent overall low signals. The 250 most differentially 
expressed genes were ranked. Of these probe sets, 191 (76.4%) were commonly modulated in 
both biological replicates (Table 7.2). The identification of genes regulated specifically by 






Figure 4-3 Overlay of differentially expressed probe sets between induced Raji replicates  
Venn diagram showing the overlay between 6,517 and 5,437 probe sets from the two replicates that was 
differentially expressed (≥2-fold) in the Affymetrix HG U133 Plus 2.0 GeneChip® array. A total of 3,884 probe 
sets were commonly regulated. Also shown are 2,633 and 1,533 genes regulated only in replicate a and b, 
respectively. 
 
4.2.4 Identification of probe sets regulated specifically by EBV lytic replication 
In order to identify which of the 191 highly differentially expressed probe sets (171 genes) 
were expressed specifically by EBV replication and not in response to lytic cycle reagents, a 
second overlap of the 191 probe sets with the 199 most highly differentially expressed probe 
sets from TPA/NaB induced EBV-negative Ramos cells was assessed (Figure 4.4). The 
overlap identified 58 probe sets (57 genes) commonly modulated in both induced Raji and 
Ramos cells and 133 probe sets (112 genes) regulated in Raji cells alone (Table 7.2). Next, 
the fold-changes for each of the 58 probe sets (57 genes) were compared between induced 
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Raji and Ramos cells to determine the likelihood that these genes were regulated in response 
to the lytic cycle inducers.  
 





Figure 4-4 Overlay of top most highly differentially expressed and regulated probe sets 
between induced Raji and Ramos replicates  
Venn diagram showing the overlay between the top 191 and 199 differentially expressed probe sets (≥2-fold) 
identified on the Affymetrix HG U133 Plus 2.0 GeneChip® from TPA/NaB induced Raji and Ramos biological 
replicates, respectively. The top 191 most differentially expressed probe sets (≥2-fold) were identified from the 
overlay of 3,884 probe sets commonly modulated between 6,157 and 5,437 probe sets from Raji biological 
replicates a and b and compared to the top 199 differentially expressed probe sets identified from duplicate 
biological replicates of induced Ramos cells, with 58 probe sets (57 genes) commonly modulated in both 
TPA/NaB induced Raji and Ramos cells. Also shown are 141 probe sets and 133 probe sets regulated in Ramos 
and Raji cells, respectively. 
 
4.2.5 Identification of 58 host probe sets regulated by lytic cycle inducers 
The 58 probe sets (57 genes) commonly modulated in both induced Raji and Ramos cells 
included 31 up-regulated probe sets (31 genes) and 27 down-regulated probe sets (26 genes) 
(Table 7.2). The regulation and fold-change for all 58 probe sets (57 genes) was subsequently 
compared between Raji and Ramos cells. Since Raji cells do not have an EBV-negative 
counterpart, EBV-negative Ramos cells were used as controls for the effects of the inducing 
agents. Given the genetic differences between the cell lines, the reliability of the data could 
be increased by increasing the numbers of replicates used. However, in this genome-wide 
analysis, only two replicates were analysed for each cell line. The direction of regulation of 
all genes was similar between Raji and Ramos cells, with all 31 probe sets (31 genes) that 
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were increased in Raji also increased in Ramos and all 27 probe sets (26 genes) that were 
decreased in Raji also decreased in Ramos (Table 7.2). Moreover, the fold-change for all 58 
probe sets (57 genes) was similar between Raji and Ramos cells. All 58 probe sets were 
subsequently excluded from the 191 probe sets leaving a sub-set of 133 probe sets (112 
genes) which we were confident were not regulated by TPA/NaB.  
 
4.2.6 Identification of 133 probe sets regulated specifically by EBV replication  
Of the 133 probe sets (112 genes) regulated specifically by EBV lytic infection, 77 (57.89% 
[64 genes]) were up-regulated and the remaining 56 (42.10% [49 genes]) down-regulated 
(Table 7.2). The assessment of fold-changes for each probe set, revealed that the most up-
regulated gene was CHI3L1, a chitinase (18.1-fold up-regulated), and the most down-
regulated gene was RGS13, a regulator of G-protein signaling 13 (-8.7-fold down-regulated). 
The median fold-change of the up-and down-regulated genes were 4.95 (range: 2.1 – 18.1) 
and -3.6 (range: -2.1 – -8.7), respectively. The 133 probe sets were subject to further analysis.  
 
4.2.7 Identification of multiple probe sets that map to the same transcript 
Affymetrix HG U133 Plus 2.0 GeneChip® arrays contain 11-20 probe sets that span each 
gene transcript to enhance reproducibility and accuracy of the hybridisation signal intensity 
(Figure 2.1). In order to decipher the total number of individual differentially regulated genes 
from within the 133 EBV-specific probe sets, as well as the reproducibility of the Affymetrix 
data, genes represented by two or more of the probe sets were identified. In total, 112 unique 
genes were identified. Of the 112 genes, 21 were represented by multiple probe sets, 
including 14 up- and 7 down-regulated genes (Table 4.1). Moreover, with the exception of 
SQSTM1, fold-changes were similar for multiple probe sets in 20 (95.24%) of these genes, 
demonstrating high reproducibility of the Affymetrix data. Three of the genes (CCL5, 
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ANP32E and LRMP) demonstrating reproducibility across probes were selected as candidate 
markers. The average fold-change for each of these genes was 9, -3.25 and -3.5-fold, 
respectively (Table 4.1).    
 
Table 4-1 Identification of multiple probe sets for cellular genes 
Probe sets Gene symbol Fold-change for each probe set (Average fold-change) 
209969_s_at; 200887_s_at STAT-1 10.3-, 6.1-fold  (8.2) 
201694_s_at;  201693_s_at EGR1 11.2-, 10.3-fold (10.8) 
i405_i_at; 1555759_a_at; 
204655_at CCL5 8.4-, 9-, 9.6-fold (9) 
208581_x_at; 204326_x_at MT1X 6.8-, 6.5-fold (6.7) 
225842_at; 217996_at PHLDA1 11.8-, 13.1-fold (12.5) 
202497_x_at; 202499_s_at SLC2A3 10-, 8.9-fold (9.5) 
204747_at; 229450_at IFIT3 7-, 6.5-fold (6.8) 
213112_s_at; 201471_s_at SQSTM1 12.4-, 6.5-fold (9.5) 
200866_s_at; 200871_s_at PSAP 4.8-, 4.1-fold (4.5) 
35820_at; 212737_at GM2A 4.9-, 4.2-fold (4.6) 
210592_s_at; 203455_s_at SAT1 4.2-, 3.8-fold (4) 
201625_s_at; 201627_s_at; 
201626_at INSIG1 4.2-, 3-, 2.3-fold (3.2) 
-34210_at; 204661_at CD52 3-, 2.9-fold (3) 
214211_at; 200748_s_at FTH1 4.7-, 2.25-fold (3.5) 
200772_x_at; 211921_x_at PTMA -2.1-, -2.4-fold (-2.3) 
40189_at; 213047_x_at SET -2.3-, -2.4-fold (-2.4) 
211714_x_at; 209026_x_at; 
212320_at TUBB -2.3-, -2.6-, -2.7-fold (-2.5) 
214938_x_at; 200680_x_at; 
224731_at HMGB1 -2.6-, -5.6-, -3.2-fold (-3.8) 
201306_s_at; 201305_x_at ANP32E -3.1-, -3.3-fold (-3.2) 
208956_x_at; 209932_s_at DU2 -2.25-, -3.6-fold (-3) 
204674_at; 35974_at LRMP -3.4-, -3.6-fold (-3.5) 
Cellular genes with multiple probe sets selected for further analysis (bold) 
4.2.8 Identification of cellular genes as candidate markers  
In order to increase the probability of identifying an effective diagnostic marker, 22 of the 
112 EBV-regulated cellular genes were selected for preliminary analysis in clinical samples 
(Table 4.2). These genes fulfilled the following criteria: (i) not regulated in response to lytic 
cycle inducers (TPA/NaB); (ii) regulation in EBV-associated PTLD and/or EBV infection 
that was previously demonstrated in the literature; (iii) highly regulated cellular genes with 
biological functions of interest, and (iv) cellular genes identified in significantly represented 
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networks in Gene Ontology analysis. Owing to limited cDNA material derived from the 
whole blood samples, only 17 of the 22 genes were subject to gene expression profiling 
(high-lighted in bold in Table 4.2).  
 
4.2.8.1 Regulation of cellular candidate genes 
Details of the 22 candidate genes are presented in Table 4.2. Thirteen (59.09%) of these 
candidates (CHI3L1, TIMP-1, CXCL9, CCL5, ULBP2, ISG15, ANXA2, RASA1, CCL22, 
CXCL10, CCL3, CD52 and VIM), were up-regulated, including CHI3L1, which was the most 
up-regulated gene (18.1-fold, P<0.0084) (Table 7.2). The remaining nine (40.91%) genes 
(IGJ, HDGF1, ANP32E, PCNA, LRMP, MAD2L1, CDC2, HMGB1 and RGS13) were down-
regulated, including RGS13, which was the most down-regulated gene (-8.7, P<0.001).  
 
4.2.8.2  Identification of cellular candidate genes in PTLD 
A literature search revealed eight genes (CD52, ANP32E, PCNA, MAD2L1, CDC2, LRMP, 
HMGB1 and TIMP1) differential regulation in EBV-monomorphic PTLD (M-PTLD) relative 
to EBV-negative M-PTLD (Craig et al., 2007). All eight genes were involved in DNA 
replication (HMGB1, PCNA), transcription (ANP32E), cell cycle regulation (MAD2L1, 
CDC2), vesicle fusion and anti-apoptosis (LRMP), cell proliferation (TIMP-1) and anti-
apoptosis (CD52). Owing to their involvement in PTLD, all eight genes were selected as 
candidates for gene expression profiling. Biological annotations for all 22 candidates are 
presented in Table 4.2. Several of the up-regulated genes (5/13 [38.46%]) are involved in 
chemotaxis, inflammatory response and signal transduction (CCL5, CCL22, CXCL10, CCL3, 
and HDGF1). Conversely, the majority (5/9 [55.56%]) of the down-regulated genes are 
involved in cell cycle regulation, egulation of transcription, and DNA replication (MAD2L1, 
CDC2, ANP32E, HDGF1, and HMGB1).  
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Table 4-2 Summary of highly differentially expressed and regulated cellular candidate genes  
Probe set ID Gene symbol Gene name Biological process Cellular compartment Fold-change P-value 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) Chitin catabolic process Extracellular 18.1 P<0.0084 
201666_at TIMP-1 TIMP metallopeptidase inhibitor 1 
Positive regulation of cell 
proliferation/Negative regulation 
of membrane protein 
Extracellular region 14.7 P<0.00002 
203915_at CXCL9 chemokine (C-X-C motif) ligand 9 
Chemotaxis, defense, immune 
response, signal transduction, cell-
cell signalling 
Extracellular 
region/extracellular space 10.2 
 
P <0.0001 
1405_i_at CCL5 chemokine (C-C motif) ligand 5 
Chronic inflammatory response, 
chemotaxis, cell adhesion, signal 
transduction,  negative regulation 
of viral replication, response to 
NF-kappa B 
Extracellular 9.6 P <0.0003 
238542_at ULBP2 UL16 binding protein 2 Immune response, antigen processing, NK cell activation Extracellular 8 P<0.0001 
205483_s_at ISG15 ISG15 ubiquitin-like modifier 
Cell-cell signalling, response to 






















210621_s_at RAS p21 
RAS p21 protein activator 
(GTPase activating protein) 
1 
Cell adhesion, anti-apoptosis, 
signalling cascade Plasma membrane 5.4 P<0.0001 
207861_at CCL22 chemokine (C-C motif) ligand 22 
Chemotaxis, inflammatory 
response, immune response, cell 
signalling, response to virus 
Extracellular 4.4 P<0.0018 
204533_at CXCL10 chemokine (C-X-C motif) ligand 10 
Chemotaxis, inflammatory 
response, cell cycle, signal 
transduction 
Extracellular 4 P<0.0001 
205114_ s_at CCL3 chemokine (C-C motif) ligand 3 
Chemotaxis, inflammatory 
response, cell cycle, signal 
transduction 
Extracellular 3.7 P<0.0007 
201426_s_at VIM Vimentin Cell motion Cytoplasm/plasma membrane 3.3 P<0.0001 




Table 4-2 continued 
 











and mu polypeptides 


















Nucleus,cytoplasm -2.4 P<0.0014 
201202_at PCNA proliferating cell nuclear antigen DNA replication Nucleus -2.9 P<0.0001 
204674_at LRMP lymphoid-restricted membrane protein Vesicle fusion 
Integral to plasma 
membrane -3.4 P<0.0084 
203362_s_at MAD2L1 MAD2 mitotic arrest deficient-like 1 Cell division (cell cycle) Chromosome -5.3 P<0.00113 
203213_at CDC2 cell division cycle 2, G1 to S and G2 to M 
Anti-apoptosis, cell 
cycle Plasma membrane -5.4 P<0.0004 
200680_x_at HMGB1 high-mobility group box 1 
DNA unwinding during 
replication Nucleus, chromosome -5.6 P<0.0001 




Plasma membrane -5.7 P<0.0001 
List of up- and down-regulated cellular candidate genes selected from the Affymetrix HG U133 Plus 2.0 GeneChip™ array. Ranked by fold-change, where P<0.05 is 
considered statistically significant. Genes selected for further analysis (bold) 
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4.2.9  Validation of microarray data for 22 cellular candidate genes by real-time PCR 
In order to verify the regulation of the candidate genes, and to what extent, prior to further 
analysis, real-time PCR using TaqMan gene expression assays was used to validate the 
microarray data for all 22 candidate genes. Samples were run in triplicate using cDNA 
(diluted 1/100) derived from pooled duplicate flasks; two biological replicates (replicates a 
and b) of induced and uninduced Raji cells were tested by real-time PCR and fold-changes 
calculated in Prism as described previously (section 2.4.9). The single-copy house-keeping 
ACTB gene was used as the internal reference control. The regulation of the cellular genes 
was consistent between real-time PCR and microarray results with fourteen up-regulated and 
eight down-regulated genes (Figures 4.5). A comparison of the fold-change for all 22 
candidate genes derived from real-time PCR and microarray is presented in Table 4.3. 
Correlations between the microarray and PCR distributions were determined using pearson’s 


















































































































































































Figure 4-5 Validation of microarray data for Cellular candidate genes by real-time PCR  
Bar charts showing relative expression levels for CCL3, CCL5, CXCL9, CXCL10 and CCL22 (chemokines) (A), 
ISG15, IGJ, ULBP2 and RGS13 (immune response and cell-cell signaling) (B), MAD2L1, RASA1, VIM, CDC2 
and TIMP1 (cell cycle) (C) and HMGB1, HDGF1, PCNA and ANP32E (DNA replication and transcription) (D) 
and LRMP, ANXA2, CHI3L1 and CD52 (Other functions) (E) in response to EBV lytic induction in TPA/NaB 
induced Raji cells (closed bars) versus uninduced Raji cells (open bars) quantitated using real-time PCR. Total 
RNA was isolated from duplicate biological replicates of TPA/NaB induced and uninduced Raji cells using the 
Qiagen RNeasy Extraction Kit and 2 µg reverse-transcribed to cDNA using the Retroscript™ Kit. Real-time 
PCR was performed on serial 1/100 dilutions of cDNA using TaqMan gene expression assays and the TaqMan 
Gene Expression Master Mix. ACTB was used as the internal reference control. Data represents the mean fold-

























4.2.10 Validation of microarray data for TIMP1 by real-time PCR 
Real-time PCR was used to validate microarray data for the TIMP1 gene, which was up-regulated 
14.7-fold (P<0.00002) and 15.2-fold (P<0.001) in induced Raji and Ramos cells, respectively (Table 
7.2). This additional data was used to confirm that the regulation in Raji cells was a specific response 
to either TPA/NaB stimulus, as TIMP1 is known to be up-regulated regardless of EBV infection (Kim 
et al., 2008). Although TIMP1 was up-regulated by EBV infection in uninduced EBV-positive Raji 
cells (Figure 4.6), it was notably up-regulated in TPA/NaB induced Raji cells. This pattern indicated 
that TIMP1 is regulated by EBV infection and that this regulation is enhanced by TPA/NaB treatment. 
Similar regulation patterns were observed in TIMP1 between induced and uninduced Ramos cells, 
although to a marginally higher level in the induced Ramos cells, indicating some regulation by 
TPA/NaB (Table 7.2). Given that TIMP1 is regulated by EBV replication and its regulation has been 

































Figure 4-6  Validation of microarray data for TIMP1 by real-time PCR  
Bar charts showing relative expression levels for TIMP1, in response to EBV infection in TPA/NaB induced 
(closed bars) and uninduced Ramos cells (open bars), versus TPA/NaB induced (closed bars) and uninudced 
Raji cells, as determined using real-time PCR. Total RNA was isolated from duplicate biological replicates of 
TPA/NaB induced and uninduced Raji cells using the Qiagen RNeasy Extraction Kit and 2 µg reverse-
transcribed to cDNA using the Retroscript™ Kit. Real-time PCR was performed on serial 1/100 dilutions of 
cDNA using TaqMan gene expression assays and the TaqMan Gene Expression Master Mix. ACTB was used as 
the internal reference control. Data represents the mean fold-change ±SD for two independent experiments 
performed in triplicate.  
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Table 4-3 Validation of microarray data for cellular candidate genes by real-time PCR  
Probe set 





205114_s_at CCL3 Chemokines 3.7 7.96 
1405_i_at CCL5 Chemokines 9.6 17.81 
207861_at CCL22 Chemokines 4.4 13.84 
203915_at CXCL9 Chemokines 10.2 23.71 
204533_at CXCL10 Chemokines 4.0 15.87 
212592_at IGJ Immune response and cell signaling -2.6 -2.89 
205483_s_at ISG15 Immune response and cell signaling 6.4 15.87 
210258_at RGS13 Immune response and cell signaling -8.7 -7.59 
238542_at ULBP2 Immune response and cell signaling 8.0 20.20 
203213_at CDC2 Cell Cycle -5.14 0.18 
203362_s_at MAD2L1 Cell Cycle -5.3 1.67 
210621_s_at RASA1 Cell Cycle 5.4 6.81 
201666_at TIMP1 Cell Cycle 14.7 143.3 
201426_s_at VIM Cell Cycle 3.3 6.13 
221505_at ANP32E DNA replication and transcription -2.4 -1.78 
200896_x_at HDGF1 DNA replication and transcription -4.1 -3.08 
200680_x_at HMGF1 DNA replication and transcription -5.6 -5.41 
201202_at PCNA DNA replication and transcription -2.9 -2.53 
201590_x_at ANXA2 Other functions 5.9 6.54 
34210_at CD52 Other functions 3.0 2.36 
209395_at CHI3L1 Other functions 18.1 236 
204674_at LRMP Other functions -3.4 -2.35 
  
4.2.11 Gene Ontology analysis of differentially expressed genes 
Gene Ontology (GO) analysis was undertaken in MetaCore to determine the GO biological 
processes and disease biomarker processes, as well as canonical network pathways 
represented by data sets from replicates a) 6,157 probe sets and b) 5,437 probe sets, in 
response to EBV lytic induction.  Both data sets were uploaded into MetaCore and 
enrichment analysis was used to identify the most representative functions altered in response 
to EBV lytic induction in Raji cells at a threshold of 1.5 and P<0.05.   
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4.2.11.1 Functional canonical pathway analysis   
Pathway analysis revealed the ten most significantly represented (P<0.05) canonical 
pathways for both data sets as illustrated in Figure 4.7. Amongst these pathways, the three 
most significant pathways, in order of significance were the anaphase-promoting cycle (APC) 
in cell cycle regulation, the metaphase checkpoint, and the spindle assembly and chromosome 
separation.      
 
 
Figure 4-7  Canonical network pathway analysis of differentially expressed cellular genes   
Histogram showing the top ten most significantly represented canonical network pathways, in probe sets derived 
from Affymetrix microarray gene expression data, altered in response to the EBV lytic phase in TPA/NaB 
induced Raji cells. Seven of ten pathways are involved in cell cycle. Gene expression data at a threshold of 1.5 
and P<0.05 was subjected to Enrichment analysis using GeneGo MetaCore. 
 
4.2.12 Functional biological processes network analysis  
Analysis of GO biological network processes revealed the top ten most significantly 
represented biological processes altered in response to EBV lytic induction (Figure 4.8). Six 
of ten networks were involved in cell cycle regulation, with the top three most significantly 
regulated involved in cell cycle core, cell cycle synthesis (S) phase and cytoskeleton spindle 
microtubules. In order to identify additional potential candidate genes, further analysis is 
required to identify key gene interactions or genes highly differentially regulated within each 
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of the cell cycle core networks. Of interest, chemotaxis was also a highly representative 
biological process and relevant to EBV infection.  
 
 
Figure 4-8  Biological processes network analysis of differentially expressed cellular genes    
Histogram showing the top ten most significantly represented canonical network pathways, in probe sets derived 
from Affymetrix microarray gene expression data altered in response to the EBV lytic phase in TPA/NaB 
induced Raji cells. All ten pathways are involved in cell cycle. Gene expression data at a threshold of 1.5 and 
P<0.05 was subjected to Enrichment analysis using GeneGo MetaCore. 
 
4.3.14   Functional biomarker network pathway analysis 
In order to identify potential disease biomarkers in response to gene expression changes in 
lytic induced Raji cells, preliminary biomarker network processes were analysed within 
enrichment analysis in GeneGO MetaCore™. Figure 4.9 shows the ten most statistically 
significant pathways. As such, lymphoproliferative disorders were among the ten most 
significant networks represented by the Affymetrix data sets. Amongst these networks, the 
three most significant biomarker networks were lymphatic diseases, lymphoproliferative 
disorders and immunoproliferative disorders. Further analysis on functional gene interactions 




Figure 4-9  Biomarker network pathway analysis of differentially expressed cellular genes   
Histogram showing the top ten most significantly represented biomarker network pathways, in probe sets 
derived from Affymetrix microarray gene expression data, altered in response to the EBV lytic phase in 
TPA/NaB induced Raji cells. Gene expression data was set at a threshold of 1.5 and P<0.05 and subjected to 
Enrichment analysis using GeneGo MetaCore.  
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4.3 DISCUSSION  
 
In this chapter, we used Affymetrix HG U133 Plus 2.0 GeneChipTM arrays to identify highly 
differentially expressed and regulated cellular genes in response to EBV lytic induction. This 
was achieved by comparing the most highly differentially expressed probe sets from the 
TPA/NaB induced EBV-negative Ramos cells to the most highly regulated probe sets in the 
induced EBV-postivie Raji cells (Chapter 3). This microarray analysis, identified 5,437 and 
6,517 probe sets that were differentially regulated over 2-fold in two induced biological 
replicates. Amongst the two replicates, 3,884 probe sets were commonly regulated in both; of 
which 191 were commonly regulated when the top 250 most highly differentially expressed 
probe sets were ranked (Table 7.2). These 191 probe sets were analysed further to identify 
any potential candidate genes that could serve as markers for PTLD. Given that phorbol 
esters, such as TPA, can induce uniform gene transcription (Fields et al., 2007), a further 
filter was performed to remove any genes that were up regulated in response to TPA 
induction alone. For this filter the most highly modulated genes in the TPA/NaB induced 
EBV negative Ramos cells were subtracted from the most modulated genes in the TPA/NaB 
induced EBV positive Raji cells. This analysis revealed 58 probe sets (57 genes) that were 
potentially regulated in response to TPA/NaB treatment, leaving 133 probe sets (112 genes) 
that were likely to be regulated specifically by EBV (Figures 4.4; Table 7.2). Within the 133 
probe sets that were regulated in response to EBV reactivation, 77 probe sets (64 genes) were 
up-regulated (≥2-fold) and 56 probe sets (49 genes) down-regulated (≤2-fold) (Table 7.2).  
 
For the preliminary investigation, a maximum of 17 cellular candidate genes could be 
evaluated per clinical sample in each real-time PCR run using limited cDNA template. To 
select the initial 17 genes, we devised criteria for identifying potential targets based on the 
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following: (i) no regulation in response to TPA/SB lytic inducers, (ii) previous regulation by 
EBV and/or PTLD, (iii) highly regulated cellular genes with other biological functions of 
interest, and (iv) Gene Ontology pathways. Our rationale was that any highly regulated 
cellular genes likely to be regulated in response to the EBV lytic phase could also drive 
PTLD pathogenesis. 
 
Analysis of cellular gene expression in vitro 
In this study, TPA/NaB induced Raji cells were used to examine cellular gene regulation in 
response to EBV lytic induction. However, other studies have examined cellular gene 
regulation in response to EBV reactivation in other LCLs (Cahir-McFarland et al., 2004; 
Yuan et al., 2006). For instance, in a previous study, IgG cross-linking was used to mimic B-
cell activation of the EBV-positive Akata cell line (Yuan et al., 2006). When we compared 
our findings to this study, several up-regulated genes overlapped, such as DUSP5, EGR1, 
SQSTM1, OAS1, OASL and PLEK. This overlap lends confidence to the hypothesis that the 
cellular genes that we have identified are being modulated in response to EBV expression. 
However, one gene, LRMP, was observed to be upregulated in this study, while being down 
regulated in our array. One potential reason for this discrepancy could be to differences in 
time-points between the two studies, as well as differences in the kinetics of EBV gene 
expression. Interestingly in the study by Yuan and colleagues, they noted that temporal 
difference influenced the magnitude and direction of modulation of particular genes. For 
instance, while OASL and OAS1 were up-regulated between 24 to 48 hr time-points, they 
were down-regulated at earlier time-points (8-24 hrs). This suggests that differences in gene 
regulation may relate to temporal changes in EBV gene expression patterns following 
activation of viral replication (Yuan et al., 2006). Of note these temporal differences in EBV 
gene expression could also account for the discrepancies in another study that found LRMP to 
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be down-regulated 48 hrs after reactivation, using IgG cross-linking in Akata cells relative to 
EBV-negative AK31 cells (Broderick et al., 2009). Therefore, these findings suggest that the 
time-point (24 hrs) at which RNA was harvested in our array could potentially influence the 
level of expression of the EBV genes and also the cellular candidate genes chosen for further 
analysis.  
 
In the study by Yuan and colleagues, the effects of EBV latent genes on cellular gene 
expression were also investigated (Yuan et al., 2006). When we compared their results to our 
analyses we identified several overlapping genes, including SGK1, STAT-1, ANXA2, DUSP5, 
TIMP-1, ETV7 and EGR1, all of which were previously shown to be regulated in response to 
EBV LMP-1 (Cahir-McFarland et al., 2004) (Table 7.2). Moreover, DUSP5 was shown to be 
up-regulated by latency III in two studies, suggesting that these highly regulated cellular 
genes could be regulated by latency III in our model system (Cahir-McFarland et al., 2004; 
Yuan et al., 2006). During latency III, all EBV latency proteins are expressed (Fields et al., 
2007). Latency III expression has been demonstrated previously during lytic replication and 
is thought to facilitate viral replication (Yuan et al., 2006). In the previous chapter (Chapter 
3) we demonstrated low fold-induction levels for certain EBV latent genes, the remainder of 
which were down-regulated. For instance, we demonstrated a 1.6-fold and 1.77-fold 
induction level of LMP-1 and EBNA-3B, respectively at 24 hrs post-induction, whereas 
EBNA-2 was induced <2-fold. This suggests that the highly differentially expressed and 
regulated cellular genes could be attributable to not only lytic, but latent gene expression. We 
also identified genes known to be up-regulated directly by the EBNA-2 protein in LCLs, 
including JUND, CCL5, ILI41, PCNA and CD69 (Table 7.2) (Lucchesi et al., 2008; Spender 
et al., 2006; Zhao et al., 2006).  Importantly, ILI41 and CD69 were also regulated in Ramos, 
whereas PCNA, LRMP and CD69 that are involved in the cell cycle were down-regulated in 
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our model system. Since previous studies have demonstrated latent gene expression in a small 
proportion of IgG cross-linked Akata cells, it is uncertain which genes are truly regulated by 
EBV lytic replication alone (Yuan et al., 2006). However, both latency III coupled with lytic 
gene expression is documented in PTLD patients (Hopwood et al., 2002). Therefore, 
regardless of the discrepancy of our findings, the selection of candidate genes from this data 
set could still provide useful markers for PTLD. We selected five candidate genes (RGS13, 
LRMP, TIMP-1, ISG15, and PCNA) for further analysis. Our rationale for selecting these 
genes was that they were known to be regulated in response to EBV infection, and therefore, 
this would give us a good starting point for the clinical validation.  
 
Analysis of EBV gene expression in PTLD 
To assess how our results compared to microarray analysis carried out on PTLD biopsy 
tissue, we compared our findings to two previous studies (Baran-Marszak et al., 2002; Craig 
et al., 2007). The first study compared the gene expression profiles of EBV-positive M-PTLD 
relative to EBV-negative M-PTLD (Craig et al., 2007). The results the study were validated 
by an earlier study that investigated cellular gene expression profiles of EBV infected B cells 
versus uninfected cells, and further compared these to EBV-positive B cells in the context of 
PTLD (Baran-Marszak, 2002). Altogether, we identified two up-regulated genes (HMGA1, 
2.2-fold and TIMP1, 14.7-fold) and seven down-regulated genes (ANP32A, -2.6-fold, 
ANP32E,-2.4-fold, CDC2, -5.4-fold; HMGB1, -5.6-fold; MAD2L1, -5.3-fold; LRMP, -3.4-
fold and PCNA, -2.9-fold) (Table 4.3) that were consistent with both studies. Moreover, EBV 
latent genes are known to up-regulate four of these genes (CDC2, HMGA1, LRMP and 
TIMP1) from previous studies, indicating possible regulation by EBV infection or B cell 
regulation (Cahir-McFarland et al., 2004; Yuan et al., 2006). A further two genes were found 
to be modulated across studies (MAD2L1, -5.3-fold; CDC2, -5.4-fold). However, these genes 
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were also shown to be modulated in response to TPA/NaB treatment in our study in EBV-
negative Ramos cells, although to lower levels (-2.6-fold vs. -2.2-fold; Table 7.2), indicating 
regulation independent of EBV infection. In contrast to these studies, CD52, which encodes 
the Campath1 antigen CD52 was up-regulated 3-fold in our array analysis (Table 7.2), but 
down-regulated in PTLD and in latency III expressing cells (Cahir-McFarland et al., 2004; 
Craig et al., 2007).  
 
Eight genes (ANP32E, CDC2, CD52, HDGF1, LRMP, MAD2L1, PCNA, and TIMP1) were 
chosen as potential markers of PTLD, four (CDC2, TIMP-1, LRMP and PCNA) of which 
were also identified as regulated by EBV infection in vitro. Our rationale for selecting these 
candidate genes was to choose cellular genes that were regulated in relation to PTLD, since 
we were limited by the amount of material available for the clinical evaluation. Moreover, the 
products of the candidate genes appear to be involved in processes likely to be relevant to 
PTLD progression, such as anti-apoptosis (ANP32E), cell growth and apoptosis (CDC2; 
CD52; MAD2L1; LRMP) apoptosis, cell growth, cell invasion and apoptosis (HDGF1), 
regulation of transcription/anti-tumour immunity (HMGB1), cell proliferation (PCNA) and, 
cell proliferation, apoptosis, angiogenesis and cellular signaling (TIMP1) (Guo et al., 2010b; 
Kallakury et al., 1997; Lee et al., 2010; Liu et al., 2011; Malkas et al., 2006; Manenti et al., 
2006; Peng et al., 2011; Rodig et al., 2006; Tsukamoto et al., 2008). In addition, CHI3L1, that 
encodes the chitinase-3-like 1 protein, was also chosen since it was the most up-regulated 
gene (18.1-fold) identified in our array, and has also been implicated in several cancers 
(Eurich et al., 2009). Therefore, overall nine cellular genes were selected for further analysis.  
 
GeneOntology Analysis 
We performed Gene Ontology analysis in MetaCoreTM software on the differentially 
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expressed probe sets regulated over 2-fold in our array data (i.e., 5,437 and 6,517 probe sets 
from two biological replicates). This analysis allowed us to determine the overall functional, 
represented by the data sets following EBV lytic induction, and the potential 
microenvironment in which PTLD could develop. 
We performed GO for functional biological processes, canonical pathway analysis and 
disease biomarkers using enrichment analysis in MetaCore software. We found the cell cycle 
to be the most highly represented biological process in response to EBV reactivation. The 
events in the cell cycle are an important factor in EBV biology, components of which are 
necessary for activating naive resting B cells into proliferating lymphoblasts. In particular, 
EBNA-1, EBNA- 2, EBNA-3A, EBNA-3C, EBNA-LP and LMP-1 are known to regulate the 
cell cycle (Knight and Robertson, 2004; Sinclair et al., 1994). However, the IE gene BZLF1 
can also promote cell cycle arrest to facilitate EBV lytic replication (Zhou et al., 2010). 
Therefore, the identification of cell cycle as the most significant biological process during 
induction of EBV lytic replication could be of considerable importance. This, together with 
the identification of several cellular genes, involved in the cell cycle in our array and 
associated with PTLD in other studies, suggests a role for both latent and lytic gene 
expression in cell cycle dysregulation in PTLD (Craig et al., 2007). 
Furthermore, we also identified chemotaxis as one of the ten most highly represented 
processes in the cell cycle. In particular, we identified four highly regulated chemokines 
including CXCL9 (MIG: monokine-induced by interferon-γ), CXCL10, the interferon-γ 
(IFN-γ)-inducible protein-10 (IP-10), CCL5 (regulated upon activation of the normal T cell 
express sequence, RANTES) and CCL3 (macrophage inflammatory protein-1 alpha, MIP-1α) 
(Table 7.2, Table 4.2). Chemokines are a class of cytokines with chemoattractant properties, 
including around 40 small soluble molecules (12-14 kDa) divided into 4 major families 
including the CXC-, CC-, C- and CX3C- families (Ohshima et al., 2002). All chemokine 
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receptors are integral membrane proteins linked to G-proteins, with seven membrane 
spanning domains. A key role for chemokines is the recruitment of blood leukocytes to sites 
of inflammation (Baggiolini et al., 1997; Schluger and Rom, 1997; Uchihara et al., 2005). At 
these sites, chemokines regulate leukocyte maturation, trafficking and homing, and the 
development of lymphoid tissues (Baggiolini, 1998; Nelson and Krensky, 1998; Uchihara et 
al., 2005). Chemokines are also important in cancers, where they are involved in processes 
such as homeostasis, cell proliferation, haematopoiesis, viral/cell interactions, angiogenesis, 
neovascularisation and metastasis (Ali and Lazennec, 2007). This category of pathways is of 
particular interest since chemokines are involved in the initial phases of the immune response 
against viruses; hence are known to be regulated by EBV, and are also known to regulate 
angiogenesis, a crucial event in the development of cancers (Ali and Lazennec, 2007; 
Baggiolini et al., 1997). Furthermore, they are soluble secreted proteins that are detectable in 
the circulation and therefore represent potentially viable and non-invasive diagnostic 
markers. 
Previous studies have shown that the EBV latent genes, in particular LMP-1 are capable of 
up-regulating chemokines, including CCL5, CCL3 (macrophage inflammatory protein-1 
alpha, MIP-1α), CCL17 (thymus-associated regulatory chemokine, TARC), CCL19 (Epstein-
Barr virus-induced molecule 1 ligand chemokine, ELC), CCL22 (macrophage-derived 
chemotactic factor, MDC), CXCL10 and interleukin-8 (IL-8) via the NF-kappa B pathway 
(NF-κB) (Buettner et al., 2007; Eliopoulos et al., 1999; Nakayama et al., 2004; Uchihara et 
al., 2005; Vockerodt et al., 2005). 
In the previous chapter (chapter 3) we demonstrated a 1.6-fold induction of LMP-1 in 
TPA/NaB induced Raji cells at 24 hrs. Therefore, it is possible that the highly up-regulated 
chemokine network identified is attributable to low-level LMP-1 induction. However, it is 
possible that lytic gene expression could also be contributing to the up-regulation of these 
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chemokines. A previous study has demonstrated that the IE transactivator, BZLF1 can up-
regulate cytokines (chemokine enhancers) interleukin (IL)-6 (IL-6), IL-10, IL-13 and the IL-8 
mediated chemokine (CXCL8) (Hsu et al., 2008; Jones et al., 2007; Mahot et al., 2003; Tsai 
et al., 2009). Regulation of these latter cytokines is achieved through direct binding of 
BZLF1 to their promoters via a consensus AP-1 site (Hsu et al., 2008). BZLF1 was induced 
19-fold at 24 hrs in the model system. This suggests a potential role for EBV lytic gene 
products in enhancement of chemokine regulation in our array. 
Both CXCL9 and CXCL10 are CXC chemokine ligands, produced by IFN-γ stimulated cells 
that signal through the G-protein coupled receptor CXCR3 on Th1 activated T cells and NK 
cells (Loetscher et al., 1996; Neville et al., 1997; Thapa et al., 2008). We found a 10-fold and 
4-fold up- regulation of CXCL9 and CXCL10, respectively in our microarray analysis. While 
regulation of CXCL9 and CXCL10 by EBV lytic genes has not been demonstrated, direct 
correlations were found between EBV infection and increased up-regulation of CXCL9 and 
CXCL10 in EBV-positive HL tissue by RT-PCR (Teruya-Feldstein et al., 1999). Moreover, 
both CXCL9 and CXCL10 have anti-tumour properties and have been up-regulated in EBV-
associated lymphoproliferative disorders in vitro (Setsuda et al., 1999; Sgadari et al., 1997; 
Teruya-Feldstein et al., 1997). 
CCL3 and CCL5 both signal through the CCR1 and CCR5 receptors on monocytes and 
activated Th1 T cells, resulting in an inflammatory effect (Uchihara et al., 2005), presumably 
to control EBV infection. We found a 3.7- and 9.6-fold up-regulation of CCL3 and CCL5, 
respectively. Moreover, correlations between the presence of EBV and high levels of 
expression of CCL3 along with CXCL10 were demonstrated in Hodgkin’s disease (Teruya-
Feldstein et al., 1999; Teruya-Feldstein et al., 2000). A recent study employed the Affymetrix 
HG U133 Plus 2.0 GeneChipTM to investigate cellular gene expression in biopsy specimens 
from transplant recipients at high risk of PTLD (Allen et al., 2009). They showed up-
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regulation of CCL5 and highlighted the importance of EBV modulation of Th1 and Th2 
response on chemokine expression, suggesting a role for these proteins in PTLD 
development.  
We also demonstrated a 4-fold up-regulation of CCL22 (Table 7.2), a CC chemokine that 
signals through the CCR4 receptor and activates Th2 CD4+ T cells and NK cells upon LMP-
1 regulation (Nakayama et al., 2004). LMP-1 is known to regulate CCL3, CCL5 and CCL22 
(Nakayama et al., 2004), whereas CCL3 and CCL5 are upregulated directly by EBNA-2 in 
EBV LCLs (Spender et al., 2006; Zhao et al., 2006). However, the role of the EBV lytic 
genes in the regulation of these chemokines is uncertain. Further, chemokines recruit either 
Th1 or Th2 responses based on the receptors they interact with. Hence, EBV infection is 
controlled by the CTL response, and the different inflammatory effects following differential 
chemokine regulation could be important in the immune response to infection, and in the 
development of PTLD (Allen et al., 2009). 
These findings warrant further study on the contribution of chemokines to the development of 
PTLD, in particular the role of EBV lytic gene products in chemokine regulation during EBV 
reactivation. 
In summary, we chose five genes (CCL3, CCL5, CCL22, CXCL9 and CXCL10) that encode 
chemokines for further evaluation as markers of PTLD. Our rationale for selecting these 
genes was their known regulation by EBV and their implications in PTLD (Allen et al., 2009; 
Setsuda et al., 1999; Sgadari et al., 1997; Teruya-Feldstein et al., 1997).  
Overall summary of selected genes 
One of the main goals of this thesis was to identify potential markers for the early detection 
of PTLD. For this purpose, we analysed cellular gene expression in response to lytic 
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induction by microarray analysis, from which 191 highly regulated probe sets were identified 
(Table 7.2), representing 112 unique cellular genes. The 17 candidate genes can be further 
assigned to the following selection criteria: i) EBV infection and EBV-PTLD biopsy tissue 
(RASA1, RGS13, ANP32E, MAD2L1, TIMP1, CDC2, CD52, LRMP, HDGF1, ISG15 and 
PCNA); and ii) highly regulated cellular genes (CHI3L1), and (iii) other biological functions, 
including chemotaxis in GeneOntology (CCL3, CCL5, CCL22, CXCL9 and CXCL10). In 
addition, the majority of these genes had extracellular locations, increasing their likelihood of 
detection in whole blood. 
Once chosen, we established that our genes were truly modulated, via real-time PCR 
validation and fold-changes derived from these analyses were compared to those derived 
from the microarray analysis. Our results showed increased sensitivity of real-time PCR over 
microarray analysis based on fold-change, and therefore, a suitable system to perform 
subsequent gene expression analyses. Further, we showed that the regulation pattern of all 17 
genes was the same between real-time PCR and microarray analysis, confirming the validity 







5 CHAPTER 5. VALIDATION OF EBV AND CELLULAR GENE 
EXPRESSION IN WHOLE BLOOD FROM PAEDIATRIC AND 





In the previous chapters we employed real-time PCR and the Affymetrix Human Genome 
U133 Plus 2.0 GeneChip® to identify highly regulated EBV and cellular candidate genes 
during the EBV lytic induction phase, as potential markers for the early detection of PTLD. 
Altogether, 14 EBV and 17 cellular candidate genes were chosen for further analysis (Table 
5.1). Preliminary investigations were undertaken to assess their potential as specific, non-
invasive markers of early PTLD by screening RNA extracted from whole blood samples. 
However, three of the 17 EBV genes (BMRF1, BPLF1 and BVRF1) were only identified as 
overlapping late lytic genes genes following preliminary screening. Therefore, any results for 
these genes have been excluded from the thesis, and data is presented for 14 EBV genes only. 
Early diagnosis and the prompt initiation of treatment is crucial for the prevention of PTLD, 
to improve patient survival, and prevent graft loss (Gulley and Tang, 2008). While elevated 
EBV DNA loads have proven useful as predictive markers for PTLD, they lack specificity, 
and there is some disagreement over the significance of elevated viral loads and the 
development of disorder (Scheenstra et al., 2004).  Therefore, a better understanding of the 
correlation between EBV DNA load and the onset of PTLD was required in order to develop 
more specific assays for the early identification of patients at risk of PTLD (Gartner and 
Preiksaitis, 2010). Latency III patterns of EBV gene expression have been detected in PTLD 
positive biopsy tissue (Brink et al., 1997). Therefore, one of the aims of our study was to 
identify EBV latent gene expression profiles in PTLD and non-PTLD patients and identify 
potential markers for the early diagnosis of PTLD. Further, we wanted to investigate the role 
of the EBV lytic genes, since their role in PTLD was unclear  (Rowe et al., 1998). EBV lytic 
gene expression has been demonstrated alongside latency III in PTLD biopsies and following 
lytic activation in LCLs, and latency III can enhance EBV replication (Yuan et al., 2006). 
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Therefore, one of the aims of our study was to monitor EBV lytic gene expression profiles in 
PTLD and non-PTLD patients and identify potential markers of PTLD (Yuan et al., 2006). 
Another aim was to analyse cellular gene expression profiles in PTLD and non PTLD 
patients, since EBV gene products are known to regulate cellular genes (Spender et al., 2001; 
Spender et al., 2006; Yuan et al., 2006).  It was anticipated that any highly differentially 
expressed cellular genes could provide potential markers of PTLD as well as providing 
insight into the potential microenvironment in which PTLD could arise. A further aim was to 
examine EBV gene expression profiles in patients with variable EBV DNA loads to 
determine whether there was any association between EBV replication and viral load (Chang 
et al., 2006; Hahn et al., 2005; Morrison and Kenney, 2004; Morrison et al., 2004). It was also 
anticipated that any associations would facilitate further the identification of effective 
markers for the early detection of PTLD.  
  
5.1.1 Objectives of Chapter 5 
The primary objective of this study was to identify potential cellular and EBV gene markers 
for specific and early detection of PTLD. As part of this investigation, we developed and 
validated real-time two-step RT-PCR assays to evaluate EBV and cellular gene expression 
profiles in whole blood from paediatric solid organ transplant (SOT) and adult umbilical cord 
blood transplant (UCBT) recipients, with and without PTLD.  
The specific aims of this chapter were to determine:  
(i) To determine the EBV gene expression profiles in whole blood from PTLD 
and non-PTLD transplant patients, and determine whether these coincide with 
the latency III gene expression profile previously observed in PTLD biopsy 
tissue 
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(ii) To identify any differentially expressed cellular genes between PTLD and non 
PTLD patients 
(iii) To determine if there was any association between EBV DNA load and 
specific EBV and cellular gene expression profiles or expression of individual 
genes 
(iv) To establish whether the real-time PCR assays were sensitive and specific for 
EBV and cellular gene expression analysis in whole blood samples from 
PTLD and non-PTLD transplant patients 
 
Table 5-1 EBV and cellular genes for clinical validation in whole blood 
  





















5.2.1 Determining EBV gene expression profiling by real-time PCR 
To determine the expression of several EBV genes (BALF5, BDLF3, BDLF4, BMRF1, 
EBNA-1 and LMP-1) and ensure that we had sufficient cDNA to complete the full testing of 
17 candidate EBV genes, real-time TaqMan PCR was performed on cDNA (1/2 dilution) 
derived from 200 ng total RNA input from ten adult bone marrow transplant (BMT) controls 
(Ctrls). These samples carried varying EBV DNA loads ranging from 664 to 31,834 
copies/ml (Table 5.2). In two controls with <10 copies/ml, no EBV genes were detected. For 
unknown reasons, in two controls (Ctrls. 6 and 8), with detectable viral loads of 16,028 and 
5,709 copies/ml, respectively, no EBV gene expression was observed for the genes tested. In 
all other controls, at minimum, the expression of the viral DNA polymerase BALF5 was 
detectable, with increasing amounts detected with increasing viral loads. Real-time PCR was 
performed on minus RT-controls from each patient and confirmed the absence of EBV 









Table 5-2 Determining the expression of EBV gene targets in whole blood samples from 

















Ctrl. 4 <10       
Ctrl. 5 <10       
Ctrl. 9 664   41.99 (+ /-)    
Ctrl. 10 3,447   39.86 (+ /-)    
Ctrl. 8 5,709       
Ctrl. 2 9,607 38.74 38.59 (+ /-) 38.8 37.14 (+ /-)   
Ctrl. 6 16,028       
Ctrl. 3 16,324 43.03 (+ /-)  38.13 (+ /-)    
Ctrl. 1 19,518 39.47  37.65  40.07 (+ /-) 38.85 
Ctrl. 7 31,834   36.00    
Ctrl, control; +/-, Borderline detection Blank, not detectable; Ct, Threshold cycle; LMP-1, Latent membrane 
protein 1; EBNA-1, EBV nuclear antigen 1;  BALF5, DNA polymerase; BDLF3, Structural capsid; BDLF4, 
Structural capsid; BMRF1, DNA polymerase processivity factor. 
 
5.2.2 Determining the expression of BALF5, CXCL9 and VIM by real-time PCR 
Prior to using the full set of samples, preliminary tests were undertaken to identify the 
optimal cDNA quantity (maximising the number of genes that could be assessed) for the real-
time PCR assays. In these preliminary tests, expression of the BALF5 EBV gene, and two 
cellular genes (CXCL9 and VIM), was evaluated at 1/2, 1/3 and 1/5 dilutions of cDNA 
derived from 300 ng total RNA in four controls (Ctrls. 1, 2, 5 and 10). These results were 
analysed in combination with the previously described dilutions, for which a 1/2 dilution of 
cDNA derived from 200 ng total RNA gave high Ct values (section 5.2.1, Table 5.2).  
Table 5.3 presents the EBV DNA loads for each target tested in triplicate for each control. 
Relative expression levels were derived by normalisation against the ACTB reference control. 
EBV DNA loads for the four test samples are presented in Table 5.3. Control no. 5 served as 
the EBV-negative control with an EBV DNA load <10 copies/ml. No expression of BALF5 
was detectable in this sample. In all other samples, BALF5 was detected at all dilutions, with 
the exception of the 1/5 dilution for the control with the lowest viral load (Ctrl. 10; 3,447 
copies/ml). Both cellular genes, VIM and CXCL9, were detectable at all dilutions in all 
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controls. VIM was consistently detectable at the same Ct for the two controls with the highest 
viral load (Ctrls. 1 and 2) and, at a slightly lower Ct value for the two controls with lower 
viral loads, including control no. 5, with <10 copies/ml. The detection of VIM was decreased 
by 1 log from dilutions of 1/2 to 1/5.  Overall, 1/2 dilutions of cDNA provided the most 
reproducible data (Table 5.3). However, the 1/3 dilutions were also highly reproducible, 
maintained the required sensitivity, and enabled sufficient cDNA to investigate gene 
expression profiles for all 14 EBV and 17 cellular candidate genes. Therefore, a 1/3 dilution 
was chosen for further investigation.  However, owing to the lack of ready access to a flow 
cytometer at the time of isolation of the non-RBC fraction, the fraction of tumour B cells was 
not assessed. Future work should incorporate this analysis into the study. 
 
  184 
Table 5-3 Determining the expression of BALF5, CXCL9 and VIM over a range of dilutions by real-time PCR  
Controls EBV DNA load (copies/ml) BALF5 (Ct)  CXCL9 (Ct)  VIM (Ct)  ACTB (Ct)  
cDNA (1/2 dilution)      
no. 1 19,518 33.8 34.6 16.0 17.0 
no. 2 9,607 34.8 33.9 16.0 17.0 
no. 5 <10  29.5 17.0 17.0 
no. 10 3,447 36.1 27.2 16.0 17.0 
cDNA (1/3 dilution)      
no. 1 19,518 34.3 34.4 17.0 18.7 
no. 2 9,607 34.3 34.3 16.9 18.3 
no. 5 <10  29.5 18.0 19.0 
no. 10 3,447 36.4 27.4 17.4 18.5 
cDNA (1/5 dilution)       
no. 1 19,518 37.0 36.0 18.0 19.0 
no. 2 9,607 37.0 36.0 18.0 19.0 
no. 5 <10  30.0 19.0 19.0 
no. 10 3,447  28.0 19.0 19.0 
Blank, not detectable;  Ct, Threshold cycle; BALF5, DNA polymerase; CXCL9, CXC chemokine 9; VIM, Vimentin; ACTB, Beta actin; GAPDH, Glyceraldehyde 3-
dehydrogenase  
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5.2.3 Analysis of EBV gene expression in adult and paediatric transplant patients 
Although EBV latent genes and the latency III pattern are frequently expressed in PTLD, the 
role of the lytic genes in the development of PTLD was unclear. Therefore, relative 
expression levels of 8 latent and 6 lytic genes were examined in 33 whole blood samples 
from 21 paediatric SOT patients (5 PTLD, 16 non-PTLD), and 12 samples from 2 adult 
UCBT recipients (1 PTLD, 1 non-PTLD) (Figure 2.3). To examine EBV gene expression in 
whole blood samples, EBV gene expression levels were measured relative to the reference 
control ACTB using real-time PCR assays. Gene expression was recorded as detectable (+), 
borderline detectable (+/-) or not detectable (blank). Samples were deemed borderline 
positive, if one or two of the three replicates were positive. The integrity of the cDNA was 
confirmed by consistent Ct values (Ct~16) for ACTB. Results of the EBV gene expression 
profiling for paediatric and adult transplant recipients are presented in Tables 5.4, 5.5, 5.6 
5.7, and Tables 5.8 and 5.9, respectively. 
 
5.2.3.1  EBV gene expression analysis in paediatric transplant patients  
Eight latent genes (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP-1 
and LMP-2A) and six lytic genes (BALF5, BDLF4, BGLF4, BRRF1, BXLF1, and BZLF1) 
were assessed in whole blood from the paediatric transplant recipients. The relative 
expression levels of each EBV gene detected in samples from the paediatric PTLD and non-
PTLD patients are represented in Figures 5.1 and 5.2, respectively.  
Lytic gene expression was detected in 25/33 (76%) samples from 21 paediatric SOT patients, 
including 9/15 (60%) samples from 5 PTLD patients and 16/18 (89%) samples from 16 non-
PTLD patients (Tables 5.4 and 5.5). As expected, no EBV latent or lytic gene expression was 
detected in the single EBV-seronegative patient with no EBV viraemia (no. 21; Table 5.5). 
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Notably, expression of BALF5 was detected in 25/33 (76%) samples from paediatric patients, 
including 2 PTLD patients (no. 4, sample C and no. 5, samples C-D) with viral loads <10 
copies/ml (Table 5.4).  
In the PTLD group, lytic gene expression was detected in 9/15 (60%) samples from 5 PTLD 
patients, all of which were positive for BALF5 (Table 5.4). BDLF4 was expressed in 3/15 
(20%) samples, BGLF4 in 3/15 (20%) samples, BRRF1 in 3/15 (20%) samples, BXLF1 in 
3/15 (20%) samples, and BZLF1 in 4/15 (26.7%) samples. Therefore, BZLF1 were the most 
frequently detected genes after BALF5. BALF5 had the highest level of expression across 
samples (Figure 5.1). The mean relative expression level ±SD was 0.002984 (±0.005305) for 
BALF5. 
In the non-PTLD group, aside from BALF5, lytic gene expression (BRRF1) was detected in 
1/16 (6.25%) with elevated viral loads (Table 5.5). BALF5 was detected in 16/18 (89%) 
samples from 16 patients, whereas 1/16 (6.25%) expressed BRRF1 (Table 5.4). BALF5 had 
the highest level of expression (Figure 5.2).  The mean relative expression level ±SD was 
0.0007910 (±0.0008665) for BALF5. 
In the PTLD group, latent gene expression (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-
3C, EBNA-LP, LMP-1 and LMP-2A) was detected in 7/15 (46.67%) samples (Table 5.6). Five 
of 15 samples (33%) expressed EBNA-1, 1/15 (6.6%) expressed EBNA-2, 1/15 (6.6%) 
expressed EBNA-3A, 1/15 (6.6%) expressed -3B and 1/15 (6.6%) expressed 3-C, 5/15 (33%) 
expressed EBNA-LP, 4/15 (26.7%) expressed LMP-1 and 4/15 (26.7%) LMP-2 (Table 5.6). 
All latent genes were detected in one patient (no. 3). EBNA-LP had the highest level of 
expression across samples (Figure 5.1). The mean relative expression level ±SD for EBNA-
LP was 0.0007825 (±0.001208). 
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In the non-PTLD group, latent gene expression (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, 
EBNA-3C, EBNA-LP and LMP-1) was detected in 8/16 (50%) samples from 18 patients 
(Table 5.7). Three of 16 (18.75%) patients expressed EBNA-1, 2/16 (12.5%) expressed 
EBNA-2, 1/16 (6.25%) expressed EBNA-3A, 1/16 (6.25%) expressed EBNA-3B, 2/16 (12.5%) 
expressed EBNA-3C, 1/16 (12.5%) expressed EBNA-LP, and 5/16 (31%) expressed LMP-1. 
Therefore, LMP-1 was the most frequently detected latent gene. EBNA-LP had the highest 
level of expression across samples (Figure 5.2). The mean relative expression level for 
EBNA-LP was 0.00002565 (±0.0001026). 
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Table 5-4 Summary of EBV lytic transcripts in paediatric PTLD patients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample) Time from transplant (Days) EBV load EBV Serology BALF5 BDLF4 BGLF4 BRRF1 BXLF1 BZLF1 
no. 1 (sample A) 73 197,629 VCA IgG- + + + + +/- + 
no. 1 (sample B) 50 43,119 VCA IgG- + + + + + + 
no. 1 (sample C) 143 <10 VCA IgG-       
no. 1 (sample D) 171 <10 VCA IgG-       
          
no. 2 (sample A) 157 9,792 VCA IgG- +      
no. 2 (sample B) 131 452 VCA IgG-       
no. 2 (sample C) 154 99 VCA IgG-       
          
no. 3 47 7,609 VCA IgG- + + + + + + 
          
no.4 (sample A) 26 1,530 VCA IgG Indet +     + 
no. 4 (sample B) 89 1,033 VCA IgG Indet +/-      
no. 4 (sample C) 68 <10 VCA IgG Indet +      
          
no. 5 (sample A) 124 <10 VCA IgG+       
no. 5 (sample B) 107 <10 VCA IgG+       
no. 5 (sample C) 128 <10 VCA IgG+ +/-      
no. 5 (sample D) 142 <10 VCA IgG+ +/-      
+, Positive; +/-, Borderline detectable; Blank, Not detectable; no, number; NK, not known; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant 
lymphoproliferative disorder; BALF5, DNA polymerase;  BDLF4, Structural; BGLF4, Protein kinase; BRRF1, lytic cycle enhancer; BXLF1, Thymidine kinase; BZLF1, lytic 
cycle transactivator; ǂ, primary EBV infection 
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Table 5-5 Summary of EBV lytic transcripts in paediatric non-PTLD patients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample) Time from transplant (Days) EBV load EBV Serology BALF5 BDLF4 BGLF4 BRRF1 BXLF1 BZLF1 
no. 6 NK 68,278 VCA IgG- +      
no. 7 NK 52,351 VCA IgG Indet +      
no. 8 (sample A) 33 41,512 VCA IgG- +      
no. 9 NK 40,377 VCA IgG+ +      
no. 10 NK 28,979 VCA IgM+ +   +/-   
no. 11 NK 17,830 VCA IgG- +      
no. 12 85   15,343 VCA IgG+ +      
no. 13 NK 10,740 VCA IgG+ +      
no. 14 (sample A) 602   10,392 VCA IgG Indet +      
no. 15 NK 7,587 EBNA IgG+ +      
no. 14 (sample B) 618   7,219 VCA IgG Indet +      
no. 16 NK 4,709 VCA IgG+ +/-      
no. 8 (sample B) 17   4,461 VCA IgG- +      
no. 17 NK 182 VCA IgG+ +/-      
no. 18 NK 158 VCA IgG Indet +      
no. 19 NK 48 EBNA IgG- +/-      
no. 20 NK 48 VCA IgG-       
no. 21* 16   <10 VCA IgG-       
+, Positive; +/-, Borderline detectable; Blank, Not detectable; no, number; NK, not known; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant 
lymphoproliferative disorder; BALF5, DNA polymerase;  BDLF4, Structural; BGLF4, Protein kinase; BRRF1, lytic cycle enhancer; BXLF1, Thymidine kinase; BZLF1, lytic 
cycle transactivator; ǂ, primary EBV infection; *Primary EBV infection with no EBV viraemia 
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Table 5-6 Summary of EBV latent transcripts in paediatric PTLD patients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample) Time from transplant (Days) EBV load EBV Serology EBNA-1 EBNA-2 EBNA-3A EBNA-3B EBNA-3C EBNA-LP LMP-1 LMP-2 
no. 1 (sample A) 73 197,629 VCA IgG-      + + +/- 
no. 1 (sample B) 50 43,119 VCA IgG- +     + +/- + 
no. 1 (sample C) 143 <10 VCA IgG-         
no. 1 (sample D) 171 <10 VCA IgG-         
            
no. 2 (sample A) 157 9,792 VCA IgG-         
no. 2 (sample B) 131 452 VCA IgG-         
no. 2 (sample C) 154 99 VCA IgG-         
            
no. 3 47 7,609 VCA IgG- + + + + + + + + 
            
no.4 (sample A) 26 1,530 VCA IgG Indet +/-     + + +/- 
no. 4 (sample B) 89 1,033 VCA IgG Indet      +   
no. 4 (sample C) 68 <10 VCA IgG Indet +/-        
            
no. 5 (sample A) 124 <10 VCA IgG+ +/-        
no. 5 (sample B) 107 <10 VCA IgG+         
no. 5 (sample C) 128 <10 VCA IgG+         
no. 5 (smple D) 142 <10 VCA IgG+         
+, Positive; +/-, Borderline detectable; Blank, Not detectable; no, number; NK, not known; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant 








Table 5-7 Summary of EBV latent transcripts in paediatric non-PTLD patients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample) Time from transplant (Days) EBV load EBV Serology EBNA-1 EBNA-2 EBNA-3A EBNA-3B EBNA-3C EBNA-LP LMP-1 LMP-2 
no. 6 NK 68,278 VCA IgG-       +/-  
  no. 7  NK 52,351 VCA IgG Indet + +   +/-    
no. 8 (sample A) 33 41,512 VCA IgG-  + +/- +/-   +  
no. 9 NK 40,377 VCA IgG+       +/-  
no. 10 NK 28,979 VCA IgM+       +/-  
no. 11 NK 17,830 VCA IgG-         
no. 12 85    15,343 VCA IgG+ +/-      +/-  
no. 13 NK 10,740 VCA IgG+ +/-        
no. 14 (sample A) 602   10,392 VCA IgG Indet         
no. 15 NK 7,587 EBNA IgG+         
no. 14 (sample B) 618   7,219 VCA IgG Indet         
no. 16 NK 4,709 VCA IgG+         
no. 8 (sample B) 17    4,461 VCA IgG-         
no. 17 NK 182 VCA IgG+         
no. 18 NK 158 VCA IgG Indet     +/- +   
no. 19 NK 48 EBNA IgG-         
no. 20 NK 48 VCA IgG-         
no. 21* 16    <10 VCA IgG-         
+, Positive; +/-, Borderline detectable; Blank, Not detectable; no, number; NK, not known; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant 
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Figure 5-1 Quantitative EBV gene expression patterns in paediatric PTLD transplant recipients 
Relative expression of EBV latent and lytic EBV genes in the whole blood of paediatric transplant patients with 
PTLD. The transcripts were analysed by real-time TaqMan PCR from total mRNA extracted from 7 whole 
blood samples of transplant patients with PTLD (n = 5). Relative expression of the transcripts was normalised to 
the ACTB gene.  Data represents the means ±SD of triplicates.   
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Figure 5-2 Quantitative EBV gene expression patterns in paediatric non-PTLD transplant 
recipients 
Relative expression of EBV latent and lytic EBV genes in whole blood samples of paediatric transplant patients 
without PTLD. The transcripts were analysed by real-time TaqMan PCR from total mRNA extracted from  16 
whole blood samples of transplant patients without PTLD (n = 8). Relative expression of the transcripts was 
normalised to the ACTB gene.  Data represents the means ±SD of triplicates.   
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5.2.3.2 Analysis of EBV gene expression in adult transplant patients 
While the majority of EBV genes expressed in the paediatric group were lytic genes, 
particularly within PTLD diagnosed patients, the majority of EBV genes expressed in the 
adult group were latent genes and detectable in the single adult PTLD patient (no. 22, 
samples A-E) (Tables 5.8 and 5.9). 
Table 5.8 summarises EBV lytic gene expression in 2 adult transplant recipients. BALF5, was 
detected in all samples from the single adult PTLD patient (no. 22, samples A-E), and 5/6 
(83.33%) samples (no. 23, samples A-E) from the non-PTLD control (Table 5.8). Notably, all 
lytic genes were expressed in 1/6 (16.7%) samples (no. 22A), which also had the highest viral 
load (477,642 copies/ml). Lytic gene expression was sporadic in the remaining 5/6 (83.33%) 
samples; 8 transcripts were expressed in one sample, two transcripts in another, and three in a 
further sample. BALF5 was the most highly expressed EBV gene detected in the PTLD 
versus non-PTLD patient (Figures 5.3 and 5.4, panels A). The mean relative expression levels 
±SD for BALF5 was 0.006298 (±0.01) and 0.0002945 (±0.0002) in samples from the PTLD 
and non-PTLD patient, respectively. 
Table 5.9 summarises EBV latent gene expression in the 2 adult transplant recipients. No 
latent gene expression was detected in the non-PTLD patient (no. 23). In comparison, we 
detected latent gene expression in all samples from the PTLD patient (Table 5.9; no. 22, 
samples A-F). Further, all of the latent genes were detected in the sample (no. 22A) with the 
highest viral load (477,642 copies/ml). Notably, the most highly expressed latent gene 
detected was EBNA-LP, followed by LMP-1 and LMP-2 (Figure 5.3, panel B). The mean 
relative expression levels ±SD for EBNA-LP, LMP1 and LMP2 were 0.007024 (±0.01), 
0.006298 (±0.01) and 0.005014 (±0.01), respectively.  




Table 5-8 Summary of EBV lytic transcripts in adult transplant recipients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample no.) Time from transplant (Days) EBV load EBV serology BALF5 BDLF4 BGLF4 BRRF1 BXLF1 BZLF1 
PTLD          
no. 22 (sample A) 126 477,642 VCA IgG+ + + + + + + 
no. 22 (sample B) 139 14,170 VCA IgG+ +   +   
no. 22 (sample C) 111 10,209 VCA IgG+ +   +/-   
no. 22 (sample D) 92 7,589 VCA IgG+ +      
no. 22 (sample E) 174 6,631 VCA IgG+ + +/- + +/- + /- + 
no. 22 (sample F) 94 210 VCA IgG+ +      
          
Non-PTLD          
no. 23 (sample A) 443 26,649 VCA IgG+ +      
no. 23 (sample B) 601 1,535 VCA IgG+ +      
no. 23 (sample C) 519 1,149 VCA IgG+ +/-      
no. 23 (sample D) 517 1,208 VCA IgG+ +      
no. 23 (sample E) 524 339 VCA IgG+ +      
no. 23 (sample F) 545 <10 VCA IgG+       
+, Positive; +/-, Borderline detectable; Blank, Not detectable; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant lymphoproliferative disorder; BALF5, DNA 









Table 5-9 Summary of EBV latent transcripts in adult transplant recipients as determined by real-time PCR (ranked by viral loads) 
Patient no. (Sample no.) Time from transplant (Days) EBV load EBV serology EBNA-1 EBNA-2 EBNA-3A EBNA-3B EBNA-3C EBNA-LP LMP-1 LMP-2 
PTLD            
no. 22 (sample A) 126 477,642 VCA IgG+ + + + + + + + + 
no. 22 (sample B) 139 14,170 VCA IgG+ + + +/- +/-  + + + 
no. 22 (sample C) 111 10,209 VCA IgG+ +/- +/- +/-  +/- + +/- +/- 
no. 22 (sample D) 92 7,589 VCA IgG+ +/- +  +/-  + +/- +/- 
no. 22 (sample E) 174 6,631 VCA IgG+ +/- + + +  + + + 
no. 22 (sample F) 94 210 VCA IgG+ +/- +/-    +  +/- 
            
Non-PTLD            
no. 23 (sample A) 443 26,649 VCA IgG+         
no. 23 (sample B) 601 1,535 VCA IgG+         
no. 23 (sample C) 519 1,149 VCA IgG+         
no. 23 (sample D) 517 1,208 VCA IgG+         
no. 23 (sample E) 524 339 VCA IgG+         
no. 23 (sample F) 545 <10 VCA IgG+         
+, Positive; +/-, Borderline detectable; Blank, Not detectable; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant lymphoproliferative disorder; EBNA-1, -2, -3A, 
-3B, 3-C and –LP, EBV nuclear antigens -1, -2, -3A, 3B and -3C; LMP-1, Latent membrane protein 1; LMP2A/B, Latent membrane protein 2   
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Figure 5-3 Quantitative EBV gene expression patterns in adult PTLD and non-PTLD transplant 
recipients  
Relative expression levels of EBV latent and lytic EBV genes in whole blood from a single adult UCBT 
recipient with PTLD. Relative expression levels of EBV lytic (BALF5, BDLF4, BGLF4, BRRF1, BXLF1 and 
BZLF1) (A) and latent (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP-1 and LMP-2) (B) 
transcripts were analysed by real-time TaqMan PCR. Relative expression of the transcripts was normalised to 
the ACTB gene. Data represents the means ±SD of triplicates. 
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Figure 5-4 Quantitative EBV gene expression patterns in a single adult non-PTLD transplant 
recipient 
Relative expression of the EBV BALF5 transcript in a single adult UCBT recipient without PTLD; Data 
represents the mean of triplicates ±SD. Relative expression of EBV lytic (BALF5, BDLF4, BGLF4, BRRF1, 
BXLF1 and BZLF1) (A) transcripts were analysed by real-time TaqMan PCR; EBV latent gene expression was 
not observed in this patient. Relative expression of the transcripts was normalised to the ACTB gene. Data 
represents the means ±SD of triplicates.  
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5.2.4 Analysis of EBV latency patterns 
 
In our earlier analysis of EBV gene expression within adult and paediatric transplant patients, 
we observed a larger number of latent and lytic genes expressed in PTLD positive versus 
non-PTLD patients (Tables 5.4-5.9).   
The EBV latency patterns are detailed in Table 1.3. Latency III is defined by the expression 
of all latent EBV genes, in particular EBNA-2 and LMP-1 (Young et al., 1989). We next 
examined EBV latency patterns in the PTLD versus non-PTLD patients, since latency III was 
demonstrated in tumour cells in PTLD (Brink et al., 1997). Eight EBV latency genes were 
assessed (Tables 5.3-5.8).  
Table 5.10 details latent EBV gene expression in the PTLD groups only, ranked by viral load. 
We detected gene expression patterns typical of latency III (EBNA-2(+), LMP-1(+)) in 2/5 
(40%) paediatric PTLD patients (no. 3 and no. 4, sample A), and all samples from the single 
adult PTLD patient (no. 22). In addition, we demonstrated latency III with discrepancy for 
EBNA-2 in two samples from one paediatric PTLD patient (no. 1, samples A and B). When 
we examined the 15 paediatric non-PTLD patients, we detected latency III in 1/15 (6.7%) 
patient genes (no. 8 sample A) (Table 5.7). The remaining PTLD and non-PTLD patients 
exhibited variations in the patterns of EBV latent gene expression, not typical of latency III 
(EBNA-2(-), LMP-1(-)) (Tables 5.6 and 5.7). 
We next examined lytic gene expression in patients displaying latency III, since both have 
been demonstrated in tumour cells of PTLD (Rea et al., 1994a; Rea et al., 1994b). We 
detected latency III coupled with lytic gene expression in the two paediatric PTLD patients 
(no. 3 and no. 4, sample A) and the adult PTLD patient (no. 22), including the full spectrum 
of lytic gene expression in 2 patients (no. 3 and no. 22) (Table 5.11).  




Table 5-10 Summary of EBV latent transcripts in whole blood from five cases of paediatric and one case of adult PTLD as determined by real-
time PCR (Ranked by EBV viral loads) 
Patient no. (Sample no.) Time from transplant (Days) EBV viral load (copies/mL) EBNA-1 EBNA-2 EBNA-3A EBNA-3B EBNA-3C EBNA-LP LMP-1 LMP-2 
Paediatric           
no. 1 (sample A) 73 197,629 +     + + + 
no. 1 (sample B) 50 43,119 +     + + + 
no. 2 (sample  A) 157 9,792         
no. 3 47 7,609 + + + + + + + + 
no. 4 (sample A) 26 1,530  +/-    + + +/- 
no. 4 (sample B) 89 1,033         
no. 2 (sample B) 131 452         
no. 2 (sample C) 154 99         
no. 1 (sample C) 143 <10         
no. 1 (sample D) 171 <10         
no. 4 (sample C) 68 <10  +       
no. 5 (sample A) 124 <10         
no. 5 (sample B) 107 <10         
no. 5 (sample C) 128 <10         
no. 5 (sample D) 142 <10         
           
Adults           
no. 22 (sample A) 126 477,642 + + + + + + + + 
no. 22 (sample B) 139 14,170 + + +/- +/-  + + + 
no. 22 (sample C) 111 10,209 +/- +/- +/-  +/- + +/- +/- 
no. 22 (sample D) 92 7,589 +/- +  +/-  + +/- +/- 
no. 22 (sample E) 174 6,631 +/- + + +  + + + 
no. 22 (sample F) 94 210 +/- +/-    +  +/- 
+, positive; +/-, Borderline detectable; Blank, Not detectable; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant lymphoproliferative disorder; EBNA-1, -2, -3A, 
-3B, 3-C and –LP, EBV nuclear antigens -1, -2, -3A, 3B and -3C; LMP-1, Latent membrane protein 1; LMP2A/B, Latent membrane protein 2.  
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Table 5-11 Summary of EBV lytic transcripts in whole blood from five cases of paediatric and one case of adult PTLD as determined by real-
time PCR (Ranked by EBV viral loads) 
Patient no. (Sample no.) Time from transplant (Days) EBV viral load (copies/ml) BALF5 BDLF4 BGLF4 BRRF1 BXLF1 BZLF1 
Paediatric         
no. 1 (sample A) 73 197,629 + + + + +/- + 
no. 1 (sample B) 50 43,119 + + + + + + 
no. 2 (sample  A) 157 9,792 +      
no. 3 47 7,609 + + + + + + 
no. 4 (sample A) 26 1,530 +     + 
no. 4 (sample B) 89 1,033       
no. 2 (sample B) 131 452 +/-      
no. 2 (sample C) 154 99       
no. 1 (sample C) 143 <10       
no. 1 (sample D) 171 <10       
no. 4 (sample C) 68 <10 +      
no. 5 (sample A) 124 <10       
no. 5 (sample B) 107 <10       
no. 5 (sample C) 128 <10 +/-      
no. 5 (sample D) 142 <10 +/-      
         
Adults         
no. 22 (sample A) 126 477,642 + + + + + + 
no. 22 (sample B) 139 14,170 +      
no. 22 (sample C) 111 10,209 +   +   
no. 22 (sample D) 92 7,589 +      
no. 22 (sample E) 174 6,631 + +/- + +/- +/- + 
no. 22 (sample F) 94 210 +      
+, positive; +/-, Borderline detectable; Blank, Not detectable; VCA IgG, Viral capsid Immunoglobulin; PTLD; post-transplant lymphoproliferative disorder; BALF5, DNA 
polymerase;  BDLF4, Structural; BGLF4, Protein kinase; BRRF1, lytic cycle enhancer; BXLF1, Thymidine kinase; BZLF1, lytic cycle transactivator.  
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5.2.5 Analysis of EBV gene expression and viral load  
Overall, the majority of EBV latent and lytic genes expressed were from PTLD positive 
patients, with more latent genes expressed in samples from the adult PTLD patient, and more 
lytic genes expressed in samples from the paediatric PTLD patients. As the viral loads varied 
across these patients, we next addressed whether there was any indication of an association 
between EBV gene expression levels and viral load amongst the PTLD and non-PTLD 
groups. We detected some association between EBV gene expression and viral loads in the 
PTLD groups (Tables 5.4, 5.6, 5.8, 5.9, 5.10 and 5.11). In the non-PTLD paediatric group, we 
detected EBV lytic and latent EBV gene expression in samples with high viral loads (Tables 
5.5 and 5.7). Moreover, higher mean relative expression levels were demonstrated for two 
genes (BALF5 and EBNA-LP) in samples with higher viral loads in both PTLD and non-
PTLD groups (Figures 5.1, 5.2 and 5.3).  
 
5.2.6 Analysis of cellular gene expression profiles in the peripheral blood 
Seventeen cellular genes were assessed to examine gene expression profiles in the peripheral 
blood of all samples from paediatric PTLD and non-PTLD patients. The mean relative 
expression levels for all 17 genes, tested in each sample for all paediatric transplant patients 
are summarised in Figures 7.1. All 17 cellular genes were expressed. Scatter group column 
analysis was performed in the earliest and most closely matched samples from 5 paediatric 
PTLD and 5 non-PTLD patients to identify statistically differentially expressed cellular genes 
(Figure 5.5). Comparisons between the mean relative expression levels for each gene in each 
group were evaluated using the Mann Whitney U-test. Statistical significance was determined 
at the 5% threshold. Table 5.12 details the mean relative expression levels with standard 
deviation (SD) for all 17 genes. None of the 17 cellular genes showed statistically significant 
differences (P < ns; data not shown).  
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In addition, the ratio of the mean relative expression levels were compared for each gene in 
each group (Table 5.12). A 2-fold difference was considered significant. With the exception 
of CHI3L1, that was differentially expressed by approximately 3-fold between the PTLD and 
non-PTLD controls, no differences (≥2-fold) were found for any of the remaining 16 cellular 
genes. None of the differences were statistically significant (P < ns; data not shown). 
 
Table 5-12  Mean relative expression levels of cellular gene transcripts in 
paediatric solid organ transplant patients as determined by real-time TaqMan PCR 
Cellular gene  
Mean relative expression 
level in non-PTLD subjects 
(±SD)  
Mean relative expression 




between PTLD and 
non-PTLD patients 
ANP32E 0.2051 (±0.44) 0.01783 (±0.02) 0.09  
CDC2 0.0007935 (±0.0004) 0.0007671 (±0.0006) 0.96 
CD52 0.4268 (±0.58) 0.2261 (±0.21) 0.53 
CHI3L1 0.03085 (±0.04) 0.08823 (±0.11) 2.86 
CCL3 0.01712 (±0.02) 0.009373 (±0.006) 0.55 
CCL5 0.2516 (±0.29) 0.1385 (±0.13) 0.55 
CCL22 0.0002115 (±0.0002) 0.0001500 (±8.951e-005) 0.71 
CXCL9 0.002246 (±0.002) 0.0007526 (±0.0002) 0.33 
CXCL10 0.009595 (±0.02) 0.006038 (±0.008) 0.63 
HDGF1 0.05835 (±0.06) 0.04582 (±0.05) 0.79 
ISG15 0.09131 (±0.09) 0.1122 (±0.10) 1.23 
LRMP 0.03302 (±0.05) 0.04378 (±0.07) 1.33 
MAD2L1 0.02403 (±0.02) 0.01958 (±0.02) 0.81 
PCNA 0.001314 (±0.0008) 0.001383 (±0.001) 1.05 
RASA1 0.006034 (±0.007) 0.008621 (±0.01) 1.43 
RGS13 0.0004639 (±0.0004) 0.0002916 (±0.0003) 0.63 
TIMP1 0.1092 (±0.1) 0.1277 (±0.15) 1.17 
Mean relative expression levels (±SD, standard deviation) were calculated for each gene. Fold-differenecs (P-
value) were calculated for the PTLD group (n = 15) compared to the non-PTLD group (n = 16) from the 2-delta 
delta Ct formula.  Cellular gene in bold were differentially regulated by 2-fold. 




















































































































































































































































































































































































































































































Figure 5-5 Comparison of relative expression levels of 17 cellular candidate genes in the peripheral 
blood of paediatric PTLD and non-PTLD patients   
Relative expression levels were quantified relative to the ACTB gene using real-time TaqMan PCR.  Graphs 
refer to the relative expression level of each cellular gene in whole blood from paediatric transplant patients 
(PTLD [black squares]; n=5]) (non-PTLD [white circles]; n=5). Horizontal lines denote the mean relative 
expression level in each group of transplant patients. Each circle/square represents the means of triplicates.  
 
We next examined cellular gene expression profiles between the adult PTLD and non-PTLD 
patient (Figure 5.6). The mean relative expression levels for the 17 genes, tested in each 
sample (n=6) for both patients are summarised in Figure 7.2. Table 5.13 details the mean 
relative expression levels with SD for all 17 cellular genes as determined using the Mann-
Whitney U-test. None of the 17 genes showed statistically significant differences (P < ns; 
data not shown). In addition, the ratios between mean relative expression levels for each gene 
between each group were determined in Prism. We identified four genes (CXCL9, CXCL10, 
CDC2 and CHI3L1) as differentially expressed (>2-fold) between the adult PTLD and non-
PTLD patient. Notably, CXCL9 was the most highly differentially expressed gene (9-fold), 
followed by CXCL10 (7-fold), CDC2 (3-fold) and CHI3L1 (2-fold). None of the differences 
were statistically significant (P<ns; data not shown). 
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 Table 5-13  Mean relative expression levels of cellular genes in adult 
transplant patients as determined by real-time PCR 
Cellular gene Mean relative expression level  in a non-PTLD patient (±SD) 
Mean relative expression level   
in a PTLD patient (±SD) 






ANP32E 0.01482 (±0.02) 0.03924 (±0.02) 1.02 
CDC2 0.0003592 (±0.0003) 0.001051 (±0.001) 2.93 
CD52 0.1431 (±0.14 ) 0.1776 (±0.18) 1.24 
CCL3 0.02560 (±0.03 ) 0.02202 (±0.02) 0.86 
CCL5 0.1112  (±0.09) 0.08657 (±0.08) 0.78 
CCL22 0.0003287 (±0.0001) 0.0002974 (±0.0003) 0.91 
CHI3L1 0.01898 (±0.012) 0.03789 (±0.023) 1.99 
CXCL9 0.001646 (±0.002) 0.01512 (±0.023) 9 
CXCL10 0.0004847 (±0.0008) 0.003509 (±0.004 7.24 
HDGF1 0.04127 (±0.04) 0.04363 (±0.04) 1.06 
ISG15 0.1165 (±0.07) 0.1581 (±0.05) 1.36 
LRMP 0.03327 (±0.04) 0.01569 (±0.01) 0.47 
MAD2L1 0.01778 (±0.02) 0.01687 (±0.01) 0.95 
PCNA 0.0006464  (±0.0004) 0.0007058 (±0.0006) 1.09 
RASA1 0.00751(±0.01) 0.006366 (±0.01) 0.84 
RGS13 0.0003935 (±0.0002) 0.0004944 (±0.001) 1.26 
TIMP1 0.1372 (±0.13) 0.1387 (±0.11) 1.01 
Mean relative expression levels (±SD, standard deviation) were calculated for each gene. Fold-differences were 
calculated for the PTLD group (n = 1) compared to the non-PTLD group (n = 1) from the 2-delta delta Ct 
formula. Cellular genes in bold were differentially regulated by 2-fold. 
 





































































































































































































































































































































































































































































































Figure 5-6  Comparison of relative expression levels of 17 cellular candidate genes in the peripheral 
blood of multiple samples from a single adult PTLD and non-PTLD patient  
Relative expression levels were quantified relative to the ACTB gene using real-time TaqMan PCR.  Graphs 
refer to the relative expression level of each cellular gene in multiple whole blood samples from 2 adult UCBT 
recipients (PTLD [black squares]; n=1]) (non-PTLD [white circles]; n=1). Horizontal lines denote the mean 
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5.3 DISCUSSION 
 
Differentially expressed genes between PTLD and non-PTLD patients provide the 
identification of potential early markers of PTLD. In this study, 17 EBV (9 lytic, 8 latent) and 
17 cellular candidate genes were assessed in the whole blood of paediatric and adult 
transplant recipients. However, data has been excluded for three lytic genes (BMRF1, BPLF1 
and BVRF1), since these were subsequently realised to be overlapping genes, late lytic genes 
following analysis, and their expression levels may be overestimated. Therefore, data has 
been presented for 14 EBV genes (6 lytic, 8 latent). We determined that a 1/3 dilution of 300 
ng cDNA template derived from whole blood was sufficient and reliable for full testing of the 
candidate genes in triplicate. We used real-time PCR to evaluate EBV gene expression 
profiles in PTLD versus non-PTLD paediatric (n = 21) and adult (n = 2) transplant recipients 
as markers for PTLD. Alongside these groups, we tested an EBV-seronegative patient (no. 
21), with no EBV viraemia, and who showed no detectable EBV latent or lytic gene 
expression (Tables 5.5 and 5.7), which ensured validity of our results. The main findings of 
this study included: (i) the detection of a higher number of EBV latent and lytic genes in the 
PTLD versus non-PTLD patients, (ii) the detection of higher levels of gene expression in the 
PTLD versus non-PTLD patient, (iii) the detection of EBV latency III in PTLD patients, and 
(iv) the identification of several differentially expressed cellular genes between the PTLD and 
non-PTLD patients. The main findings of the EBV and cellular gene expression analysis and 
their potential utility as PTLD markers are discussed here.  
 
EBV gene expression analysis in paediatric SOT patients 
EBV lytic gene expression was detected in 9/15 (60%) samples from 5 paediatric PTLD 
patients and 16/18 (89%) samples from 16 paediatric non-PTLD patients, indicating 
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productive infection. Overall in the paediatric PTLD group, we detected varying degrees of 
lytic gene expression, with some association with viral load. In contrast, fewer lytic genes 
were detected in the paediatric non-PTLD group, and in association with viral load. We next 
examined individual EBV lytic gene expression in paediatric PTLD and non-PTLD patients. 
We first assessed the utility of BALF5 as a potential marker of PTLD. BALF5 is an early gene 
that encodes the viral DNA polymerase, BALF5, essential for lytic DNA replication 
(Tsurumi, 1991). We detected expression of BALF5 in the majority (60%) of paediatric 
patients, including samples from two PTLD patients with viral loads <10 copies/ml. This 
finding indicates that EBV lytic replication was ongoing, and supports further the sensitivity 
of the two-step real-time PCR approach for gene expression analysis over a range of viral 
loads.  
 
With the exception of BALF5, EBV lytic gene expression was detected in only 3/18 (16%) 
samples from 16 paediatric non-PTLD patients, indicating that the majority of lytic gene 
expression was attributable to BALF5. Furthermore, BALF5 was also the most highly 
expressed lytic gene detected in the PTLD and non-PTLD group, although a higher level of 
expression was detected in the PTLD patients. Since BALF5 was expressed highly in both 
groups, in association with lytic DNA replication, its use as a marker of PTLD needs to be 
investigated further since its expression could be associated with a role in lytic replication 
alone. 
 
Alongside BALF5, we detected the expression of BRRF1, an inducer of the lytic cycle (Hong 
et al., 2004) in one non-PTLD patient with elevated viral loads. No other EBV lytic genes 
were detected in this group. Based on their biological functions, this finding suggests further 
that active lytic replication is ongoing in these patients. Although both genes were the most 
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highly expressed lytic genes in this group, their amplifications were all borderline positive, 
suggesting expression at very low-levels. Both genes (BALF5 and BRRF1) were also 
expressed in the paediatric PTLD patients, however at higher levels.  
 
The immediate-early (IE) gene BZLF1 encodes the transcription factor, BZLF1, that is 
expressed prior to viral replication, and essential for lytic cycle activation (Fields et al., 
2007).  Therefore, we were interested in assessing its potential as a marker of PTLD. We 
detected no expression of BZLF1 in the non-PTLD group, in contrast to an earlier study, 
where 9/27 (33%) paediatric transplant patients without PTLD, and with primary EBV 
infection were positive for BZLF1, 21/27 (78%) positive for BALF2 and 19/27 (70%) positive 
for BcLF1 (Bergallo et al., 2007). However, we did demonstrate BZLF1 expression in three 
paediatric PTLD patients, two of which also had primary EBV infection. An earlier study 
detected BZLF1 expression in 13/18 (72%) paediatric liver transplant recipients with primary 
EBV infection. No association with risk of PTLD development was found, and viral load, not 
BZLF1 expression was determined as a more sensitive predictor for PTLD (Vajro et al., 
2000). Further, in a recent study, which assessed productive infection based on lytic gene 
expression (BALF2 and BZLF1), BALF2 alone was detected in the majority of non-PTLD 
HSCT patients, including asymptomatics (Zawilinska et al., 2008). Therefore, our findings 
and that of others, suggest that BZLF1 is probably expressed highly during primary EBV 
since it has a role in activating the lytic cycle. Therefore, the detection of BZLF1 in these 
patients could reflect lytic replication, possibly in association with primary EBV infection, 
and when assessed alone, is unlikely to be a specific marker of PTLD.   
 
Previous studies have suggested that the EBV late lytic genes are detected less frequently in 
tumour cells found in PTLD (Rea et al., 1994a; Rea et al., 1994b), and NPC biopsy tissue 
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(Martel-Renoir et al., 1995), and that activation of the lytic cycle may not always result in 
productive infection. Indeed, it has been suggested that an abortive lytic cycle occurs in 
tumours of  several EBV-associated malignancies, resulting in survival of the infected host 
cells (Martel-Renoir et al., 1995). We did however detect EBV late lytic gene expression 
(BPLF1 and BVRF1) in the whole blood of paediatric PTLD patients only. Therefore, further 
analysis is required to identify their utility as markers for PTLD. 
 
EBV latent gene expression in paediatric transplant recipients 
We next examined EBV latent gene expression in paediatric PTLD and non-PTLD patients. 
While latent gene expression was detected mostly at higher viral loads (>10,740 copies/ml) in 
non-PTLD patients, it was also detected sporadically in samples from 4/5 (80%) PTLD 
patients, with viral loads ranging from <10 to 197,629 copies/ml. Overall, a higher level and 
frequency of latent gene expression was confirmed in PTLD versus non-PTLD patients (47% 
versus 44%, respectively).  
 
We detected expression of EBNA-3A, EBNA3B and EBNA3C in two non-PTLD patients, with 
elevated viral loads, and also primary EBV infection. However, these amplifications were all 
borderline positive. Similarly, these genes were expressed in the single paediatric PTLD 
patient who exhibited the full spectrum of latent genes. The EBNA3s act as transcriptional 
regulators of latency by modulating EBNA-2 up-regulation of cellular and viral promoters as 
well as having oncogenic properties, and could be important markers for PTLD (Tomkinson 
et al., 1993). We also detected expression of both EBNA-LP and 3C in a non-PTLD patient 
with a low viral load (158 copies/ml). EBNA-LP was also expressed in 3 PTLD patients, and 
at a higher level of expression than the non-PTLD group. Moreover, EBNA-LP was the most 
highly expressed latent gene detected in PTLD patients, suggesting a potential role in PTLD. 
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EBNA-LP is one of the first latency genes to be expressed following EBV infection, and acts 
as a transcriptional co-activator of EBNA-2 that plays a crucial role in EBV-induced B-cell 
transformation (Mannick et al., 1991; Sinclair et al., 1994).  
In addition, we detected expression of LMP-1, EBNA-1 and EBNA-2 in non-PTLD patients 
with elevated viral loads (>10,000 copies/ml). In the PTLD group, we detected sporadic 
expression of LMP-1, LMP-2A, EBNA-1 and EBNA-2 in viral loads ranging from <10 to 
197,629 copies/ml. LMP-1 is considered to be the primary EBV oncogene and encodes the 
LMP-1 protein that is essential for EBV-induced B-cell transformation in vitro, as 
demonstrated in both rodent fibroblast and epithelial cells (Kilger et al., 1998; Kim et al., 
2000; Kulwichit et al., 1998; Wang et al., 1985). LMP-1 also inhibits apoptosis and can 
induce B cell lymphomas in transgenic mice (Kulwichit et al., 1998). Indeed, up-regulation of 
LMP-1 is implicated in Hodgkin’s lymphoma (Herbst et al., 1991). The majority of the 
effects of LMP-1 occur through activaton of the nuclear-factor kappa B (NF-κB) pathway 
(Kaye et al., 1993; Rowe, 1999). EBNA-2 functions as the key transcriptional activator of 
latency (Wang et al., 1991). However, EBNA-1 is not required for B-cell transformation but 
is essential for replication and maintenance of the EBV genome (Yates et al., 1984). Notably, 
EBNA-2 and LMP-1 are characteristic of latency III and essential for B-cell transformation, 
suggesting that their expression could lead to PTLD (Thorley-Lawson and Gross, 2004).  
 
In summary, we detected EBV latent and lytic gene expression in both PTLD and non-PTLD 
patients, however a higher number of lytic genes in the PTLD group. In addition, a higher 
level of lytic gene expression was detected in the PTLD group, suggestive of an important 
role in PTLD. While the majority of studies have evaluated EBV gene expression in 
paediatric liver transplant recipients with chronic high EBV loads (CHL) (Gotoh et al., 2010; 
Qu et al., 2000), fewer studies have been conducted in paediatric SOT patients who are not 
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CHL carriers. Therefore, further studies are warranted to evaluate latent and lytic gene 
expression in PTLD in transplant recipients in order to determine EBV gene expression 
patterns predictive of PTLD in this setting.  
 
EBV gene expression in adult transplant recipients 
The environment for the onset of EBV-associated PTLD in adults appears to differ slightly 
from that in paediatric transplant recipients. In the case of UCBT, donor cells are considered 
to EBV negative, whereas adult recipients are usually EBV seropositive. Therefore, EBV 
infection in adult UCBT recipients is likely to arise in one of two ways: (i) reactivation of the 
endogenous EBV strain and (ii) infection with a new exogenous EBV strain (Kawa et al., 
2011). PTLD is likely to arise from reactivation of EBV latently infected B cells or 
uncontrolled proliferation of the EBV positive B cell pool.  
 
Only 2 adult patients were examined, both with multiple samples ranging between <10 to 
477,642 copies/ml, respectively. On examination of EBV latent gene expression profiles in 
the adult PTLD patient, we confirmed transcripts in all 6 samples. Notably, the entire set of 
latent genes was observed in one sample, and almost the entire set was observed in four 
samples. Furthermore, the transcriptional co-activator, EBNA-LP was expressed in all 
triplicates tested from this patient, regardless of viral load. This finding supports the earlier 
observation of high EBNA-LP gene expression in the paediatric PTLD patients, indicating a 
potential role in PTLD. In contrast, no latent gene expression was detected in samples from 
the adult non-PTLD patient, the reasons of which are unclear. 
 
We next examined lytic gene expression patterns in the adult patients. The full set of lytic 
genes was also detected in two samples from the PTLD patient. However, sporadic lytic gene 
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expression was detected in other sequential samples with higher viral loads. As with the 
paediatric cohort, we detected expression of BALF5 in both patients, indicating active EBV 
lytic DNA replication. Previous studies have reported EBV latent and lytic gene expression in 
the peripheral blood of adult transplant recipients with and without PTLD (Bergallo et al., 
2007; Zawilinska et al., 2008). Together, both studies assessed four latent genes (EBNA1, 
EBNA2, LMP1 and LMP2) and two lytic genes (BZLF1, BALF2). EBV latency and lytic gene 
expression was confirmed in adult HSCT transplant patients without PTLD, indicating a high 
risk for PTLD (Zawilinska et al., 2008). Notably, EBNA-2 and LMP-1 were associated with 
higher viral loads. Consistent with our study where BALF5 was detected in samples from the 
single adult non-PTLD patient, productive infection was also confirmed in the adult HSCT 
patients as detected by the expression of BZLF1 and BALF2 in 19% and 83% of samples, 
respectively (Zawilinska et al., 2008). However, we detected no latent gene expression in this 
patient, suggestive of the stage of engraftment. While latent and lytic gene expression were 
detected in the single adult PTLD patient, no lytic gene expression was detected in the four 
adult SOT patients with PTLD in the study by Bergallo and colleagues, suggestive of higher 
levels of EBV reactivation in HSCT transplant recipients (Zawilinska et al., 2008). In 
summary, EBV latent and lytic gene expression was detected in all samples from the adult 
PTLD patient. BALF5 gene expression was also confirmed in most samples from the adult 
non-PTLD patient however none of the other genes were detected.  
 
Analysis of EBV latency III profiles  
In order to determine the type of latency found in whole blood, and to determine any 
associations between latency III and PTLD, we analysed EBV latent gene expression patterns 
in the whole blood of PTLD and non-PTLD patients. Latency III is defined by the expression 
of all latency genes, notably EBNA-2 and LMP-1, and is frequently detected in EBV-positive 
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B cells within PTLD biopsy tissue (Brink et al., 1997; Gratama et al., 1991; Knowles, 1999; 
Young et al., 1989). Therefore, a latency III profile is considered to be high risk for PTLD 
development. However, latency III is also associated, although less frequently, with 
infectious mononucleosis (Farrell, 1995; Tierney et al., 1994). Previous studies have 
examined a limited set of latent genes and confirmed latency type III based on the 
demonstration of EBNA-2 and LMP-1 genes in the peripheral blood of adult HSCT patients 
without PTLD (Zawilinska et al., 2008). However, latency III was not detected in any of the 
four adult SOT patients with PTLD examined using the same targets (Bergallo, 2007). As 
mentioned earlier, both EBNA-2 and LMP-1 function in B-cell transformation, suggestive of 
their importance to latency III (Thorley-Lawson and Gross, 2004).  
 
We assessed the full set of EBV latent genes however none of the latent RNAs were 
examined. Firstly, we detected latent gene expression patterns typical of latency III (EBNA-
2(+), LMP-1(+)) in 2/5 (40%) paediatric PTLD patients, and all samples (100%) from the adult 
PTLD patient, indicating some associations between latency III and PTLD. Notably, the full 
spectrum of latent genes was detected in one of the paediatric PTLD patients and in 3/5 
(60%) samples from the adult patient. However, we also detected a type III latency profile 
(EBNA-2(+), EBNA-3A (+), EBNA-3B (+), LMP-1(+)) in 1/16 (6%) paediatric non-PTLD patients 
suggesting that latency III is not always specific to PTLD. Secondly, we detected more varied 
EBV latent gene expression patterns, not typical of latency III in the remaining PTLD and 
non-PTLD patients, the reasons for which are unclear. For instance, in one paediatric PTLD 
patient, EBNA-1, EBNA-LP, LMP-1 and LMP-2A were expressed and EBNA-2 was absent. 
Taken together, these findings suggest that latency III is not always specific to PTLD, and 
that variations in latent gene expression patterns are found in whole blood from PTLD 
patients. This is consistent with the earlier study by Bergallo and colleaugues where latency 
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III was detected in the peripheral blood, although in only 1/4 (25%) adult SOT patients with 
PTLD (Bergallo et al., 2007).  
 
Possible reasons for our findings may be technical rather than biological (i.e. transient or low-
level expression of the transcripts). Such factors may include (i) variations in sampling times, 
(ii) delays in blood at collection, (iii) number of tumour B cells, (iv) presence of inhibitors of 
PCR in the sample, (v) poor quality RNA due to freeze-thawing and storage, (vi) inefficient 
cDNA synthesis. All of these could have affected the detection of the mRNA transcripts. 
Secondly, other factors that could result in the absence of the transcripts could be the 
robustness of the PCR, including amplification efficiency and variations in TaqMan PCR 
assays or cDNA template. Also, the sensitivity of detection of target transcripts in each 
sample, since this was not validated during the PCR runs.  
 
Another possible explanation for the observed variations in EBV latent gene expression may 
be the origin of B cells in which gene expression was measured. Earlier studies have 
suggested that latency III can be heterogeneous at the single cell level, owing to a potential 
switch between different latency types, or a reflection of the different phases in the cell cycle 
of the EBV-infected B cells (Brink et al., 1997; Niedobitek et al., 1995; Oudejans et al., 1995; 
Pallesen et al., 1993; Rea et al., 1994b). Therefore, changes in cellular morphology can be 
attributable to such heterogeneity (Brink et al., 1997). Moreover, Brink and colleaugues also 
suggested that latency III cells appeared to represent an intermediary stage between EBNA-
2(+)/LMP-1(-) and EBNA-2(-)/LMP-1(+) expressing cells. Further, a more recent study found 
that late onset PTLD was often associated with more restricted latency types (EBNA-2(-), 
LMP-1(+) and LMP-1(+), EBNA-2(-)) (Timms et al., 2003). Therefore, this heterogeneity in 
latency profiles could explain our findings, and further work is required to clarify the latency 
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profiles detected in EBV-positive B cells present in whole blood. For instance, latency II 
(EBNA-2(-), LMP-1(+)) was detected in two paediatric PTLD cases, however not in all samples 
(Table 5.6). Since we detected latency III in some cases, as described above, it is likely that 
the latency II profile represents borderline detection of latency III, as not all samples 
exhibited latency II. Therefore, the detection efficiency of the RT-PCR could be limiting. 
Although we assessed the sensitivity of the PCR assays in a range of cDNA dilutions by 
amplification of several EBV targets, no target cDNA controls were used to validate the 
sensitivity during the PCR runs. Owing to the absence of such controls, the detection of 
latency II could be attributable to the absence of EBNA-2, due to poor amplification 
efficiency of this target. However, more than one transcript was detected in the latency II 
positive samples (i.e., LMP-1 and LMP-2), and the latency II profile was specific to two of 
five PTLD cases, independent of viral load. EBNA-1 was also detectable in samples of low 
viral load (<10 copies/ml), indicating that sensitivity and efficiency of detection was not a 
limiting factor, and that EBNA-2 was genuinely not expressed. Further, the β-actin reference 
control (ACTB) was amplified in each PCR run and gave similar Ct values (~17 cycles), 
indicating that the RT-PCR was efficient. Therefore, it is likely that the latency II profile 
observed is genuine, and a number of factors could account for the absence of this profile in 
the remainder samples/patients. Firstly, aside from the lower viral load samples, differences 
in sampling times post-transplant could account for the latency II profile. For instance, 
latency III is characteristic of the lymphoblast stage of early EBV infection, whereas latency 
II is characteristic of B cells that have entered the GC, suggesting that the gene expression we 
have measured reflects the stage of B cell infection.  
Again, this finding highlights the fact that heterogeneity of gene expression is a characteristic 
feature of B cells in whole blood from PTLD patients. We also detected EBV latent gene 
expression patterns typical of latency III in one paediatric non-PTLD patient. Moreover, this 
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patient also had primary EBV infection, indicating that the latency III profile could reflect the 
lymphoblastoid stage of the infected B cells. Taken together, this suggests firstly that latency 
III is also found in transplant recipients without PTLD, and secondly that this profile could be 
predictive for PTLD. Further, the detection of latency III in adult HSCT patients without 
PTLD in a recent study, supports further that latency III is not specific to PTLD, but may be 
predictive of PTLD (Bergallo et al., 2007; Zawilinska et al., 2008).  
 
Earlier studies also detected lytic replication in a small proportion of cells in PTLD tumours 
expressing latency III (Rea et al., 1994a; Rea et al., 1994b; Thomas et al., 1990). We detected 
latency III accompanied by lytic gene expression in all patients investigated, except for the 
paediatric non-PTLD patient, suggesting a role for the lytic genes in PTLD. These 
observations concur with a previous study where both latency III and lytic gene expression 
were detected in 5/11 (45%) cardiothoracic PTLD patients (Hopwood et al., 2002). However, 
in contrast to these observations, in another study, no lytic gene expression was detected in 
any of the adult SOT PTLD patients, possibly owing to transient or low-level expression 
(Bergallo et al., 2007). Previous work detected both latency III and lytic gene expression in 
non-PTLD HSCT patients (Zawilinska et al., 2008), supporting further the previous 
suggestion that isolated detection of unrestricted latent gene expression together with lytic 
gene expression is not specifically indicative of PTLD development (Hopwood et al., 2002). 
Interestingly, latency III coupled with lytic gene expression has been reported in astronauts 
during flight, suggesting further that these gene expression patterns are characteristic of the 
immunosuppressed state (Stowe et al., 2011). Notably, we observed that all paediatric 
patients exhibiting latency III also had primary EBV infection, indicating that the latency III 
pattern observed in the non-PTLD patient could represent infectious mononucleosis or the 
early stages of PTLD, as lymphoblasts in both scenarios can express latency III (Thorley-
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Lawson et al., 1999). In summary, although the study size was small, our findings suggest 
that although latency III coupled with lytic gene expression is more frequently detected in 
PTLD. However, it is not necessarly associated with the condition as it can be exhibited in 
other conditions such as primary EBV infection.     
 
Associations between EBV gene expression and viral load    
Several studies have identified associations between high EBV DNA load in the peripheral 
blood and risk of PTLD development in both SOT and HSCT recipents (Baldanti et al., 2000; 
Kenagy et al., 1995; Lucas et al., 1998; Riddler et al., 1994; Savoie et al., 1994; Wagner et 
al., 2002; Wagner et al., 2001). Further, associations between EBV gene expression, viral 
loads and PTLD have also been reported (Bergallo et al., 2007; Hopwood et al., 2002). 
However, this correlation is not perfect, indicating that, in addition to total viral DNA load, 
other factors influence PTLD development. Moreover, only a limited panel of EBV genes 
were assessed in these studies. We suspected that the expression levels of one or more viral 
proteins might influence the onset of PTLD. To further evaluate the correlation between the 
aforementioned variables in a broader set of EBV genes, EBV gene expression profiles were 
analysed in both groups with varying viral loads. We detected some association between the 
expression of two EBV lytic genes (BALF5 and BRRF1) and viral load in three paediatric 
non-PTLD patients. Similarly, in the paediatric PTLD group two genes (BALF5 and EBNA-
LP) were highly expressed in association with viral load. In the adult PTLD patient, five 
genes (EBNA-LP, BRRF1, BALF5, LMP-1 and LMP-2), were highly expressed in association 
with viral loads, whereas BALF5 was highly expressed in the non-PTLD patient. Notably, 
BALF5 was highly expressed in both PTLD and non-PTLD groups, however EBNA-LP was 
highly expressed in samples with higher viral loads in the majority of PTLD patients, 
suggestive of its potential as a marker of PTLD. 
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EBNA-LP is a co-transcriptional activator of EBNA-2 that functions to up-regulate factors 
necessary for B-cell growth. Except for one sample with a low viral load from a paediatric 
non-PTLD patient, EBNA-LP detected markedly high expression in PTLD patients with 
higher viral loads, indicating its involvement in B-cell proliferation (Figure 5.5) (McCann et 
al., 2001). Furthermore, EBNA-LP is known to regulate the thymus activated responsive 
chemokine (TARC), a Th2-responsive chemokine that leads to a Th2 response (Kanamori et 
al., 2004). Previous studies have demonstrated that a Th2-predominant response, may lead to 
the development of cancers such as PTLD as a consequence of a less potent T-cell response 
to EBV-latently infected B-cells, and a Th2-like cytokine environment  (Burke et al., 1992; 
Mathur et al., 1994; Nalesnik et al., 1999; Yuling et al., 2009); Moreover, CD4+ T-cells, 
which are primarily active against the EBV lytic genes, are known to induce a Th2 response 
(Ma et al., 2010). Therefore, the overexpression of EBNA-LP may contribute to the 
development of PTLD through the induction of EBNA-LP-induced TARC, whereas EBV 
lytic replication could induce this response further. In summary, we showed that more EBV 
latent genes were associated with viral load in the adult PTLD patients compared to the 
paediatric PTLD patients. In particular, we identified EBNA-LP as highly expressed in 
association with viral load in PTLD patients only. An earlier study demonstrated detection of 
circular and linear genomes in the peripheral blood representing latent and lytic infection, 
respectively (Babcock et al., 1999). Therefore, possible reasons as to why viral loads do not 
correlate with PTLD include: (i) high viral loads could be attributable to viral lytic DNA 
replication not just latent DNA replication and (ii) the combination of both could 
cumulatively contribute to overall viral burden, however in the case of PTLD the proportion 
of one versus the other could be a significant factor in the onset of PTLD (Babcock et al., 
1999). This could account for increased viral loads in the peripheral blood, suggesting that 
lytic gene expression contributes to total viral DNA burden in transplant patients. Therefore, 
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by measuring a single EBV gene target in a real-time PCR assay, an accurate assessment as 
to how much latent or lytic infection could be contributing to the onset of PTLD, is not 
possible. 
 
Cellular gene expression analysis 
EBV lytic genes are known to regulate cellular gene expression (Carter et al., 2002; Chang et 
al., 2006; Hahn et al., 2005; Morrison and Kenney, 2004; Morrison et al., 2004). PTLD stems 
from an inability to control the proliferation of EBV transformed B cells, however it has been 
shown that viral loads and therefore, EBV infection per se is not solely responsible for the 
development of PTLD. Our next set of results show how the host cell response could, 
potentially, be contributing to the onset of PTLD through a complex interplay between viral 
and cellular gene products.   
 
We used real-time PCR to identify differentially expressed cellular genes between PTLD and 
non-PTLD patients. We assessed 17 cellular genes that were highly differentially expressed 
in a model system of lytic-induced Raji LCLs. Owing to the availability of multiple samples 
for some PTLD patients, but not for others, we examined gene expression profiles in 5 of the 
earliest and most closely matched samples from 5 PTLD patients. The main findings of the 
cellular gene expression analysis was the identification of four genes (CDC2, CXCL9, 
CXCL10 and CHI3L1) that were differentially expressed between multiple samples from the 
adult PTLD and non-PTLD patient (Table 5.13). Similarly, no significant differences were 
detected in the paediatric group for any of the 17 cellular genes, although CHI3L1 was 
differentially expressed (Table 5.12).  Of the genes identified in the adult group, CXCL9 was 
the most highly differentially regulated (9-fold), followed by CXCL10 (7-fold), CDC2 (4-
fold) and CHI3L1 (2-fold). Previous studies have reported up-regulation of CXCL9 and 
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CXCL10 in PTLD (Teruya-Feldstein et al., 1997). CXCL10 has also been reported in EBV-
positive cases of classical Hodgkin lymphoma (HL), where EBV genes regulate this 
chemokine, suggesting further that EBV regulation of chemokines can influence tumour-host 
interactions (Maggio et al., 2002; Setsuda et al., 1999; Teruya-Feldstein et al., 1997; 
Vockerodt et al., 2005).  
 
CXCL9 (Monokine-induced chemokine, MIG) and CXCL10 (interferon-inducible IP 
chemokine, IP-10) are interferon-γ (IFN-γ) responsive Th1-chemokines that share a CXCR3 
receptor and chemoattract CXCR3+ Th1 cells and NK T-cells, leading to a Th1-predominant 
response (Loetscher et al., 1996; Teichmann et al., 2005). LMP-1 can lead to up-regulation of 
various inflammatory factors, such as cytokines and chemokines that mediate proliferation, 
angiogenesis and inflammation in vivo (Hannigan et al., 2011; Morris et al., 2008). 
Furthermore, previous studies have demonstrated that LMP-1 can up-regulate the expression 
of various chemokines, including CXCL9 and CXCL10, through LMP-1-mediated NF-κB 
induction (Kaye et al., 1993). Hence, the NK-κB pathway is important in cancer progression. 
We detected EBV LMP-1 expression in the PTLD patient, however not from the non-PTLD 
patient. Therefore, it is likely that the increased levels of CXCL9 and CXCL10 in this patient 
are attributable to LMP-1. Moreover, previous studies have demonstrated that both 
chemokines have anti-tumor properties (Arenberg et al., 1996; Brunda et al., 1993; Luster 
and Leder, 1993; Sgadari et al., 1996; Sgadari et al., 1997). For instance, up-regulation of 
CXCL10 and CXCL9 has been reported to promote PTLD tumour regression in T-cell 
deficient athymic mice models (Setsuda et al., 1999; Sgadari et al., 1996; Sgadari et al., 
1997). However, an earlier study demonstrated that CXCL10 does not have anti-neoplastic 
functions as demonstrated in vitro (Teichmann et al., 2005). Therefore, through the LMP-1-
activated (NF-κB) induction, we postulate that these chemokines probably contribute to 
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processes relevant to the regression and/or progression of PTLD. Therefore, further studies 
are required to determine the significance of these chemokines in PTLD. 
 
CDC2 (cell division cycle 2) encodes CDC2, a protein kinase that is essential for G1/S and 
G2/M phase transitions of cell cycle. Previous studies have shown that EBNA-2 can induce 
up-regulation of cell-cycle regulating proteins including CDC2, however, whether the effects 
are direct or indirect is uncertain (Spender et al., 2001). As a result of its role in cell cycle 
proliferation, CDC2 has been associated with progression in lung cancer patients and diffuse 
large B cell lymphoma (Bai et al., 2005; Zhao and Gartenhaus, 2009), and CDC2 regulation 
has been reported in EBV-positive monomorphic (MP) PTLD patients in a previous study 
(Craig et al., 2007). In the study, CDC2 showed decreased levels of expression in EBV-
positive MP relative to EBV-negative MP, suggesting down-regulation by EBV. CHI3L1 
encodes the chitinase 3-like 1 protein CHI3L1 (also called YKL-40 or HC-gp39), a member 
of the mammalian chitinase-like protein (CLPs) family, which lack enzymatic activity and 
have carbohydrate binding proteins (Qureshi et al., 2011). CHI3L1 functions as a lectin that 
binds heparin, chitin and collagen, and is secreted by many cell types, including leucocytes 
and macrophages (Biggar et al., 2008). Although the exact biological function of CHI3L1 is 
largely unknown, CHI3L1 appears to be important in host defense mechanisms, where it is 
suggested to play an important role in proliferation and differentiation of tumour cells, 
angiogenesis, antiapoptosis, invasion and extracellular tissue remodeling (Biggar et al., 2008; 
Johansen, 2006; Lee et al., 2009). Indeed, CHI3L1 has been linked to both autoimmune and 
inflammatory diseases, as well as various solid cancers (Eurich et al., 2009; Johansen et al., 
2008). Furthermore, elevated levels of CHI3L1 have been found in the serum and/or plasma 
of patients with these conditions, and are associated with poor prognosis (Eurich et al., 2009; 
Kucur et al., 2008). Therefore, serum levels of CHI3L1 have been suggested as a reliable and 
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sensitive biomarker of cancer progression, such as Hodgkin’s lymphoma (Biggar et al., 2008; 
Johansen et al., 2009; Qin et al., 2007). 
 
In addition, although the association of CHI3L1 with EBV is unclear, its isoform, CHI2L1 is 
known to be up-regulated by EBNA-2 in LCLs (Spender et al., 2006). Indeed, CHI3L1 is up-
regulated in Hodgkin’s lymphoma and multiple sclerosis, of which a previous EBV infection 
is a risk factor (Ascherio and Munger, 2010; Brune et al., 2008). Therefore, further studies 
are required to identify the use of CHI3L1 as a potential marker for PTLD.  Moreover, except 
for CDC2 and CHI3L1, the differences in expression of CXCL9 and CXCL10 were similar to 
those found in the lytic induced Raji LCLs where CDC2, CXCL9, CXCL10 and CHI3L1 were 
regulated to -5.4-, 10-, 4- and 18.1-fold, respectively, compared to control LCLs. This 
suggests that CXCL9 and CXCL10 might be regulated further by EBV lytic replication 
during PTLD, and that CDC2 that functions in anti-apoptosis and cell cycle might be up-
regulated by EBV latent proteins in PTLD to sustain B-cell proliferation. However, the exact 
contribution of these genes to the development of PTLD needs to be investigated further. One 
possible explanation for the up-regulation in the single adult PTLD patient could be due to its 
involvement in cell cycle, proliferation and anti-apoptosis, respectively and could be 
regulated in response to EBV infection to ensure an optimised environment for B-cell 
transformation. This also implies that such processes are regulated by EBV and might be 
relevant to PTLD. Despite these preliminary findings, one of the major limitations of the host 
gene expression analysis in the adult group was the small number of PTLD cases and controls 
investigated. Therefore, further work is needed to investigate these four genes as possible 
markers of PTLD. Whilst a larger sample number is required to assess this differential gene 
expression further, differences in gene expression in PTLD might provide further information 
on the processes involved in PTLD. Further work is required to clarify whether these genes 
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are beneficial for use as markers of PTLD, and whether EBV lytic replication is involved in 
the development of PTLD.   
 
In summary, we have detected the following: (i) a higher number and level of latent and lytic 
gene expression in PTLD versus non-PTLD patients, (ii) variations in latent gene expression 
patterns, including profiles typical of latency III in three PTLD patients and one paediatric 
non-PTLD patient; (iii) no significant differences in cellular gene expression between the 
groups, however >2-fold fold-differences in expression of four cellular genes (CXCL9, 
CXCL10, CDC2 and CHI3L1), and (iv) demonstrated that the real-time PCR assays are 
sensitive enough for evaluation of EBV and cellular candidate genes the whole blood of these 
patients.  
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6 CHAPTER 6. GENERAL DISCUSSION 
 
Importance of study 
The identification of specific markers for the development of PTLD is crucial for the early 
diagnosis of PTLD. This study was important since previous investigations have resulted in 
conflicting evidence for the association between viral loads and the development of PTLD 
(Scheenstra et al., 2004). The findings of this thesis provide several potential candidate genes, 
both viral and cellular, which could be investigated further as markers for the early detection 
of PTLD. In addition, it was important to gain insight into the potential microenvironment in 
which PTLD could arise during EBV infection. 
 
Objectives of study 
In order to identify potential candidate genes as markers for PTLD, we carried out an analysis 
of EBV and cellular gene expression in an in vitro model system of TPA/NaB lytic induced 
Raji cells, using real-time PCR and whole genome microarrays, respectively. This was 
followed by a preliminary analysis of EBV and cellular gene expression in whole blood from 
PTLD versus non-PTLD patients, to evaluate the candidate genes as suitable markers for 
PTLD.  
 
Summary of main findings 
In our in vitro model system, we detected firstly, successful lytic cycle activation by the 
induction of the BZLF1 gene, followed by the identification of several highly induced EBV 
early and late genes, at 24 and 48 hrs, respectively. Secondly, we detected low-level 
induction of several latent genes. In the microarray experiment, we detected 133 highly 
differentially expressed and regulated probe sets, of which 112 genes were found to be 
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induced in response to EBV alone. From these experiments, we selected 17 EBV (9 lytic, 8 
latent) and 17 cellular genes as candidate markers for the clinical evaluation. However, three 
genes (BMRF1, BPLF1 and BVRF1) were overlapping and/or late lytic genes and data for 
these genes were subsequently excluded from the thesis since their expression levels may be 
overestimated. So, only 14 EBV genes (6 lytic, 8 latent) were analysed. These genes were 
highly induced in response to the EBV lytic induction phase. The cellular genes were 
previously implicated with EBV and/or PTLD and likely to be involved in processes relevant 
to PTLD, including anti-apoptosis, cell proliferation, angiogenesis and chemotaxis. In 
addition, Gene Ontology analysis of cellular genes regulated in response to lytic cycle 
induction, revealed highly significantly representative pathways for canonical networks (cell 
cycle), biological processes (chemotaxis), and biomarkers (lymphoproliferative disorders), 
from which additional candidate genes can be selected for further investigation. These 
pathways also indicate the potential microenvironment found in the induced EBV lytic phase 
in Raji cells.   
 
In the preliminary analysis of the EBV candidate genes in whole blood, firstly, we detected 
higher numbers and levels of EBV latent and lytic gene expression in the PTLD versus non-
PTLD group, including higher levels of latent and lytic gene expression for two genes BALF5 
and EBNA-LP. Notably, BALF5 was detected in the vast majority of PTLD and non-PTLD 
patients, suggesting it was necessary for viral DNA replication, and therefore a potential 
target for antivirals in the prevention of PTLD. Secondly, we detected EBV latent gene 
expression patterns typical of latency III (EBNA-2(+), LMP-1(+)) in three PTLD patients (1 
adult, 2 paediatric) and one non PTLD patient, however, more varied EBV latent gene 
expression patterns in the remaining patients, the reasons for which are unclear. In addition, 
we detected latency III together with lytic gene expression, consistent with earlier studies, 
  235 
suggesting an important role for the EBV lytic genes in PTLD (Hopwood et al., 2002). 
Latency III is often associated with EBV-positive B cells in PTLD, although more restricted 
latency profiles have been found (Brink et al., 1997), particularly in late onset PTLDs 
(Timms et al., 2003). It is possible that the observed variations in latent gene expression are 
due to heterogeneity of the latency types, and therefore, further studies are necessary to 
clarify the latency profiles found within tumour cells in whole blood. Such a profile might be 
useful to determine those patients at most risk of developing PTLD. Finally, we detected 
some associations between EBV gene expression and viral loads, including BALF5 and 
BRRF1 in the PTLD and non-PTLD groups, and EBNA-LP, LMP-1, and LMP-2 in the adult 
PTLD patient. This finding was important since there is a disagreement over the significance 
of increasing viral loads and the development of PTLD (Gulley and Tang, 2008). This 
difficulty is that while an association between high EBV DNA viral loads and PTLD can be 
demonstrated, the condition can also arise in patients with low viral loads (Gotoh et al., 2010; 
Qu et al., 2000). In the preliminary analysis of cellular gene candidates, we identified four 
differentially expressed cellular genes between the PTLD and non-PTLD groups, including 
(CXCL9, CXCL10, CDC2 and CHI3L1), of which their potential implications with PTLD are 
discussed below. Finally, we demonstrated the successful development and validation of a 
two-step real-time RT-PCR approach for gene expression analysis in routinely collected 
whole blood samples.  
 
Potential contributions of viral and cellular candidate genes to PTLD  
Our findings suggest potential markers for the early detection of PTLD, and their potential 
contributions to PTLD are discussed here. We identified BALF5 as the most highly expressed 
EBV lytic gene between PTLD and non-PTLD groups and, in association with viral load.    
BALF5 is necessary for viral DNA lytic replication, suggesting ongoing EBV lytic 
  236 
replication. We also identified EBNA-LP as the most highly expressed latent gene in both 
PTLD groups, indicating an important role for this gene. EBNA-LP functions in B-cell 
transformation and is known to up-regulate TARC, which attracts a Th2 response (Lee et al., 
1997; Sinclair et al., 1994). A Th2 response is predominant amongst malignancies, including 
PTLD, and associated with a poor outcome (Holley-Guthrie et al., 2005; Lee et al., 1997; 
Nalesnik et al., 1999; Sinclair et al., 1994). Our findings suggest potential roles for BALF5 
and EBNA-LP in the development of PTLD, and the possible contribution of an EBV-induced 
Th2 microenvironment.  
 
Chemokines function in the recruitment of T cells and NK cells and their involvement in 
cancer are well established (Allavena et al., 2011; Rollins, 2006). CXCL9 and CXCL10 
attract a Th1 response that has anti-neoplastic properties in vivo and have been implicated in 
the regression of PTLD (Sgadari et al., 1996; Sgadari et al., 1997; Teruya-Feldstein et al., 
1999). However, CXCL10 is also suggested to have pro-invasive properties (Zipin-Roitman 
et al., 2007). In addition, CDC2 functions in cell cycle progression in several cancers (Bai et 
al., 2005), whereas CHI3L1 functions in metastasis and is associated with poor prognosis 
(Qureshi et al., 2011), and could both contribute to the development of PTLD. Therefore, all 
four genes could serve as potential markers for progression to PTLD. 
 
Broader implications of our findings  
Earlier studies have proposed a model of EBV persistence (Figure 1.5). This model suggests 
that in the absence of immunosuppressive drugs, EBV infects naive resting B cells to become 
lymphoblasts that reside in the lymph nodes and behave as normal antigen activated B cells 
(Figure 1.5) (Thorley-Lawson, 2001). These activated B cells proliferate and differentiate 
into resting memory B cells that migrate into the peripheral blood to establish a persistent 
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infection (Thorley-Lawson, 2001; Thorley-Lawson and Babcock, 1999; Thorley-Lawson and 
Gross, 2004). Occasionally, memory B cells will differentiate into plasma cells that undergo 
EBV reactivation to release infectious virus (Laichalk and Thorley-Lawson, 2005). The 
earlier studies propose further that increasing levels of infectious virus derived from either 
newly infected B cells or re-infections from reactivated memory B cells not only drives the 
formation of activated lymphoblasts exhibiting latency III, but increases the likelihood of 
infection of B cells other than naive B cells, known as ‘bystander’ B cells into an 
intermediate state of activation (Thorley-Lawson and Gross, 2004). Rarely, these bystander 
cells escape from the lymph nodes into the peripheral circulation where they accumulate 
genetic changes resulting in extra nodal PTLD (Babcock et al., 1999). Such a rare event is 
more likely to occur during immunosuppression when uncontrolled proliferation of 
lymphoblasts arises.  
 
We detected varied latent EBV gene expression patterns in the PTLD patients, including 
latency III in two cases. Since latency III is associated not only with the lymphoblastic stage 
of B cells, but epithelial cells and even germinal centre (GC) and post-GC B cells, this 
suggests that PTLD can arise from a variety of different bystander B cell types (Rowe et al., 
1998; Siemer et al., 2008). Therefore, the detection of latency III-expressing cells could be 
derived from either of these cell types found in whole blood. In addition, we detected lytic 
gene expression patterns in most cases of PTLD, possibly derived from lytically 
infected/reactivating B cells, dead cells (necrotic tumours), and active EBV replication from 
epithelial cells in the oropharynx (Laichalk and Thorley-Lawson, 2005; Prang et al., 1997). 
We know that EBV-reactivation arises as a consequence of increased B cell proliferation 
following T cell immunosuppression in transplant recipients. This results in an increased 
level of viral shedding and consequently an increased number of newly infected B cells in the 
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peripheral blood (Thorley-Lawson and Babcock, 1999). Thus, any increase in B cell 
proliferation in the absence of a functional cytotoxic T cell (CTL) response ultimately leads 
to uncontrolled proliferation, with eventual progression to PTLD. Indeed, an earlier study has 
suggested that in healthy individuals, a fully functional CTL response targeting lytic rather 
than latent genes explains why expression of latency III alone does not predispose to PTLD 
development and that lytic reactivation is an important risk factor for PTLD development 
during immunosuppression (Hopwood et al., 2002).  
 
Therefore, in the context of our findings, we postulate that the demonstration of latency III 
coupled with lytic gene expression probably resulted from an impaired CTL response 
directed against EBV lytic replication. This impairment could have lead to an increased 
production of infectious virus from an expansion of GC memory B cells, expressing latency 
III, or alternatively, from the expansion of newly infected primary B cells exhibiting latency 
III. Any newly infected  naive B cells exhibiting latency III and any pre-existing GC B cells 
could then proliferate into PTLD (Hopwood et al., 2002). Furthermore, the concomitant EBV 
reactivation and lytic infection could accelerate either approach through increased horizontal 
spread between B cells, increasing the total number of latently infected B cells and increasing 
the likelihood of bystander B cells (Hong et al., 2005).  
 
Taken together, this overall increase in EBV lytic reactivation and enhanced proliferation of 
lymphoblasts could account for the higher levels of latent and lytic gene expression in the 
PTLD as compared to non-PTLD patients.  Furthermore, the up-regulation of EBV-induced 
cellular genes, such as EBNA-LP-induced TARC and the various chemokines could enhance 
any progression to PTLD.   
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Comparison with other studies 
While latency III was detected in only 1/4 (25%) PTLD SOT patients, no lytic gene 
expression was detected (Bergallo et al., 2007). The absence of lytic gene expression in 
PTLD patients exhibiting latency III in this study could be due to a number of reasons 
including the low sensitivity of their assay. While these earlier studies tested one, two and 
three lytic genes, respectively (Bergallo et al., 2007; Hopwood et al., 2002; Zawilinska et al., 
2008), we extended this analysis further by examining nine lytic genes, which increases the 
number of lytic genes detected. While we detected some lytic gene expression in adult and 
paediatric non-PTLD patients with high viral loads, the level of expression was not as high as 
in the PTLD patients, indicating that lytic gene expression is important for PTLD regardless 
of viral load, where the full set of lytic genes analysed were expressed in two PTLD patients. 
Notably, the viral DNA polymerase, BALF5 was detected consistently in PTLD and non-
PTLD patients, including those with viral loads ≤10 copies/ml, providing further evidence for 
active EBV lytic DNA replication. Our study is limited by the lack of matched controls and a 
prospective longitudinal analysis in patients at high risk for PTLD. However, limitations of 
the earlier studies include the use of semi-quantitative PCR, which is both prone to 
contamination and also time-consuming. Real-time PCR occurs in a closed system, and offers 
an alternative method for measurement of gene expression levels which is sensistive and 
rapid and highly specific when TaqMan probes are used. Further, only two or three lytic 
genes were evaluated. This is compared to nine lytic genes investigated in our study, which 
more broadly detected active EBV lytic infection, in doing so we could better account for 
transient or temporal expression of these genes. We also tested twice as many latent genes, 
rather than the four latent (EBNA-1, EBNA-2, LMP-1 and LMP-2) examined in each of the 
studies (Bergallo et al., 2007; Zawilinska et al., 2008). This allowed us to analyse the 
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different latency profiles exhibited in whole blood. In addition all gene targets were tested in 
triplicate to increase the confidence of any expression.  
 
Discussion of study limitations 
Limitations of this study were primarily the small study size, including the number of PTLD 
cases, particularly in the adult group, where only 1 patient was available at follow-up post-
transplant. As a consequence, we were unable to draw definitive conclusions on the findings. 
In addition, due to the small number of matched controls to draw from, the majority of 
controls in the paediatric group were unmatched based on age and sex and matching was 
based primarily on sampling time post-transplant (<1 yr). Furthermore the infrequent follow-
up for the majority of patients meant that few sequential samples were available and that 
matched controls (sex/age) were hard to draw from the available paediatric transplant 
population for testing. Furthermore, while we wanted to identify non-invasive markers of 
PTLD, in the paediatric group, a limited whole blood volume (0.5 ml) and the frequency of 
samples received in our laboratory was often unpredictable for both PTLD and non-PTLD 
groups. A larger volume is ideal for isolation of WBCs, particularly for the extraction of high 
yields of total RNA. As a consequence, few EBV-seronegative paediatric patients were 
available for analysis that gave sufficient total RNA yields and a prospective longitudinal 
analysis was not undertaken. More importantly, the fraction of tumour B cells in whole blood 
was not assessed by i.e. flow cytometry analysis, which would have been useful for the 
interpretation of our data, particularly in cases where no transcripts were detectable in 
samples with high viral loads. Other limitations include the number of replicates analysed and 
consequently the reliability of the data, in particular for the model system of lytic induction in 
Raji cells, where only one bioloigal replicate was analysed for EBV gene expression. 
Additional replicates are necessary to validate the highly induced EBV genes identified in our 
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system. Consequently, only two replicates were analysed in the microarray analysis, however 
probe sets were regulated similarly between the arrays and significant P-values (P<0.05) 
determined. Further, Ramos cells were used to assess the effects of the inducing agents, since 
a Raji EBV-negative cell line is not available. The caveat is that there are many genetic 
differences between Ramos and Raji cells independent of EBV and the effects of the inducing 
agents cannot be assessed reliably. The reliability of the data could be increased by increasing 
the numbers of replicates used since only two replicates were analysed for each cell line in 
the genome-wide analysis. Further, the reliability of the data could be confirmed by analysis 
in an alternative EBV-positive cell line such as the Akata cell line, for which an EBV-
negative counterpart is available. However, strengths of our study include the large number 
of EBV and cellular gene targets assessed. 
 
Future work 
Owing to the limitations encountered in this study, the focus of future work should be to 
assemble a large prospective study in a well-defined cohort of PTLD and non-PTLD controls, 
and to use the RT-PCR approach to examine any contributions of the genes evaluated in our 
study to PTLD. Further, an evaluation of more genes is needed to validate our findings and to 
identify other potentially interesting candidate genes. Any differentially expressed genes 
could be useful as markers in real-time RT-PCR assays for the early detection of PTLD. In 
addition, longitudinal studies should also be carried out to determine significant correlations 
between viral loads and any differentially expressed genes as markers for routine testing 
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Conclusion 
In conclusion, the findings made in this study are important since specific markers of PTLD 
are lacking. Further, these findings have provided insight into the types of EBV gene 
expression patterns found in whole blood of transplant recipients monitored routinely in our 
laboratory, and the potential microenvironment in which PTLD could develop. Any future 
studies will be valuable in identifying viral and host factors predictive of PTLD development 
as well as developing our understanding of the EBV biology and the exact role of EBV gene 
products in the pathogenesis of PTLD.   
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7 APPENDIX 
 
Table 7-1 Fold change for 88 EBV genes at early time-points following TPA/NaB induction 
in Raji cells 
Gene 0 hr 2 hr 6 hr 
BZLF1 1.01 0.56 2.21 
BRLF1 1.5 1.06 0.5 
BALF1 - - - 
BALF2 - - - 
BALF3 1.12 0.71 1.17 
BALF5 1.01 0.81 0.91 
BaRF1 1.11 0.36 0.96 
BARF1 - - - 
BBLF2/BBLF3 0.87 0.23 1.03 
BBLF3/ BBLF2 0.97 0.32 0.68 
BBLF4 1.14 0.77 1.07 
BcRF1 0.64 0.78 0.72 
BDLF4 0.63 0.31 1.20 
BFRF1 0.96 0.60 1.59 
BFRF2 0.18 0.29 0.04 
BGLF5 0.95 0.39 0.29 
BGLF4 1.08 1.02 1.05 
BGRF1/ BDRF1 0.65 0.77 0.24 
BHRF1 0.74 0.76 0.73 
BKRF3 1.11 0.49 0.39 
BLLF2 1.02 0.52 0.90 
BLLF3 1.33 1.14 1.34 
BSMLF1 0.16 0.08 0.33 
BMRF1 0.85 1.15 1.32 
BNLF2a 0.32 0.07 0.12 
BNLF2b 0.86 0.89 1.40 
BORF2 0.56 0.87 0.99 
BRRF1 0.76 0.90 76.84 
BSLF1 0.02 0.17 297.1 
BXLF1 0.99 0.32 1.30 
BXRF1 0.73 1.24 1.60 
LF1 1.62 0.44 1.42 
LF2 0.98 0.47 1.02 
LF3 0.55 0.43 0.74 
BALF4 1.15 0.40 0.76 
BBLF1 0.79 0.49 0.27 
BBRF1 0.31 0.43 0.28 
BBRF2 0.99 0.41 0.11 
BBRF3 0.83 0.37 0.32 
BcLF1 0.69 1.11 0.51 
BCRF1 0.65 0.76 1.06 
BDLF1 1.99 1.09 0.22 
BDLF2 0.89 1.29 1.19 
BDLF3.5 1.10 0.18 0.16 
BDLF3 1.08 1.02 1.20 
BDRF1/ BGRF1 0.85 0.49 0.92 
BdRF1 - - - 
BFLF1 1.29 0.33 0.44 
BFLF2 0.36 0.55 0.89 
BFRF1A 0.80 0.32 1.10 
BFRF3 0.14 1.35 0.76 
BGLF1 1.32 0.30 0.56 
BGLF2 1.09 0.36 0.53 
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BGLF3.5 0.76 0.41 0.28 
BGLF3 0.41 0.25 0.26 
BGRF1/BDRF1 0.65 0.77 0.24 
BILF1-gp64 1.01 0.53 0.81 
BILF2-gp78/55 0.49 0.89 1.33 
BKRF2-gp25 0.75 0.86 0.65 
BKRF4 1.33 1.14 1.34 
BLLF1a 1.11 0.19 0.56 
BLLF1b - - - 
BLRF1 1.15 0.30 0.49 
BLRF2 3.67 0.48 0.92 
BMRF2 0.68 0.26 2.95 
BNRF1 0.38 1.17 0.32 
BOLF1    
BORF1 1.12 1.31 - 
BPLF1 10.83 0.64 1.48 
BRRF2 1.12 0.49 0.61 
BSRF1 1.13 0.55 0.67 
BTRF1 0.65 0.72 0.43 
BVRF1 1.11 0.87 2.48 
BVRF2 0.85 0.94 0.46 
BWRF1 2.06 0.56 0.32 
BXLF2 1.17 1.88 4.55 
BVLF1 0.86 0.71 0.54 
BZLF2-gp42 * - - - 
A73/ RPMS1 splice - - - 
BARF0 - - - 
EBER-1 0.68 1.03 1.29 
EBNA-1 0.79 1.29 0.80 
EBNA-2 1.01 1.55 0.59 
EBNA-3A 1.49 0.58 0.23 
EBNA-3B 1.55 0.49 0.43 
EBNA-3C - - - 
EBNA-LP 1.25 0.54 0.72 
LMP-1 1.01 0.88 1.37 
LMP-2A / 2B 1.03 0.85 0.96 
-, not detected 
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Table 7-2 Summary of the top 191 highly differentially expressed and regulated probe sets identified from the Affymetrix HG U133 Plus 2.0 
GeneChip® array in response to EBV lytic induction in Raji cells (ranked by fold-change) 
Probe set ID Gene  name & symbol GO biological 
GO molecular 










Carbohydrate metabolic process 
Chitin catabolic process Catalytic activity Extracellular 18.1  
201105_at 
lectin, galactoside-
binding, soluble, 1 
(LGALS1) 
Apoptosis; regulation of apoptosis; 










Small GTPase mediated signal 
transduction 
Nucleotide 
binding/GTP binding Intracellular 16.1  
205249_at early growth response 2 (EGR2) 
Transcription/regulation of 
transcription Nucleic acid binding Intracellular/nucleus 15.7 14.6 








inhibitor 1 (TIMP1) 
Positive regulation of cell 















n/a n/a n/a 14.6  
204179_at myoglobin (MG) Response to hypoxia/transport 
Oxygen transporter 
activity/iron, oxygen, 
heme and metal ion 
binding 




domain, family A, 
member 
1(PHLDA1) 
Apoptosis/Induction of apoptosis; 
FasL biosynthetic process Protein binding nucleus 13.1  
213112_s_at sequestosome 1 (SQSTM1) 
Ubiquitin-dependent protein 
catabolic 
Protein kinase C 
binding Nucleus/cytoplasm/endosome 12.4  






domain, family A, 
member 1 
(PHLDA1) 
Apoptosis/Induction of apoptosis; 







n/a RNA binding/Catalytic binding mitochondrion 11.4 5.3 
201694_s_at early growth response 1(EGR1) 
Positive and negative regulation of 
transcription from RNA polymerase 
II promoter 
Nucleic acid binding Intracellular nucleus 11.2 12.9 
230966_at interleukin 4 induced 1 (IL4I1) Oxidation reduction 
L-amino acid oxidase 












junction 10.9 11.4 
209969_s_at 
signal transducer 
and activator of 
transcription 1, 
91kDa (STAT1) 
Regulation of transcription/signal 
transduction/response to 
virus/induction of apoptosis/DNA 
dependent RNA transcription from 






















xon/dendrite 10.3  
201693_s_at early growth response 1 (EGR1) 
Positive and negative regulation of 
transcription from RNA polymerase 
II promoter 
Nucleic acid binding Intracellular nucleus 10.3  
203915_at 
chemokine (C-X-C 








region/extracellular space 10.2  
202497_x_at solute carrier Carbohydrate metabolic Transporter Cytoplasm/plasma membrane 10  
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Central nervous system 

















n/a 9.7  
1405_i_at 
chemokine (C-C 





transduction/response to tumour 
necrosis factor/ negative regulation 

























and activator of 
transcription 1, 
91kDa (STAT1) 
Regulation of transcription/signal 
transduction/response to 
virus/induction of apoptosis/DNA 
dependent RNA transcription from 








and DNA binding 
Nucleus/nucleolus/cytoplasm/a
xon/dendrite 9.1  
1555759_a_at 
chemokine (C-C 





transduction/response to tumour 
necrosis factor/ negative regulation 








fraction/cytoplasm 9  
202499_s_at solute carrier family 2 (facilitated 
carbohydrate metabolic 
process/glucose, carbohydrate and transporter activity 
Cytoplasm/plasma 
membrane/membrane/integral 8.9  

































side of plasma membrane 8.6  
204655_at 
chemokine (C-C 





transduction/response to tumour 
necrosis factor/ negative regulation 








fraction/cytoplasm 8.4  
238542_at UL16 binding protein 2 (ULBP2) 
Immune response/antigen 
processing and presentation/natural 
killer cell activation 













repeats 1 (IFIT1) 
n/a Binding cytoplasm 7.9  
204415_at 
interferon, alpha-
inducible protein 6 
(IFI6) 
Release of cytochrome c from 
mitochondria/anti-
apoptosis/immune 
response/nregative regulation of 
caspase activity/negative regulation 
of mitochondrial depolarization 
Protein binding Mitochondrion/membrane/integral to membrane 7.9  








and activator of 





xon/dendrite 7.6  
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5_3_at transcription 1, 
91kDa (STAT1) 
virus/induction of apoptosis/DNA 
dependent RNA transcription from 






and DNA binding 
201531_at 
zinc finger protein 






transcribed mRNA poly(A) tail 
shortening/protein kinase C 
binding/regulation of mRNA 















repeats 3 (IFIT3) 
n/a Binding n/a 7  
208581_x_at metallothionein 1X (MT1X) Response to metal ion 
Copper, zinc, cadmium 
and metal ion binding n/a 6.8  
204326_x_at metallothionein 1X (MT1X) Response to metal ion 
Copper, zinc, cadmium 





repeats 3 (IFIT3) 
n/a Binding n/a 6.5  









cascade/positive regulation of 
transcription from RNA polymerase 
II promoter 
















Cell-cell signalling/response to 
virus/modification-dependent 
protein catabolic process/ISG15-
protein conjugation interspecies 




space/cytoplasm 6.4  
  250 
202388_at 
regulator of G-
protein signaling 2, 
24kDa (RGS2) 
Cell cycle/regulation of G-protein 
coupled receptor/signaling 








n/a 6.3 RGS2 (202388_at) 3.8 
200887_s_at 
signal transducer 
and activator of 
transcription 1, 
91kDa (STAT1) 
? antigen binding ? 6.1  
212185_x_at metallothionein 2A (MT2A) Cellular copper ion homeostasis 
Protein, zinc and metal 





n/a n/a n/a 6.1  














206461_x_at metallothionein 1H (MT1H) 
Cellular zinc ion homeostasis/nitric 
oxide mediated signal 
transduction/detoxification of 
copper ion 
Copper, protein, zinc 
ion, cadmium ion and 
metal ion binding 










Inactivation of MAPK 






ne phosphatase activity 
Nucleus 5.6  
210621_s_at 




Cytokinesis/negative regulation of 
cell-matrix adhesion/signal 
transduction/intracellular signalling 
cascade/positive regulation of anti-
apoptosis/regulation of small 
GTPase mediated signal 












’plasma membrane 5.4  
202677_at RAS p21 protein Cytokinesis/negative regulation of Glycoprotein Ruffle/intracellular/cytoplasm/ 5.3  






cascade/positive regulation of anti-
apoptosis/regulation of small 
GTPase mediated signal 











204141_at tubulin, beta 2A (TUBB2) 










Microtubule protein complex 5.3  
209911_x_at 













catalytic subunit 1 
(PDP1) 

















m ion binding/sugar 
binding 
Integral to plasma 
membrane/external side of 







Response to virus/phospholipids 
scrambling/platelet activation 








35820_at GM2 ganglioside activator (GM2A) 
Lipid, sphingolipid and ganglioside 
metabolic process/lipid 
transport/oligosaccharide, 
glycolipid, and sphingolipid 
process/neurological 








































Iron ion transport/cellular iron ion 
homeostasis/intracellular 
sequestering of iron ion/immune 
response/cell proliferation/negative 







ion, calcium, protein, 
chloride, metal ion, 
transition metal ion 














 phosphoprotein phosphatase activity nucleus 4.4 8.1 
202081_at immediate early response 2 (IER2) n/a n/a cytoplasm 4.4  3.1 
207861_at 
chemokine (C-C 





signalling/response to virus/cell 
migration 
Cytokine and 










metal ion binding 
Extracellular region 4.4  
207826_s_at 





Negative regulation of transcription 
from RNA polymerase II 
promoter/regulation of DNA 
replication/positive regulation of 
apoptosis/negative regulation of 
transcription factor 
activity/regulation of cell 







nucleus 4.3  
201739_at serum/glucocorticoi Protein amino acid Nucleotide Nucleus/cytoplasm/endoplasmi 4.2 11.4 
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process/lipid transport/lipid and 














exchanging ATPase complex 























of apoptosis Protein binding cytoplasm 4.2 10.6 
201625_s_at insulin induced gene 1 (INSIG1) 
Lipid metabolic process/cell 
proliferation/ER-nuclear sterol 
response/metabolic response/ 
Protein binding Endoplasmic reticulum/integral membrane 4.2  
200871_s_at prosaposin (PSAP) 
lipid metabolic process 


















surface receptor linked signal 
transduction/cell-cell 









Extracellular region/space 4  
221269_s_at SH3 domain Cell redox/homeostasis Electron carrier Nucleus/cytoplasm 4 4.9 



























RING1 and YY1 
binding protein 
(RYBP) 
Negative regulation of transcription 






ion and metal ion 
binding 
Intracellular/nucleus/nucleopla








class rRNA transcription/tRNA 







complex,nucleus 3.9  
201393_s_at 
insulin-like growth 








































fraction/cytoplasm 3.8  
205114_s_at 
chemokine (C-C 
motif) ligand 3 
(CCL3, 







region/extracellular space 3.7  
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CCL3L1,CCL3L3) transduction/G-protein coupled 
receptor/protein signalling 
pathway/cell-cell 
signalling/negative regulation of 














Apoptosis/induction of apoptosis Protein and ATP binding 
Golgi apparatus/integral to 







Positive regulation of defense 
response to virus by host 
transcription/RNA dependent 
response to virus/innate immune 
response/negative regulation of 
retroviral genome 
replication/negative regulation of 
viral reproduction 



















production/protein amino acid N-
linked glycosylation/lipid metabolic 







Extracellular region/lysosome 3.3 4 
201426_s_at vimentin (VIM) 















203752_s_at jun D proto-oncogene (JUND) 
Regulation of transcription/DNA-
dependent regulation of 









Chromatin/nucleus 3.2 3.6 

















Extracellular region 3.2 11.2 
211962_s_at 
zinc finger protein 
36, C3H type-like 1 
(ZFP36L1) 
Nuclear transcribed mRNA 
catabolic process/deadenylation-
dependent decay/mRNA catabolic 
process/regulation of 











Nucleus/cytoplasm/cytosol 3.2 4.3 
201627_s_at insulin induced gene 1 (INSIG1) 
Lipid metabolic process/response to 
sterol depletion/metabolic 
process/cell proliferation/ER-
nuclear sterol response pathway 
Protein binding ER/membrane/integral to membrane 3  
34210_at CD52 molecule Elevation of cytosolic calcium ion concentration/respiratory burst n/a 
Membrane fraction/plasma 
membrane/integral to plasma 
membrane/membrane 








of transforming growth factor beta 






ion, and metal ion 
binding 
Nucleus/cytoplasm 3  
229872_s_at hypothetical protein LOC100132999 n/a n/a n/a 3  
204661_at CD52 molecule Elevation of cytosolic calcium ion concentration/respiratory burst n/a 
Membrane fraction/plasma 
membrane/integral to plasma 
membrane/membrane 
anchored to membrane 
2.9  




Nucleus/cytoplasm/cytosol 2.8  

















Inositol metabolic process/transport 





















Inositol metabolic process/transport 













RAP1A, member of 
RAS oncogene 
family (RAP1A) 
Signal transduction/small GTPase 















isomerase 1 (IDI1) 
Steroid, lipid, cholesterol, 
carotenoid and isoprenoid 
biosynthetic process 






metal ion binding 
... 
 
Peroxisome/cytosol 2.4  
204897_at 
prostaglandin E 




receptor protein signaling 
pathway/G-protein 
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Protein amino acid 
phosphorylation/apoptosis/inductio










nucleus 2.4  
201626_at insulin induced gene 1(INSIG1) 
Lipid metabolic process/response to 
sterol depletion/metabolic 
process/cell proliferation/ER-
nuclear sterol response pathway 





Iron ion transport/cellular iron ion 
homeostasis/intracellular 
sequestering of iron ion/immune 
response/cell proliferation/negative 







ion, calcium, protein, 
chloride, metal ion, 
transition metal ion 












cell death 1 
(DAD1) 
Apoptosis/antiapoptosis/response to 
nutrient protein amino acid N-
linked glycosylation via 










integral to membrane 
2.25 2.5 
201201_at cystatin B (stefin B) (CSTB) 
Negative regulation of peptidase 






















cytoplasm 2.25  




high mobility group 
AT-hook 1 
(HMGA1) 
DNA unwinding during 
replication/nucleosome 
disassembly/loss of chromatin 
silencing/regulation of 
transcription/DNA-dependent 
protein complex assembly/provirus 


















complex, class I, E 
(HLA-E) 
Antigen processing and 
presentation of peptide antigen via 
MHC class I/immune 
response/antigen processing and 
presentation 
















process/response to oxidative 
























translational initiation/cell cycle 







translation/intitiation factor 4F 
complex 
-2 -2.3 

















nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 
DNA replication 
nucleotide metabolic process 
dUTP metabolic process 






l -2.25  







DNA replication/DNA unwinding 
during replication/DNA replication 
inititation/transcription/cell 









Nucleus/cytoplasm -2.25  
205133_s_at 




Protein folding/activation of 
caspase activity/response to 







ochondrial matrix -2.25 -2.4 
211714_x_at tubulin, beta (TUBB) 
Cell motion/microtubule based 










binding/MHC class I 
protein binding 
Cytoskeleton/microtubule/floti
llin complex/protein complex -2.3  
















region of cytosol 
-2.3  













cytoplasm -2.4 -3.1 










phosphatise type 2A 
Nucleus/nucleoplasm/cytoplas
m/ER/cytosol/perinuclear 
region of cytosol 
-2.4  



















protein 1 (HSPH1) 
Response to stress/response to 
unfolded protein/chaperone 





cytoplasm -2.5  
214938_x_at 
high-mobility 
group box 1 
(HMGB1) 
DNA unwinding during 
replication/DNA repair/base-
excision repair/DNA ligation/DNA 
recombination/chromatin 
organisation/regulation of 
transcription from RNA polymerase 
II promoter/anti-apoptosis/signal 
















alpha and mu 
polypeptides (IGJ) 
Immune response antigen binding Extracellular -2.6  
209026_x_atD tubulin, beta (TUBB) 
Cell motion/microtubule based 










binding/MHC class I 
protein binding 
Cytoskeleton/microtubule/floti
llin complex/protein complex -2.6 -2.0 
212330_at transcription factor Dp-1 (TFDP1) 
Transcription/regulation of 
transcription/DNA-dependent 
regulation of transcription from 
RNA polymerase II promoter/cell 









tion factor complex -2.6  












cascade/regulation of transcription 
Protein binding Nucleus/cytoplasm/ER/perinuclear region of cytoplasm -2.6 -2.4 
202413_s_at ubiquitin specific peptidase 1 (USP1) 







nucleus -2.7 -2.1 
212320_at Tubulin, beta (TUBB) 
Cell motion/microtubule based 










binding/MHC class I 
protein binding 
Cytoskeleton/microtubule/floti










































DNA replication/regulation of 
DNA replication/DNA repair/base-

























or deletion binding 
MutLalpha complex 
binding 




























































































group box 1 
(HMGB1) 
DNA unwinding during 
replication/DNA repair/base-
excision repair/DNA ligation/DNA 
recombination/chromatin 
organisation/regulation of 
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II promoter/anti-apoptosis/signal 







family, member B 
(ANP32B) 













group box 1 
(HMGB1) 
DNA unwinding during 
replication/DNA repair/base-
excision repair/DNA ligation/DNA 
recombination/chromatin 
organisation/regulation of 
transcription from RNA polymerase 
II promoter/anti-apoptosis/signal 















family, member B 
(ANP32B) 
n/a Protein binding nucleus -3.3  
216250_s_at leupaxin (LPXN) Protein complex assembly/cell adhesion/signal transduction 
Zinc ion binding/metal 






Epithelial to mesenchymal 
transition/positive regulation of 
gene-specific transcription/negative 











specific DNA binding 
Nucleus/cytoplasm/ribonucleo
protein complex ?  
204674_at lymphoid-restricted membrane protein Vesicle targeting/vesicle fusion n/a 
Cytoplasm/ER/ER 
membrane/integral to -3.4  
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(LRMP) plasmamembrane/membrane/i
















metal ion binding 







response/negative regulation of cell 

































region of cytoplasm 
-3.4  
200806_s_at 




B cell cytokine production (IL-6, 
10, 12)/MyD88-dependent toll-like 
receptor signalling pathway 
positive regulation of T cell 
mediated immune response to 
tumour cell/protein folding/B-cell 
proliferation/positive and negative 

























n/a -3.5 -3.3 
209932_s_at deoxyuridine triphosphatase 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 
magnesium ion binding 
dUTP diphosphatase 
Nucleus/mitochondrion/cytoso
l -3.6  
  266 
(DU2) DNA replication 
nucleotide metabolic process 

















7, 35kDa (SFRS7) 










nucleus -3.7 -2.0 




ion channel, 5 
(P2RX5) 
Transport/ion transport/signal 
transduction/positive regulation of 











202503_s_at KIAA0101 n/a nucelotide binding Nucleus/mitochondrion -3.8  
219117_s_at 
FK506 binding 




trans isomerase activity 
isomerase activity 
Membrane/integral to 













nucleus -3.8  
217301_x_at 
retinoblastoma 








































































Regulation of cyclin-dependent  
protein kinase activity/cell 
cycle/cell proliferation/cell division 





nucleoplasm -4.1 -2.8 

































Mitotic sister chromatid 
segregation/cell cycle/cell 









219014_at placenta-specific 8 (PLAC8) n/a n/a n/a -4.7  
225310_at 
RNA binding motif 
protein, X-linked 
(RBMX) 
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228153_at ring finger protein 144B (RNF144B) 
Apoptosis/modification-dependent 
protein catabolic process/protein 
ubiquination during ubiquitin-











226319_s_at THO complex 4 (THOC4) 
Nuclear mRNA splicing via 
spliceosome/mRNA 
processing/RNA splicing/mRNA 
export from nucleus transport/RNA 
splicing/intronless viral mRNA 















72, member A 
n/a n/a n/a -5.2  
208808_s_at 
high-mobility 
group box 2 
(HMGB2) 
DNA unwinding during 
replication/DNA repair/base-
excision repair/DNA ligation/DNA 
recombination/chromatin 
organisation/regulation of 
transcription from RNA polymerase 
II promoter/anti-apoptosis/signal 














1 (yeast)  
(MAD2L1) 
Mitotic sister chromatid 
segregation/cell 










cell division cycle 
2, G1 to S and G2 
to M (CDC2) 
















terminal domain kinase 
activity/ 
Nucleus/cytoplasm/cytosol/spi
ndle/microtubule midbody -5.4 -2.2 
203755_at budding Apoptosis/cell cycle/spindle nucelotide Kinetochore/condensed -5.5  


















DNA replication/DNA unwinding 
during replication/DNA replication 
initiation/nucleosome 
assembly/transcription/cell 
















group box 1 
(HMGB1) 
 protein binding nucleus -5.6  









n/a -5.6 -3.3 
201292_at 
topoisomerase 
(DNA) II alpha 
170kDa (TOP2A) 
DNA replication/DNA topological 
change/DNA ligation and 
repair/response to DNA 
damage/chromosome 
segregation/positive regulation of 
apoptosis/positive regulation of 
















204026_s_at ZW10 interactor (ZWINT) 










202589_at thymidylate synthetase (TYMS) 
DNA replication/DNA 








nucleus -5.7 -4.1 
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210258_at 
regulator of G-
protein signaling 13 
(RGS13) 
G-protein coupled receptor protein 
signalling pathway/negative 
regulation of signal 
transduction/negative regulation of 
















Cytoplasm/cell surface -5.7  
221286_s_at hypothetical protein MGC29506 apoptosis 
serine-type 
endopeptidase extracellular region/cytoplasm -5.7  


















229147_at n/a n/a n/a n/a -6.6  
210559_s_at 
cell division cycle 
2, G1 to S and G2 
to M (CDC2) 
















terminal domain kinase 
activity/ 
Nucleus/cytoplasm/cytosol/spi






Mitotic sister chromatid 
segregation/cell 















catabolic process cell cycle/spindle 
organization/mitosis/protein 
ubiquitination/positive regulation of 







Nucleoplasm/cytosol -7  
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conjugating protein 
ligase activity 
1554696_s_at thymidylate synthetase (TYMS) 
Nucleobase, nucleoside, nucleotide, 










cytosol -7.3  
1568752_s_at 
regulator of G-
protein signaling 13 
(RGS13) 
G-protein coupled receptor protein 
signalling pathway/negative 
regulation of signal 
transduction/negative regulation of 





membrane -8.7 -3.8 
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Figure 7-1 Gene expression levels for 17 cellular candidate genes in the peripheral blood of PTLD 
and non-PTLD paediatric patients   
Relative expression levels were quantified relative to the ACTB gene using real-time TaqMan PCR. (A) Relative 
expression levels in 15 samples from 5 PTLD patients (Black bars); (B) Relative expression levels in 18 samples 
from 16 non-PTLD patients (Grey bars). Horizontal lines denote the mean relative expression level in each 
group of transplant patients. Each bar represents the mean relative expression level ±S.D of triplicates for each 
gene.   
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Figure 7-2 Gene expression levels for 17 cellular candidate genes in the peripheral blood of adult 
PTLD and non-PTLD patients   
Relative expression levels were quantified relative to the ACTB gene using real-time TaqMan PCR.   Relative 
expression levels in 6 samples from 1 PTLD (Black bars) and 6 samples from 1 non-PTLD patients. Each bar 
represents the mean relative expression level ±SD of triplicates for gene.   
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